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1. THESIS SUMMARY 
 
Metastatic dissemination is responsible for more than 90% of cancer-related deaths. 
However, the molecular features underlying the metastatic process are largely uncharacterized. 
Cancer cells that leave a primary tumor and enter the bloodstream are referred to as circulating 
tumor cells (CTCs). While extraordinarily rare compared to normal blood cells, their isolation 
and characterization offers a unique opportunity to study how metastasis occurs. Recent 
breakthrough developments in microfluidics technology have enabled a more detailed 
examination of blood samples, highlighting that tumor cells in circulation are organized as 
single and clustered CTCs, with the latter being associated with a greater metastatic potential. 
Moreover, an additional subtype of CTCs was observed and characterized as white blood cells 
(WBCs) – associated CTCs with unknown prevalence and function. 
 
The goal of my PhD Thesis was to investigate CTCs in depth by implementing a novel 
approach in cancer metastasis research. For the first time, a single cell-resolution, parallel 
genome and transcriptome sequencing of single, clustered and WBC-associated CTCs of cancer 
patients and metastatic mouse models has been applied. This technique provided a mean for 
multiple observations including a breakthrough discovery – WBCs circulating in association 
with tumor cells have a crucial impact on their metastatic potential and these cell aggregates 
were described as the most metastatic CTC subtype. Moreover, single-cell RNA sequencing 
revealed a specific pattern of these WBCs, with neutrophils representing the majority of the 
cases. Additionally, cell-cell junction and cytokine-receptor pairs that define CTC-neutrophil 
clusters were described and proposed as key vulnerabilities of the metastatic process. Thus, the 
association between neutrophils and CTCs fuels cell cycle progression within the bloodstream 
and expands the metastatic potential of CTCs, providing a rationale for targeting this interaction 
in breast cancer.    
 
Over the course of three and a half years more than 160 patients with diverse cancer 
types agreed to donate blood for the ‘CTC Study’. The association between crucial clinical 
parameters and CTC characteristics have been evaluated in a selected group of 73 consecutive 
patients characterized by progressive invasive breast cancer, high tumor load and treatment 
discontinuation.  Among  these  patients,  a correlation between a treatment with the monoclonal  
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antibody denosumab and the absence of CTCs was observed. Additionally, low red blood cell 
count  was  associated  with  the  presence  of  CTCs, whereas high CA 15-3 tumor marker, high  
mean corpuscular volume, high white blood cell count and high mean platelet volume associated 
specifically with CTC clusters. These findings carry clinical applications, however further 
studies will be needed to validate the involvement of denosumab in the prevention of CTC 
generation. 
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2. INTRODUCTION  
 
2.1. CANCER METASTASIS 
 
Cancer is a commonly known group of diseases occurring as a result of uninhibited cell growth 
in various organs. The likelihood of certain tissues to give raise to cancer is highly correlated 
with the total number of cell divisions necessary for homeostasis [1]. Majority of cases (i.e. 
solid cancers) are presented with abnormal cell formations called neoplasms (from greek neo 
("new") and plasma ("formation") or simply tumors. Globally, around 15 million new cases and 
8 million deaths occur every year, with the frightening prediction of 27 million new patients to 
be diagnosed in 2030 [2, 3]. Notably, the development of a metastatic disease accounts for more 
than 90% of cancer-related deaths and clinical  data  indicates  a  strong  correlation  between 
metastases occurrence and poor prognosis [4].  
 
Metastasis has been described as a series of sequential steps that begins with the intravasation of 
primary cancer cells into the bloodstream, followed by the survival within circulation, 
extravasation into secondary distant sites and finally outgrowth of metastatic cancer cells 
deposits [5]. Initiation of this cascade can result from a cellular stress upon nutrient deprivation 
and it requires acquisition of features (e.g. via mutagenesis) that allow cells to separate from the 
tumor mass and avoid anoikis, a detachment-induced apoptosis [6, 7]. This phenomenon is 
observed in patients when necrotic regions are more common in higher grade (i.e. more 
aggressive) tumors and they positively correlate with metastatic occurrence [8, 9]. Another 
crucial factor enabling metastatic processes is the ability to evade immune attacks and to “trick” 
other cells to serve as support to tumor growth and invasiveness [10]. Interestingly, certain 
cancers tend to spread only to specific organs. For example, breast cancer often migrates to 
multiple tissues thorough the body, including the brain, bones, lungs and liver, whereas colon 
cancer favors seeding mostly to the liver [11, 12]. Detailed evidence explaining differences in 
frequency or site-specific secondary lesions across different tumor types is yet to be described.  
 
Asymptomatic early-stage cancers tend to be difficult to detected without proper screening 
programs and the dissemination of cancer cells may have already occurred at the time of 
diagnosis (e.g. lung cancer) [13]. Initially, these scattered tumor cells are undetectable and form 
only small colonies (micrometastases). Studies have shown that disseminated tumor cells can 
survive  in  dormancy  even  20  years  before they will cause a secondary disease outbreak [14].   
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Currently, patients that developed a metastatic disease are considered incurable. One of the main 
reasons for this outcome is treatment difficulty due to the intra- and inter-patient heterogeneity. 
No two cases are identical and therefore clinical choices are often problematic. Moreover, 
cancer is a dynamic disease with genetic and epigenetic changes occurring as a consequence of 
treatment-induced selection [15]. Many metastatic patients struggle with a recurring disease (i.e. 
cancer relapse) and therapy-resistance, therefore consecutive lines of treatment are administered 
until a non-responsive terminal cancer develops [16]. This explains ongoing efforts to develop 
relapse prediction tools based on the molecular variables of primary tumor [17]. Additional 
obstacle is the difficulty of direct sampling and characterization of metastatic lesions, which 
reflects into poor treatment strategies [18]. It is in this context that analysis of circulating tumor 
cells (CTCs) on their way to form a secondary lesion may offer an extraordinary opportunity to 
characterize the molecular features of a progressing metastatic disease, leading to personalized 
treatment [19]. 
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2.2. BIOLOGY AND CLINICAL SIGNIFICANCE OF CTCS 
 
CTCs originate from a solid tumor, which sheds cells in order to spread. First description of 
these phenomenon is dated back to the 19th century, when an autopsy of a metastatic cancer 
patient revealed similar cells in the blood and distant tumors. This observation suggested that 
cancer cells could be carried in the circulation to reach secondary sites. Since then, the vital role 
of CTCs in metastatic processes has been suspected, however detailed studies were not possible 
due to the isolation difficulties. It is estimated that one CTC can be surrounded by ten million of 
white blood cells and ten billion of red blood cells causing the analysis extremely challenging. 
Recent development of novel isolation technologies enabled first attempts in characterization of 
these unstudied cells. 
 
Tumors can spread via single CTCs or CTC clusters [20], however the reasons for these 
subtypes to co-exist are still far from being completely understood. A more recent study 
described that CTC clusters are kept together by intraepithelial cell junctions and are up to 50 
times more metastatic than single CTCs [21]. Furthermore, CTC clusters have occasionally been 
found associated to platelets [21], leukocytes [22, 23], as well as to sporadically express 
mesenchymal markers [24]. Interestingly, clustering with white blood cells (WBC) has been 
shown to correlate with worse prognosis [25]. Altogether, these characteristics contribute to the 
high metastatic potential of CTC clusters [26], yet they do represent points of attack for 
subverting a metastatic disease.  
 
In epithelial cancers (e.g. breast or lung), primary tumors and metastatic deposits generally 
display an epithelial phenotype. In contrast, CTCs have been shown to persist in a dynamic state 
while associated to platelets and leukocytes, and to display both mesenchymal and epithelial 
phenotypes [24]. Several studies have suggested that the epithelial to mesenchymal-transition 
(EMT) contributes to early-stage dissemination of cancer and is pivotal for invasion and 
metastasis. However, recent results seem to oppose this model, showing that mesenchymal 
phenotype is associated with therapy resistance, but not required for tumor dissemination [27, 
28].  
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Introduction Figure 1. Schematic view of metastatic formation by CTCs. Tumor cells intravasate as either 
single or clustered cells and are carried in the bloodstream toward the secondary sites. Upon extravasation a 
metastatic outgrowth may occur. (adapted from Gkountela et.al., 2016 [29]) 
 
CTCs have been proven beneficial in prediction and monitoring of treatment responses. For 
example, detection of mutation changes in CTCs were shown to reflect the therapy effects in 
lung cancer [30]. Additionally, molecular analysis of blood-derived tumor cells (e.g. expression 
of HER2, hormone receptors ER and PR) can be vital when tumor biopsy is impossible due to 
localization. This approach has been described as liquid biopsy (i.e. blood-derived) and is 
appreciated as a non-invasive method of cancer screening. Moreover, some biomarkers can 
change during disease recurrence and evaluation of CTC status can be used for making clinical 
decisions. 
 
Enumeration of CTCs can also carry an evident prognostic value. In a recent retrospective 
analysis of 2436 metastatic breast cancer patients, a threshold of five or more CTCs was used to 
determine the group of patients with a shorter overall survival [31]. Results were indicative for 
all studied patients, irrespective of the breast cancer subtype (i.e. hormone receptor-positive, 
HER2-positive or triple-negative) and regardless of de novo or recurrent metastatic disease. 
Altogether, reliable CTC detection methods are currently highly desirable to facilitate 
personalized treatment choices. 
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2.3. CTCS DETECTION AND ISOLATION METHODS 
 
The fact that CTCs are surrounded by billions of blood cells has hindered their analysis until 
recently. In order to be effective, the applied detection method needs to be specific and sensitive 
enough to capture these rare cells. As a potential clinical tool, it also requires high reliability and 
cost-efficiency necessary for routine analyses. An additional consideration while choosing the 
appropriate procedure includes the maintenance of cell viability, which is required for certain 
downstream analyses (e.g. culture or drug-testing). 
 
First-generation detection methods of CTCs were based on biological features of CTCs, such as 
the expression of epithelial-specific markers (e.g. EpCAM or cytokeratin), which are absent in 
the normal blood cells [32]. An additional staining detecting white blood cells (anti-CD45) may 
be applied to increase the detection confidence. This approach is utilized in CellSearch 
technology [33], the only FDA-approved tool for CTC enumeration from the blood of patients 
with cancer, which uses magnetic beads coated with anti-EpCAM antibodies to capture CTCs. 
Another example of immunoaffinity based CTC enrichment platform is ‘CTC-chip’ with anti-
EpCAM antibodies covering a large surface of microfluidic chip, that enabled identification of 
CTCs in 115 of 116 studied metastatic cancer patients [34]. Importantly, the positive selection 
and antigen-dependent approach can overlook cells that express low levels of the markers of 
choice. Therefore, antigen independent methods focused on depletion of red and white blood 
cells (iChip [35]), physical aspects (Cluster Chip [23], Parsortix [36]), centrifugation [37] or 
ultrasound-based enrichment [38] have emerged.  Until now, CTC cluster-specific methods are 
represented by the minority of available methods.  
 
Varying with the isolation method of choice, molecular characterization of CTCs can now be 
applied upon further CTC micromanipulation and purification. To this end, technologies that 
facilitate CTC enrichment continue to emerge and enable a full spectrum of downstream 
applications including DNA and RNA sequencing, CNV characterizations and others. 
 
CTC isolation and characterization methods are providing fundamental insights into those 
mechanisms that underlie the metastatic process. Unquestionable influence on these complex 
biochemical and biological changes is attributed to immune cells in tumor microenvironment 
[39-42].  
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2.4. IMMUNE REGULATION OF METASTASIS 
 
Principles of an immune-dependent tumor progression can be divided into three steps: 
elimination, equilibrium and escape. The first stage involves an initial contact between 
neoplastic and immune cells, which typically results in eradication of most or all tumor cells. 
The second stage describes the process during which both sides start to co-exist, while further 
selective pressure and clonal selection of neoplastic cells occurs. Lastly, the third phase is 
characterized by an active growth of a tumor, regardless of the opposed efforts from the immune 
system (i.e. immune escape). Mounting evidence indicates the tumor intelligence seen as turning 
of the hostile immune system into co-conspirator and conversion of other cell types into potent 
immunosuppressive agents. 
 
Multiple non-malignant cells co-exist with cancer cells forming together a tumor niche, 
including neutrophils [43], myeloid-derived suppressor cells MDSCs [44], T cells [45], 
macrophages [46] and dendritic cells [47]. These cells are not just bystanders as both anti- and 
pro-tumor activity involving them have been described [48-51]. In this respect, metastasis 
promotion can take on multiple forms. Firstly, immunosuppressive activity protects from 
surveillance by killer cells, such as MDSCs inhibition of hostile CD8+ T cells [52] or PD-L1-
mediated checkpoint inhibition of natural killer (NK) cells by tumor-associated macrophages 
[53]. Then, maintenance of a chronic inflammatory environment by infiltrating immune cells 
leading to further recruitment of pro-tumor immune cells leading to promotion of cancer spread 
[54]. Additionally, secretion of vascular endothelial growth factor (VEGF) by metastasis-
associated macrophages attracts vasculature into the tumor and induces vascular permeability, 
which facilitates extravasation of cancer cells [55].  
 
CTCs after leaving the tumor site might become vulnerable to immune-associated elimination. 
In the context of liquid biopsy, a positive correlation has been observed between the presence of 
CTCs and immune cells in the circulation (i.e. MDSCs and T regulatory cells) [56, 57]. 
Considering that also increased circulating levels of pro-inflammatory IL-1β and IL-6 are 
strongly predictive of poor clinical outcome, it seems logical that tumor spread might be 
supported by the suppression of peripheral antitumor responses. Further studies are required to 
address  the  question  whether  the immunosuppressive mechanism is tumor-specific or whether  
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they represent the systemic immunomodulation. Moreover, a causal relationship between CTCs 
and pro-tumor circulating cells needs an additional clarification.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction Figure 2. Tumor niche with infiltrating immune cells. Recruited non-malignant cells play vital 
role in regulatory networks and promote tumor expansion. G-CSF, granulocyte colony-stimulating factor; GM-
CSF, granulocyte-macrophage colony-stimulating factor; NK, natural killer; NO, nitric oxide; ROS, reactive 
oxygen species. (adapted from Kerkar et.al., 2012 [58]). 
 
 
Detailed characterization of immunomodulatory mechanisms in cancer has led to development 
of novel therapeutic strategies ([59-61]). Importantly, the idea of targeting immune-checkpoint 
inhibitors in order to restore the antitumor immunity is currently the main focus of numerous 
ongoing clinical trials.  
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2.5. SINGLE-CELL GENOME AND TRANSCRIPTOME SEQUENCING 
 
Single cell-resolution approaches have been successfully implemented for genome or 
transcriptome analysis [62-64], providing a detailed characterization of cancer cells and 
assessment of their heterogeneity. Collected expression patterns, mutational profiles and copy-
number analyses can be utilized in the clinic as both treatment evaluation and prognostic tools.  
 
Until recently, technical challenges have held research back from understanding transcriptome 
dynamics in relation to the mutational profile of each single tumor cell. For example, parallel 
genome and transcriptome sequencing (G&T-Seq) method [65] offers a unique tool for such 
analysis, which could not previously be obtained from DNA or RNA sequencing alone.  
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
Introduction Figure 3. Parallel Genome and Transcriptome Sequencing Workflow. Each single circulating 
tumor cell (CTC) will be lysed and mixed with beads capturing polyA mRNA. After magnetic separation, both 
mRNA and gDNA will be amplified using Smart-seq2 or Multiple Displacement Amplification (MDA), 
respectively, followed by sequencing (based on Macaulay et.al.[65]) 
 
Single-cell multiomics can also include epigenome [66] and protein [67] analyses. Undoubtedly, 
further interrogations of multiple parameters in parallel can be extremely challenging (e.g. 
interpretation of noisy data), but also highly beneficial, not only in the context of cancer 
research. 
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3. METHODS 
3.1. PATIENT SELECTION  
After obtaining written informed consent, breast cancer patients donated 7.5 –15ml of blood in 
EDTA vacutainers at least once. Involved patients were characterized by invasive breast cancer, 
high tumor load, progressive disease at the time of blood sampling and treatment 
discontinuation at the time of CTC isolation (before the next line of therapy). Preselection for 
breast cancer subtype or specific metastatic sites was not applied during enrollment for the 
study. Eligible patients were > 18 years old with any menopausal status and had an Eastern 
Cooperative Oncology Group performance status of 0–3. Disease had to be measurable by 
Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 or non-measurable bone 
only disease. Tumor load was defined by either the size of the primary tumor or the number and 
size of metastatic lymph nodes or distant sites, and patients with higher tumor load were 
prioritized. All blood specimens were obtained at the University Hospital Basel under the study 
protocols approved by the Swiss authorities (EKNZ, Ethics Committee northwest/central 
Switzerland) and in compliance with the Declaration of Helsinki. 
 
3.2. CLINICAL PARAMETER ASSESSMENT  
Primary tumor samples were collected at the initial diagnosis, and IHC was performed for 
estrogen receptor (ER), progesterone receptor (PR), HER2 and Ki-67. If the patient had primary 
metastatic disease, a biopsy from the metastatic site was obtained when possible, including 
marker assessment: ER, PR and HER2. Histopathological diagnosis was conducted by two 
independent pathologists from the breast cancer unit at the University Hospital Basel. All 
patients were treated at the Breast Cancer Unit University Hospital Basel according to local 
standard operating procedures and National Comprehensive Cancer Network and European 
Society for Medical Oncology guidelines by senior breast oncologists. If a patient had a 
progression within new distant sites, a new biopsy from that site was taken, when possible, to 
determine ER, PR and HER2. Patients under systemic treatment had tumor assessment at least 
every 12 weeks with computed tomographic scans or earlier if tumor progression was 
anticipated. CTC collection was performed at progression and prior to the next line of therapy or 
before any treatment was conducted. The patients’ data was retrieved by detailed retrospective 
chart review. Data collection included demographics and disease-specific and treatment-specific 
data including age, gender, primary stage, histologic subtype, ER/PR/HER2 status, grading, Ki- 
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67, date of primary diagnosis and relapse, type of relapse (localized, metastatic), site of distant 
disease, bone-modifying agents (bisphosphonates, denosumab), palliative irradiation, and type 
of systemic treatment, including time on treatment and time to next subsequent treatment. Data 
was correlated with CTC counts. 
 
3.3. BLOOD PARAMETER ASSESSMENT 
Complete blood counts were measured with the ADVIA 120 Hematology Analyzer (Siemens 
Healthcare Diagnostics, Tarrytown, NY, USA) using Multispecies version 5.9.0-MS software 
(Bayer Diagnostics, Tarrytown, NY, USA). Blood samples were taken before each new therapy 
cycle or at least every month, including cancer antigen 15-3 (CA 15-3), alkaline phosphatase, 
Ca2+, C-reactive protein, lactate dehydrogenase, red blood cells (RBC), hemoglobin, 
hematocrit, mean corpuscular volume (MCV), mean corpuscular hemoglobin concentration, 
white blood cells (WBC), neutrophils, lymphocytes, monocytes, eosinophils, basophils, large 
unstained cells, platelets and mean platelet volume (MPV). In the vast majority of cases, blood 
samples were taken simultaneously with the CTC sample or within 7 days after CTCs were 
taken. Eight of 73 patients had only partial data available, whereas no blood counts were 
reported at the time of CTC detection for nine of 73 patients. 
 
3.4. CELL CULTURE  
MDA-MB-231 LM2 human breast cancer cells (obtained from Dr. Joan Massagué, MSKCC, 
NY, USA) and 4T1 murine breast cancer cells (ATCC) were grown in DMEM medium 
(#11330-057, Gibco) supplemented with 10% FBS (#10500064, Gibco) and 
antibiotic/antimycotic (#15240062, Gibco) in a humidified incubator at 37 °C with 20% O2 and 
5% CO2. Py2T cells were a gift from Dr. Gerhard Christofori (University of Basel, Switzerland). 
Human CTC-derived BR16 cells were generated as previously described [68] and propagated as 
suspension cultures in a humidified incubator at 37 °C with 5% O2 and 5% CO2. All cell lines 
were transduced with lentiviruses carrying GFP-Luciferase (GFP) at a multiplicity of infection 
(MOI) < 5. For CRISPR screening 4T1 cells were transduced with the lentiviruses carrying 
pLentiCas9-EGFP (#63592, Addgene) at a MOI of 1. GFP-positive cells were sorted as single 
cells into 96-well plates and cultured as clonal cell lines. Lines with 100% GFP-positivity were 
kept and Cas9 expression was confirmed by western blotting (#844301, Biolegend). 
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3.5. MOUSE EXPERIMENTS  
All mouse experiments were carried out according to institutional and cantonal guidelines 
(approved mouse protocol #2781, cantonal veterinary office of Basel-City).  Nod  Scid  Gamma  
(NSG)  and  Balb/c  mice  were  purchased from The Jakson Laboratory (Bar Harbor, Maine, 
USA) and kept in pathogen-free conditions, accordingly to institutional guidelines. Transgenic 
MMTV-PyMT mice were obtained from Dr. Gerhard Christofori (University of Basel). 
Orthotopic breast cancer lesions were generated in 8-10 weeks old NSG females upon the 
injection with either 1x106 LM2-GFP, 0.5x106 4T1-GFP or 1x106 BR16-GFP cells into the 
mammary fat pad. Similarly, Balb/c mice received a syngeneic graft of 0.5x106 4T1-GFP cells. 
In all cases, breast cancer cells were inoculated in 100µl of 50% Cultrex PathClear Reduced 
Growth Factor Basement Membrane Extract (#3533-010-02, R&D Biosystems) in PBS. Blood 
draw for CTC analysis and organ dissection were performed after 3 weeks for NSG-4T1-GFP, 
4-5 weeks for Balb/c-4T1-GFP and NSG-LM2-GFP, 5 months for NSG-BR16-GFP and at 13 
weeks of age for MMTV-PyMT mice. Generally, immunocompetent models (Balb/c-4T1-GFP 
and MMTV-PyMT) developed a primary tumor that reached the maximum allowed size before 
developing overt metastatic disease. For this reason, they were rather used throughout the 
manuscript as models to assess direct metastatic potential of cancer cells injected directly in the 
venous circulation (i.e. tail vein). In contrast, immunocompromised models (NSG-4T1-GFP, 
NSG-LM2-GFP and NSG-BR16-GFP mice) were used as the preferred system to assess 
spontaneous CTC and metastasis formation from the primary tumor. All experiments whereby 
both immunocompetent and immunocompromised mice were used side by side have led to the 
same conclusions.  
 
3.6. CTC CAPTURE  
Human CTCs were captured from unprocessed peripheral blood samples with the Parsortix 
microfluidic device using Cell Separation Cassettes (GEN3D6.5, ANGLE), within 1 hour from 
blood draw. Next, in-cassette staining was performed with an antibody cocktail containing 
antibodies against EpCAM-AF488 (#CST5198, Cell Signaling Technology), HER2-AF488 
(#324410, BioLegend), EGFR-FITC (#GTX11400, GeneTex) and CD45-BV605 (#304042, 
BioLegend). For mouse experiments, 500–1000µl of blood was collected through cardiac 
puncture and processed immediately on the Parsortix microfluidic device. For tumor-draining 
vessel experiments, the tumor was first exposed by opening the mouse flank. The largest tumor- 
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associated vessel was then localized and approximately 2µl of blood was collected upon a small 
incision. CTCs from the MMTV-PyMT mouse model were stained with antibodies against 
mouse EpCAM-AF488 (#118210, BioLegend) and CD45-BV605 (#103140, BioLegend). For 
all other models (xenografts and syngeneic), carrying cancer cells stably expressing a GFP 
Luciferase reporter, only anti-CD45 staining was performed, while CTCs were identified based 
on GFP expression. The number of captured CTCs, including single CTCs, CTC clusters and 
CTC-WBC clusters, was determined while cells were still in the cassette. CTCs were then 
released from the cassette in DPBS (#14190169, Gibco) onto ultra-low attachment plates 
(#3471-COR, Corning). Representative pictures were taken at 40x magnification with Leica 
DMI4000 fluorescent microscope using Leica LAS and analyzed with ImageJ.  
 
3.7. ASSESSMENT OF THE DIRECT METASTATIC POTENTIAL OF CTCS 
8-10 weeks old NSG females were injected with 0.5x106 4T1-GFP or 1x106 BR16-GFP cells. 8-
10 weeks old Balb/c females were injected with 0.5x106 4T1-GFP cells. Upon tumor 
development, blood was collected via heart puncture and run through the Parsortix device. 
Single CTCs, CTC clusters and CTC-neutrophil clusters were individually micromanipulated 
and 100 cells per mouse (for NSG-4T1-GFP model) or 500 cells per mouse (for NSG-BR16-
GFP and Balb/c-4T1-GFP models) from each category were injected into the tail vein of 
recipient mice (NSG or Balb/c, respectively). Metastasis onset and growth rate in lungs was 
noninvasively monitored on a weekly schedule with the IVIS system, or through lung 
immunohistochemical staining of pan-cytokeratin (#GTX27753, Genetex) at the time of 
experiment termination.  
 
3.8. WHITE BLOOD CELL SORTING  
Reference WBCs were obtained from the peripheral blood of breast cancer patients (n=5) and 
healthy individuals (n=3) after signing informed consent, naïve NSG and Balb/c mice (females 
at 8-12 weeks), Balb/c-4T1-GFP and NSG-CDX-BR16-GFP mouse models at the time of 
experiment termination. In brief, red blood cells, granulocytes and mononuclear cells were 
separated by gradient centrifugation with Lymphoprep (#1114545, STEMCELL Technologies). 
Desired fractions were manually isolated and washed with 1% BSA/PBS buffer. Additionally, 
the granulocyte fraction was purified from contaminating red blood cells by 10 minutes 
incubation in 0.16M ammonium chloride. Unspecific antibody binding was prevented by 
blocking  the  Fc  receptor  for  15  minutes  (human:  #422301,  BioLegend;  mouse:  #101320,  
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BioLegend). Cells were stained with white blood cell markers: human – anti-CD14-APC 
(#301808, BioLegend), anti-CD66b-FITC (#305104, BioLegend), anti-CD3-BV421 (#317344, 
BioLegend), anti-CD19-FITC (#302206, BioLegend), anti-CD335-PE  (#331908, BioLegend)  
anti-CD41-PE/Cy5  (#303708, BioLegend);  mouse – anti-Gr-1-APC/Cy7 (#108423, 
BioLegend), anti-CD11b-APC (#101211, BioLegend), anti-CD3-BV421 (#100227, BioLegend), 
anti-CD19-FITC (#115505, BioLegend) or anti-CD19-BV605 (#115539, BioLegend; for mouse 
models with GFP reporter), anti-CD49b-PE (#108907, BioLegend), anti-CD41-PE/Cy5 
(#133921, BioLegend). Cell populations were determined by the expression of characteristic 
markers: for human granulocytes (CD66b+CD41-), monocytes (CD14+CD3-CD19-CD335- 
CD41-), T cells (CD14-CD3+CD19-CD335-CD41-), B cells (CD14-CD3-CD19+CD335-CD41-), 
NK cells (CD14-CD3-CD19-CD335+CD41-); for mouse granulocytes (Gr-1+CD41-), monocytes 
(CD11b+CD3-CD19-CD49b-CD41-), T cells (CD11b-CD3+CD19-CD49b-CD41-), B cells 
(CD11b-CD3-CD19+CD49b-CD41-), NK cells (CD11b-CD3-CD19-CD49b+CD41-). One 
hundred cells from each population were sorted (FACSAria III, BD Biosciences) directly into 
microcentrifuge tubes containing 2.5µl RLT Plus lysis buffer (#1053393, Qiagen). 
 
3.9. NEUTROPHIL CO-CULTURE WITH TUMOR CELLS  
Human neutrophils were purified from healthy donor blood upon gradient centrifugation with 
LymphoprepTM (Stemcell Technologies). 8’000 neutrophils were added to 100’000 LM2, BR16 
or Brx50 CTC-derived cells and co-cultured in CTC media for 72 hours. Then, gDNA was 
isolated from tumor cells (or untreated control cells) and processed for whole exome 
sequencing. 
 
3.10. EXOME AND TRANSCRIPTOME SEQUENCING  
Individual cells from CTCs alone or CTC-WBC clusters were mechanically separated with 
gentle micromanipulation (CellCelector, ALS). AF488/FITC-positive (or GFP-positive) and 
BV605-negative CTCs or AF488/FITC-negative and BV605-positive WBCs were immediately 
transferred into individual tubes (#321-032-501, Axygen) containing 2.5µl RLT Plus lysis 
buffer (#1053393, Qiagen) and 1U/µl SUPERase In RNase Inhibitor (#AM2694, Invitrogen). 
Samples were immediately frozen on dry ice and kept at -80°C until further processing. 
Following previously published protocol for parallel DNA and RNA sequencing from individual 
cells [69], genomes and transcriptomes of lysed cells were separated and amplified (#25-6601-
97, GE Healhcare for genome and Smart-seq2 from for transcriptome). Reference white blood  
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cells were prepared solely with Smart-seq2 protocol. Libraries were prepared with Nextera XT 
(Illumina), exomes were enriched using SureSelect XT Human All Exon v6+Cosmic kit 
(Agilent technologies) and sequenced on HiSeq 2500 (Illumina) in 100bp paired-end mode for 
DNA sequencing and on NextSeq 500 (Illumina) 75bp single read mode for RNA sequencing. 
 
3.11. DIFFERENTIAL WHITE BLOOD CELL STAINING ON CTC-WBC 
CLUSTERS  
Live CTCs captured within the Parsortix microfluidic cassette were stained with anti-Biotin-
CD45 (#103104, BioLegend) and detected with Streptavidin-BV421 (#405226, BioLegend), 
anti-mouse Ly-6G-AF594 (#127636, BioLegend) and anti-CD11b-AF647 (clone M1/70, kind 
gift from Dr. Roxane Tussiwand, University of Basel) or with anti-F4/80-AF594 (#123140, 
BioLegend) and CD11b-AF647. Additionally, MMTV-PyMT-derived CTCs were marked with 
EpCAM-AF488 (#118210, BioLegend). Next, cells were gently released from the microfluidic 
system into ultra-low attachment plate and immediately imaged (Leica DMI400). The number 
of CTC-WBC clusters with neutrophils (Ly-6G+CD11bmed), monocytes (Ly-6G-CD11bmed/high) 
and macrophages (F4/80+CD11b+) was assessed. Immediately after imaging, cells were 
centrifuged (500rpm, 3 minutes) on a glass slide and fixed in methanol for 1 minute. After brief 
air-drying, slides were stained using Wright-Giemsa stain kit (#9990710, ThermoFisher) to 
visualize nuclear morphology of captured cells, following the manufacturer’s instructions.  
 
3.12. IMMUNOFLUORESCENCE STAINING  
Formalin-fixed, paraffin-embedded (FFPE) sections were obtained from primary tumors and 
metastatic sites of patients with ER/PR-positive breast cancer (Department of Pathology, 
University Hospital Basel) who had detectable CTC-WBC clusters. Similarly, mouse-derived 
primary tumors and metastases were fixed in 4% paraformaldehyde and prepared according to a 
standard paraffin embedding protocol. Human and mouse sections were handled according to a 
standard immunofluorescent paraffin-embedded tissue staining protocol. Briefly, after 
deparaffinization in xylene and re-hydratation, antigen retrieval was carried out in 10mM 
sodium citrate (pH 6.0) at 95°C for 25 minutes. For CTC and DTC staining, cell suspension was 
centrifuged (3min, 500 rpm) on a coated glass slide (#5991056, ThermoFisher) and air-dried. 
Cells were fixed in 4% paraformaldehyde for 12 min and stored in PBS until needed. For both 
FFPE sections and cells, after 1 hour of blocking with 10% horse serum, specimens were co-
stained for pan-cytokeratin (#GTX27753, Genetex) detected with anti-mouse IgG-AF488 (#A- 
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21202, ThermoFisher), myeloperoxidase (#AF3667-SP, R&D) detected with anti-goat IgG-
AF568 (A-11057, ThermoFisher), Ki67 (#ab15580, Abcam) detected with anti-rabbit IgG-
AF647 (A-31573, ThermoFisher) and DAPI (#D1306, ThermoFisher).  
 
3.13. IN VITRO CYTOKINE TREATMENT  
100’000 4T1-GFP cells per well were seeded in a 6-well plate and cultured in growth medium 
overnight. Next morning, cells were washed 3 times with PBS and given starvation medium 
(0.1% FBS). After 48h, the medium was supplemented with 25ng/ml recombinant mouse IL6 
(#575702, BioLegend), IL1β (#575102, BioLegend), TNFα (#575202, BioLegend) and OSM 
(#762802, BioLegend), either individually or in combination. Cells were stimulated for 24h and 
then harvested upon trypsinization, enumerated using automatic cell counter and 300’000 cells 
were injected intravenously into 8-10 weeks old female mice.  
 
3.14. MUTAGENESIS  
Lentiviral vectors with human MERTK (CCSB-Broad LentiORF, CloneId: 
ccsbBroad304_11503, Dharmacon) and human TLE1 (Precision LentiORF, CloneId: 
PLOHS_100005903, Dharmacon) served as base for introduction of specific mutations using 
QuikChange II XL site-directed mutagenesis kit (#200522, Agilent Technologies). Lentiviral 
particles were then prepared with Dharmacon Transduction Starter Kit and upon transduction, 
4T1-GFP cells were selected with 9 µg/ml Blasticidin S for 6 days.  
 
3.15. MYLEOID CELLS DEPLETION  
For neutrophil depletion studies in primary tumor models, mice were injected intraperitoneally 
with 400µg of anti-Ly-6G IgG2a (#127650, BioLegend) or control IgG2a (#400566, 
BioLegend) when tumors were palpable (day two after injection of 4T1-GFP cells, day six after 
injection of LM2-GFP cells and day 30 after injection of BR16-GFP cells). Efficiency of 
immune cell depletion was monitored after 48 hours with Advia120 Hematology Analyzer 
(Siemens) using Multispecies version 5.9.0-MS software (Bayer). Additionally, NSG-4T1-GFP 
mice received a second dosage of anti-Ly-6G or control IgG2a antibodies (100 µg) on day 19, 
NSG-LM2-GFP mice on day 25 and NSG-BR16-GFP mice on day 45. Tumor size was 
determined with caliper measurements every seven days and tumor volume was calculated using 
modified ellipsoid formula: V=1/2(Length × Width2). At termination, lung metastases were  
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measured with IVIS Lumina II (Perkin Elmer) and metastatic index was determined by 
normalizing the photon/second count of the metastasis with that of the primary  tumor.  For 
neutrophil pre-depletion experiments, a single dose of 400µg of anti-Ly-6G IgG2a was injected 
intraperitoneally 24h before tumor cells intravenous inoculation. Mice were sacrificed in 
accordance to our approved protocol and the survival data was inferred accordingly.  
 
3.16. G-CSF OVEREXPRESSION  
Human G-CSF was transduced into 4T1-GFP, LM2-GFP and BR16-GFP cells using the 
Precision LentiORF (GE Healthcare) system. Construct-positive cells were selected with 9µg/ml 
Blasticidin S for 4 days (4T1) or 7 days (LM2, BR16). Overexpression of G-CSF was confirmed 
by qPCR using human-specific primers for LM2 and BR16 cells (Forward: 
5’GAGTTGGGTCCCACCTTG3’, Reverse: 5’TGGAAAGCAGAGGCGAAG3’) or primers 
recognizing both mouse and human transcripts for 4T1 cells (Forward: 5’TGTGCCACCTAC 
AAGCTGTG3’, Reverse: 5’CCATCTGCTGCCAGATGGTGGT3’).  
 
3.17. sgRNA MINIPOOL DESIGN, TRANSDUCTION AND IN VIVO 
TRANSPLANTATION  
All sgRNAs were designed using the GPP Web Portal (https://portals.broadinstitute.org/gpp/ 
public/analysis-tools/sgrna-design) and sgRNA oligos were synthesized by Microsynth. Each 
sgRNA was individually cloned into the pLentiGuide-Puro vector (#52963, Addgene). 4T1-
Cas9-GFP cells were then transduced separately with each individual sgRNA vector at 
MOI=0.4. Upon seven days of puromycin selection, 4T1-Cas9-GFP cells carrying individual 
sgRNAs were mixed in equal cell numbers, taken for genomic DNA extraction and, at the same 
time, subcutaneously injected (≥ 1000 cells per sgRNA; 500’000 total cells) into the mammary 
fad pad of NSG mice.  
 
3.18. sgRNA SEQUENCING  
gDNA was extracted from cells at different stages (prior to injection, upon primary tumor 
growth and from spontaneously formed CTCs) using salt precipitation. The library preparation 
was carried out using two-step PCR, where the first PCR amplifies a broad region including the 
sgRNA sequence cassette and the second PCR adds Illumina sequencing adapters to the 
products from the first PCR, as described previously[70]. Samples were then sequenced on  
- 30 - 
 
 
 
NextSeq 500 SR75 sequencers. After quality control using FastQC (https://www.bioinformatics. 
babraham.ac.uk/ projects/fastqc), reads were trimmed using cutadapt (v1.9.1) and aligned to  the 
sgRNA sequences using bowtie2 (v2.2.9), allowing for one mismatch. The normalized counts of 
each sgRNA were computed by dividing the number of reads for each sgRNA by the library 
size. 
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4. COMPUTATIONAL METHODS 
Note. All of these crucial for my projects computational analyses were performed by 
bioinformatician, Dr. Francesc Castro-Giner. Additional support with E&T-sequencing 
validation was provided by Dr. Robert Ivanek.   
 
4.1. SINGLE-CELL RNA-SEQ DATA PROCESSING  
After sequencing, initial quality assessment for RNA-seq data was performed using FastQC 
(https://www.bioinformatics.babraham.ac.uk/projects/fastqc), FastQ Screen (https://www. 
bioinformatics.babraham.ac.uk/projects/fastq_screen), and visualized with MultiQC (v0.8). 
Adaptor sequences, first 9 base pairs and low-quality ends were removed with Trim Galore 
(v0.4.2, http://www.bioinformatics.babraham.ac.uk/projects/trim_galore/; parameters : --
phred33 --length 36 --clip_R1 9). Trimmed reads were aligned to a combined human (GRCh38) 
and mouse (GRCm38) genome reference using STAR (v 2.5.2a; parameters:  --runMode 
alignReads --genomeLoad LoadAndExit). Quality control of resulting BAM files was 
performed with RSeQC (v2.6.4). The gene-level expression counts were computed with 
featureCounts (v1.5.1) using the gene annotations obtained from RefSeq (release 70). Samples 
with less than 800 features detected (threshold ≥ 1 mapped read) or showing more than 5% of 
contamination from the other species were removed from further analysis. To normalize gene 
counts for cell-specific biases, we used size factors computed utilizing the deconvolution 
implemented in the scran package (v1.6.5) available on R/Bioconductor. After normalization, 
the effect of technical factors (library size and number of detected features) on variance was 
evaluated using t-distributed stochastic neighbor embedding (t-SNE) adjusted by patient or 
mouse model. CTCs showing a substantial contribution of stromal genes and the absence of 
cancer-associated genes, and CTC-associated WBCs showing no expression of CD45 were 
removed from the analysis. scRNA-seq data processing, quality control, and visualization was 
performed with the help the R/Bioconductor package scater (v 1.6.0). 
 
4.2. REFERENCE COMPONENT ANALYSIS  
Reference component analysis (RCA) was utilized to identify single cell types using reference 
transcriptomes. For human samples, the reference bulk transcriptomes were obtained from the 
Human U133A/GNF1H Gene Atlas and the Primary Cell Atlas (http://biogps.org/), averaging 
expression levels when multiple replicates were present. Mouse transcriptomes were obtained 
from  the  Mouse  GNF1M  and  MOE430  Gene  Atlas  (http://biogps.org/).   The   initial   gene  
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selection for the reference transcriptome panel was performed as previously described  [71].  An 
additional filtering of genes was achieved by removing genes specific to CTCs from the human 
panel and by selecting highly variable genes (HVGs) from the mouse panel. A gene was defined 
as CTC-specific if its normalized expression (log-counts) relative to the median across the 
reference WBCs set exceeded 5 in at least 5% of CTC samples. In mouse, only genes that 
showed high variability in their expression across reference WBCs were included. In order to 
select HVGs in mouse, gene-specific variance of expression across reference WBCs was 
estimated using trendVar and decomposed into biological and technical components using 
decomposeVar from scran package. Highly variable genes were selected on the basis of their 
biological component (biological variance ≥ 5) and adjusted P-value (threshold ≤ 0.05). A total 
of 5,279 genes were selected for the human reference panel and 655 for the mouse panel. 
Projection of each sample onto the reference transcriptome was performed as previously 
described[71], calculating the Pearson correlation between the log10 (FPKM) values of the 
scRNA-seq samples and the log10 expression values of the global panel using the functions 
provided by the RCA R package (v1.0; https://github.com/GIS-SP-Group/RCA). For 
visualization, reference cell types with a low correlation with query samples and non-immune 
related features were removed. Hierarchical clustering was performed to cluster samples based 
on their projection values. 
 
4.3. DIFFERENTIAL EXPRESSION AND GENE SET ENRICHMENT 
ANALYSES  
We determined differentially expressed genes by the edgeR likelihood ratio test method 
(v3.20.1) using the normalized counts with the deconvolution approach and the robust 
dispersion of estimates options. Gene set over-representation analysis of KEGG pathways in the 
differentially expressed genes (adjusted p-value threshold ≤ 0.25) was performed with the kegga 
method implemented in the edgeR R/Bioconductor package (v3.20.1). Enrichment of the KEGG 
pathways ‘Cell cycle’ (hsa04110) and ‘DNA replication’ (hsa03030) in patient samples was 
tested with the self-contained rotation gene set test (roast) from the limma R/Bioconductor 
package (3.34.2) using the msq option as a gene set summary statistic and 5’000 rotations to 
compute p-values. 
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4.4. CYTOKINE AND CYTOKINE LIGAND ANALYSIS  
A comprehensive collection of cytokines and their receptors was obtained from KEGG pathway 
‘Cytokine-cytokine receptor interaction’ (accession codes hsa04060 and mmu04060 for human 
and mouse, respectively). Next, human one-to-one orthologous genes for the mouse gene set 
were obtained from Ensembl (v91) using the biomaRt (v2.34) R/Bioconductor package in order 
to combine human and mouse datasets. A cytokine-receptor pair was considered to be expressed 
in a CTC-neutrophil cluster if the cytokine gene in the neutrophil sample and its corresponding 
receptor in the CTC were expressed at log2 normalized counts per million mapped reads (CPM) 
≥ 5. For CTC-neutrophil clusters containing more than one detached CTC, all possible CTC-
neutrophil pairs were considered. 
 
4.5. SINGLE-CELL DNA-SEQ DATA PROCESSING  
Paired-end reads were aligned to the GRCh38 human or GRCm38 mouse reference genomes 
using BWA-mem algorithm (v0.7.13; parameters: -M) (https://arxiv.org/abs/1303.3997) and 
sorted using SAMtools (v1.3.1). Reads were then deduplicated using Picard MarkDuplicates 
(v2.9.0; http://picard.sourceforge.net/) on a per-sample basis and local realignment was 
performed using the Genome Analysis Toolkit (GATK) IndelRealigner (v3.7.0) at the sample 
and donor level to improve alignment accuracy around indels. Quality control and coverage and 
exome enrichment statistics were generated using FastQC, CollectHsMetrics from Picard suite, 
and QualiMap (v 2.2.1) and visualized using MultiQC (v0.8). 
 
4.6. SOMATIC MUTATION CALLING AND MUTATION SPECTRUM  
Mpileup files were generated with SAMtools (v1.3.1; parameters: -B -q 40) and variants were 
called using Monovar (v2016-05-14) on all samples from the same donor simultaneously. 
Resulting variants were annotated using SnpEff on ENSEMBL v86 (www.ensembl.org), dbSNP 
(build 150), 1000 genomes project (phase 1), and coding mutations from cosmic (v81) using 
SnpSift (v4.3p). Somatic mutation rates were calculated as the ratio of the number of somatic 
variants and the number of nucleotides covered in the exome at ≥ 2x. Putative damaging somatic 
mutations were identified exclusively in donors with matched WBC sequenced using an 
empirical filtering strategy removing (1) variants present in public databases (dbSNP, 1000 
genomes project) at a frequency ≥ 1% or found in 2 or more founders, (2) variants present in at 
least one reference WBC sample from the same donor, (3) variant  loci  not covered in reference  
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WBC samples (threshold ≥ 3 reads), and (4) likely damaging events (truncating, frameshift or 
splice site variant). VCF processing, downstream filtering, and analysis was performed using the 
VariantAnnotation and vcfR R/Bioconductor packages. Trinucleotide context of the somatic 
mutation spectrum was generated and visualized with the SomaticSignatures package (v2.14.0). 
 
4.7. SURVIVAL ANALYSES  
Survival analyses were performed using the survival R package (v 2.41-3). Kaplan-Meier curves 
were generated and Log-Rank test was used to estimate the significance of the difference in 
survival between groups. For patients, progression-free survival was defined as the period of 
time between primary tumor diagnosis and first relapse. For NSG-4T1-GFP mouse model 
analysis, death was selected as the endpoint for the analysis and defined as the moment a given 
animal had to be euthanized according to our mouse protocol guidelines. 
 
4.8. STATISTICAL ANALYSIS OF CLINICAL PARAMETERS  
We first screened our data to exclude variables and patients with high content of missing 
information, as well as observations with implausible values. Cancer therapies were simplified 
into three main nonexclusive categories (targeted therapy, chemotherapy and hormone therapy). 
Some patients had undergone multiple lines of therapy. For this reason, we assessed the effects 
of accumulated therapies and the therapy at CTC evaluation separately. We investigated the 
association between the different variables of interest and the presence of CTCs using Fisher’s 
exact test for categorical variables, two-sided Wilcoxon rank-sum test for continuous variables 
(e.g., complete blood counts) and Kruskal-Wallis test for ordinal variables with more than two 
levels (e.g., stage at diagnosis). For each test, we present the nominal P value. An estimate and 
95% CI are also provided for continuous and two-level categorical variables. The estimate 
corresponds to the OR in Fisher’s exact test and to the estimated median of the difference 
between samples from both groups in the Wilcoxon rank-sum test. To account for potential 
confounding variables, logistic regression analysis was conducted, adjusting by age at primary 
diagnosis, tumor stage at diagnosis, tumor grade and histologic subtype. Adjusted P values were 
calculated following the Benjamini-Hochberg method, combining all tests performed in this 
work. Associations with an adjusted P value ≤ 0.05 are highlighted in the text. We conducted 
the data wrangling and statistical analysis in R (version 3.4.0; R Foundation for Statistical 
Computing, Vienna, Austria).  
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5. RESULTS 
 
5.1. FIRST-AUTHOR MANUSCRIPTS 
 
5.1.1. “NEUTROPHILS ESCORT CTCS TO ENABLE CELL CYCLE PROGRESSION” [72] 
 
Circulating tumor cells (CTCs) are precursors of metastasis in various solid cancers including 
breast cancer [73], and are occasionally found in association to white blood cells (WBCs) [26]. 
The role of CTC-WBC clusters in metastasis development as well as the principles that govern 
the interplay between CTCs and WBCs during blood-borne metastasis are largely 
uncharacterized.  
 
We first sought to determine the number and composition of CTC-WBC clusters in breast 
cancer patients and mouse models. We obtained blood samples from 70 patients with invasive 
breast cancer that discontinued their treatment due to progressive disease, as well as from five 
different breast cancer mouse models, and we enriched for CTCs using the Parsortix 
microfluidic device [74] (Extended Data Fig. 1a-e). Live CTCs were stained for cancer-
associated cell surface markers EpCAM, HER2, and EGFR or imaged directly for the 
expression of GFP, as well as labeled for CD45 to identify WBCs (Fig. 1a and Extended Data 
Fig. 1f). Among 70 patients, 34 (48.6%) had detectable CTCs, with a mean number of 22 CTCs 
per 7.5ml of blood (Supplementary Tables 1 and 2). While the majority of CTCs were single 
(88.0%), we also detected CTC clusters (8.6%) and CTC-WBC clusters (3.4%) (Fig. 1b and 
Extended Data Fig. 1g,h). Similarly, we observed that CTC-WBC clusters were present in all 
tested mouse models, comprising those with immunodeficient or immunocompetent 
background, ranging from 0.05% to 61% of the total CTC population (Fig. 1b and Extended 
Data Fig. 1i,j). Importantly, CTC abundance and ratios dramatically changed when drawing 
blood upstream of capillary beds as opposed to more downstream locations, indicating that 
clustered CTCs are shed early, yet may be trapped in capillaries before reaching the periphery 
(Extended Data Fig. 1k-n). Thus, CTC-WBC clusters are rare in the peripheral circulation, yet 
consistently found across breast cancer patients and mouse models. 
 
We then asked what type of WBCs is found in CTC-WBC clusters. We made use of a robotic 
micromanipulator to dissociate CTC-WBC clusters, enabling single-cell RNA sequencing 
analysis  of  cluster-associated  WBCs and  their  comparison to  reference WBCs from matched  
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donors (Fig. 1c) using reference component analysis (RCA) [71]. In patients, we found that 75% 
of  CTC-associated  WBCs  relate  to  the  myeloid  lineage, while the remaining ones (25%) are 
similar to T cells (Fig. 1d and Extended Data Fig. 2a,b). Similarly, we found that 93% of CTC-
associated WBCs from mouse models are also characterized by a myeloid cell-like expression 
profile (Extended Data Fig. 2c-e). To dissect the exact proportion of CTC-associated WBCs that 
are neutrophils, monocytes or macrophages, we labeled CTC-WBC clusters for Ly-6G, CD11b, 
F4/80, as well as with Wright-Giemsa staining to define nuclear morphology (Extended data 
Fig. 2f,g). We found that the vast majority (85.5-91.7%) of CTC-associated WBCs are positive 
for Ly-6G and display a nuclear morphology typical of neutrophils, while a minority (8.3-
14.5%) are monocytes (CD11b+/F4/80-/Ly-6G-) and no F4/80+ macrophages are found (Fig. 1e,f 
and Extended Data Fig. 2h-j). Further, RNA sequencing analysis also revealed ARG1, CXCL1, 
CXCL2, CXCL10, CCL2, CXCR2 and VEGFA expression in most CTC-associated neutrophils 
from both patients and mouse models (Extended Data Fig. 2k), indicating that CTC-associated 
neutrophils share gene expression features of pro-tumor N2-like cells [75].  
 
We next asked whether the presence of CTC-neutrophil clusters in breast cancer patients could 
predict disease outcome. Strikingly, patients in whom at least one CTC-neutrophil cluster is 
detected in 7.5ml of peripheral blood are characterized by a significantly worse progression-free 
survival compared to patients with ≥ 5 CTCs per 7.5ml of peripheral blood (previously defined 
as a threshold for adverse outcome [76]) (Fig. 1g), as well as when compared to all patients with 
no CTC-neutrophil clusters, patients with at least one CTC per 7.5ml of blood, or patients in 
whom either single CTCs or CTC clusters are found (Extended Data Fig. 3a-c). Additionally, 
we individually micromanipulated equal numbers of CTCs from CTC-neutrophil clusters, CTC 
clusters and single CTCs, spontaneously generated from tumor-bearing mice, and intravenously 
injected 100 CTCs per mouse in tumor-free recipient mice from each of these categories. We 
found that mice injected with CTCs from CTC-neutrophil clusters develop overt metastasis 
much faster than those injected with CTCs alone, and accordingly, survive less (Fig. 1h and 
Extended Data Fig. 3d-h). Thus, CTC-neutrophil clusters represent the most efficient metastasis-
forming cell subpopulation among breast CTCs, and their presence in the bloodstream of 
patients is associated with a poor prognosis. 
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Figure 1. CTC-neutrophil clusters are highly-efficient metastatic precursors. a, Representative images of a 
CTC–WBC cluster, a CTC cluster and a single CTC from NSG-CDX-BR16-GFP mice. CTCs are expressing GFP 
(green) and CTC-associated WBCs are labelled with anti-CD45 antibodies (red) (n = 8). b, Pie charts displaying the 
mean percentage of single CTCs (grey), CTC clusters (green) and CTC–WBC clusters (red) in patients with breast 
cancer and in mouse models. The number of independent biological replicates (n) is shown for each model. c, 
Schematic of the experimental design. CTC–WBC clusters are dissociated into individual cells and processed for 
RNA sequencing (RNA-seq). The transcriptome of CTC-associated WBCs is then compared to reference (ref.) 
WBCs. d, Reference component analysis clustering of CTC-associated WBCs and reference WBCs from patients 
with breast cancer, displaying projection scores of cells (columns; n = 50) on the immune reference panel (rows). e, 
Representative images of CTC–WBC clusters stained for Ly-6G (neutrophils, gold) together with GFP (cancer 
cells, green) (top) or processed with the Wright–Giemsa (WG) assay to define nuclear morphology (bottom) 
(n = 8). f, Pie charts showing the mean percentage of CTC–neutrophil clusters and CTC–monocyte clusters in 
individual models. The number of independent biological replicates (n) is shown for each model. g, Kaplan–Meier 
plot showing progression-free survival of patients with breast cancer (n = 9 for patients with one or more CTC–
neutrophil clusters and n = 10 for patients with five or more CTCs); P value by two-sided log-rank test is shown. h, 
Schematic of the experimental design. One hundred CTCs from CTC–neutrophil clusters or CTCs alone are 
injected in the tail vein of recipient mice to measure their metastatic potential (left). Kaplan–Meier plot showing 
overall survival of mice (right). n = 5 for CTC–neutrophil clusters and n = 10 for CTCs alone; P value by two-sided 
log-rank test is shown. 
 
 
We next sought to determine the molecular consequences of the interaction between CTCs and 
neutrophils by dissociating CTC-neutrophil clusters and comparing the expression profile of 
CTCs from CTC-neutrophil clusters to that of CTCs alone (Fig. 2a). We first determined 
differential  gene  expression in the Balb/c-4T1-GFP model, where we could retrieve the highest  
 
 
- 38 - 
 
 
 
number of CTCs from CTC-neutrophil clusters (n=25). Compared to CTCs that were not 
associated to neutrophils, we found that CTCs from CTC-neutrophil clusters are characterized 
by differential expression of a set of 51 genes, of which 41 are upregulated and 10 are 
downregulated (Fig. 2b and Supplementary Tables 3,4). Pathway analysis with the upregulated 
genes revealed that CTCs from CTC-neutrophil clusters display a remarkable enrichment in 
positive regulators of cell cycle and DNA replication programs compared to CTCs alone (Fig. 
2c), independently of the number of detected features or reads in each individual sample 
(Extended Data Fig. 4a). The same results were also obtained from CTCs of patients (Fig. 2c 
and Extended Data Fig. 4b). Immunofluorescence staining of CTCs confirmed higher levels of 
Ki67 expression in CTCs from CTC-neutrophil clusters (Fig. 2d,e), in line with the RNA 
sequencing results. In contrast, no significant differences were observed for genes involved in 
epithelial-to-mesenchymal transition, cancer stem cell markers, or platelet-related genes [77] 
(Extended Data Fig. 4c-h). Further, we asked whether neutrophil proximity would confer a 
proliferative advantage to cancer cells at the level of the primary tumor, disseminated tumor 
cells (DTCs) and overt metastasis. Surprisingly, we found that Ki67 expression does not 
increase in cancer cells that surround tumor-infiltrated neutrophils in the primary tumor or overt 
metastasis (Extended Data Fig. 5a-d). Yet, a higher Ki67 expression is retained in DTCs from 
CTC-neutrophil clusters (Extended Data Fig. 5e,f), i.e. when they are deprived of other stromal-
derived signals that are typical of overt disease.  
 
We then asked which cytokines are expressed by CTC-associated neutrophils and paralleled by 
simultaneous expression of matching cytokine receptor(s) in the corresponding cancer cells. We 
found that four cytokines (TNFα, OSM, IL1β, and IL6) are most frequently expressed by CTC-
associated neutrophils of patients or patient-derived mouse models, and matched by the 
expression of their receptors by the corresponding cancer cells (Extended Data Fig. 6a). With a 
reverse approach, we also found that CTCs from CTC-neutrophil clusters most frequently 
express cytokines such as CSF1, CSF3 (a.k.a. granulocyte colony-stimulating factor, G-CSF), 
TGFβ3, and IL15, possibly involved in neutrophil stimulation [78-81], while corresponding 
neutrophils express their receptors (Extended Data Fig. 6b). Consistently, we observed that a 
24h in vitro treatment (coherent with neutrophil lifespan [82]) with IL6, IL1b or both was 
sufficient to confer proliferative advantage to 4T1 cells upon dissemination, leading to faster 
metastasis development and shorter overall survival of mice (Fig. 2f,g and Extended Data Fig. 
6c-e). Further,  CRISPR-mediated  knockout  of  IL6  or  IL1b  receptors in cancer cells, namely  
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IL6ST and IL1R1, did not alter the frequency of spontaneously-generated CTC-neutrophil 
clusters but it suppressed their proliferative advantage (Extended Data Fig. 6f-h). 
  
 
 
 
 
 
 
 
 
 
 
 
Figure 2. CTCs from CTC-neutrophil clusters are highly proliferative. a, Schematic of the experimental 
design. CTC–neutrophil clusters are dissociated and then processed for RNA sequencing. The transcriptome of 
CTCs from CTC–neutrophil clusters is compared to that of CTCs alone. b, Heat map of genes differentially 
expressed between CTCs from CTC–neutrophil clusters (n = 25) and CTCs alone (n = 4), isolated from BALB/c-
4T1-GFP mice. The heat map displays gene-scaled (z-score) log2 counts per million mapped reads values after 
normalization, with columns representing samples (n = 29) and rows representing genes (q < 0.05 by edgeR 
likelihood ratio test). c, KEGG pathways over-represented (P < 0.05 by one-sided hypergeometric test) among 
upregulated genes in CTCs of CTC–neutrophil clusters from BALB/c-4T1-GFP mice (left) and test of selected 
pathways in patients (P < 0.05 by rotation gene set test (ROAST); right). d, Representative pictures of CTC–
neutrophil clusters and CTCs alone from NSG-CDX-BR16-GFP mice, stained for pan-cytokeratin (pCK, green), 
myeloperoxidase (MPO, gold), Ki67 (purple) and DAPI (nuclei, blue) (n = 3). e, Plots showing the mean 
percentage of Ki67-positive CTCs. n = 3 for all; error bars, s.e.m.; P values by two-sided Student’s t-test are 
shown. f, Schematic of the experimental design. 4T1-GFP cells are stimulated for 24 h with IL6, IL-1β or both 
(pool), then injected in recipient mice to assess their metastatic potential. g, Kaplan–Meier survival analysis of NSG 
(left) or BALB/c (right) mice injected with cytokine-treated 4T1-GFP cells. n = 4 for NSG-4T1-GFP, n = 3 for 
BALB/c-4T1-GFP, P values by two-sided log-rank test are shown. 
 
 
Given recent findings highlighting that the presence of myeloid cells in the primary tumor site 
leads to accumulation of mutational events [83], we asked whether the mutational load of CTCs 
obtained from CTC-neutrophil clusters is different from that of CTCs alone in patients (Fig. 3a).  
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Interestingly, we found that the mutational burden is similar both between CTCs isolated from 
CTC-neutrophil clusters and CTC alone, as well as when comparing donors with or without 
CTC-neutrophil clusters (Extended Data Fig. 7a,b). Yet, we observed that the overall frequency 
of C>T mutations was increased in CTCs from CTC-neutrophil clusters compared to CTCs 
alone, as well as in donors with CTC-neutrophil clusters, independently of the nucleotide 
context (Fig. 3b and Extended Data Fig. 7c,d). While a general, age-related accumulation of 
C>T mutations has been reported [84], we did not observe any age difference between the two 
groups (Extended Data Fig. 7e). Next, considering only high-impact mutations, we asked 
whether specific genes are exclusively and recurrently mutated in donors with CTC-neutrophil 
clusters. This scenario would be consistent with a model whereby certain genetic alterations 
would influence the recruitment of immune cells to the primary tumor [85], and increase the 
likelihood of generating CTC-neutrophil clusters. We found that a number of genes are indeed 
carrying high-impact mutations exclusively in donors with CTC-neutrophil clusters (Extended 
Data Fig. 7f and Supplementary Table 5). We then engineered 4T1-GFP cells to individually 
express all the mutations found in two of the most frequently mutated genes, i.e. MERTK and 
TLE1, and injected them in the mammary gland of NSG mice. We observed that the 
introduction of TLE1 mutations 1787G>A or 1509G>C leads to a higher infiltration of 
neutrophils in the primary tumor and a higher proportion of spontaneously-generated CTC-
neutrophil clusters (33-41-fold increase), without affecting primary tumor size (Fig. 3c and 
Extended Data Fig. 7g-k). These results are in line with recent observations involving TLE1 
function in regulating myeloid cells infiltration into normal and neoplastic tissues[86]. 
Conversely, co-culture of cancer cells with neutrophils did not result in the acquisition of 
mutations within the same hotspots (Extended Data Fig. 8a,b). Together, our data reveals that 
while the overall mutational load remains unchanged, donors with CTC-neutrophil clusters 
feature a higher proportion of C>T substitutions and the presence of high-impact recurrent 
mutations in genes that promote neutrophil recruitment, such as TLE1.  
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Figure 3. Whole-exome sequencing highlights recurrent mutational events in CTCs from CTC-neutrophil 
clusters. a, Schematic of the experimental design. CTC–neutrophil clusters are dissociated and then processed for 
whole-exome sequencing (WES). CTCs that were associated to neutrophils are compared to CTCs alone. b, 
Mutation distribution in CTCs from CTC–neutrophil clusters (n = 14) compared to CTCs alone (n = 56). Lines 
within the violin plots show the 25th, 50th and 75th percentile, respectively, and dots represent individual CTCs. P 
value by two-sided Wilcoxon sign-ranked test is shown. c, Pie charts displaying the mean percentage of single 
CTCs (grey), CTC clusters (green) and CTC–neutrophil clusters (gold) in mice injected with 4T1-pLOC, 4T1-TLE1 
WT, 4T1-TLE1 G1787A or 4T1-TLE1 G1509C cells (top). The number of independent biological replicates (n) is 
shown for each condition. The plots show the mean fold change of CTC ratios (bottom). n = 3; error bars, s.e.m.; P 
values by two-sided Student’s t-test are shown. 
 
 
We next tested whether the depletion or augmentation of the total neutrophil population would 
affect the ratio of spontaneously-generated CTC-neutrophil clusters. We depleted neutrophils by 
in vivo treatment with neutralizing antibodies against Ly-6G (αLy-6G) or conversely, we stably 
overexpressed G-CSF to stimulate the production and recruitment of neutrophils to the tumor 
site (Extended data Fig. 9a). As expected, while treatment with αLy-6G reduced neutrophil 
infiltration to the primary tumor site, G-CSF augmented it without altering primary tumor size 
(Extended Data Fig. 9b,c). Yet, αLy-6G-treated mice completely lack CTC-neutrophil clusters 
from the circulation and display a delayed CTC shedding rate compared to control mice, while 
overexpression of G-CSF leads to an earlier CTC release and substantially increases the 
proportion of CTC-neutrophil clusters (>88-fold) (Fig. 4a and Extended Data Fig. 9d-f). 
Consequently, neutrophil depletion or augmentation results in a delayed or accelerated 
metastasis development, respectively, mirrored by a shorter or longer overall survival of treated 
mice (Extended Data Fig. 9g,h). In contrast, neutrophil depletion with αLy-6G is not effective 
when cancer cells are administered directly through intravenous injection of pretreated mice 
(Extended Data Fig. 9i-l).  Of  note,  in  our  cohort,  G-CSF  treatment  of breast cancer patients  
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occurred more often in those patients that were positive for CTCs, including CTC-WBC clusters 
(Extended Data Fig. 9m). Thus, overall neutrophil abundance impacts the likelihood that a 
tumor has to spontaneously shed CTC-neutrophil clusters. 
 
We next sought to identify actionable vulnerabilities of CTC-neutrophil clusters without 
targeting the entire neutrophil population. To this end, we investigated cell-cell junction pairs 
expressed by CTC-neutrophil clusters and possibly mediating their heterotypic cell binding 
(Extended Data Fig. 10a,b). We engineered a CRISPR/Cas9-based loss-of-function minipool 
screen in vivo, whereby a pool of cells carrying individual knockouts for F11R, ICAM1, ITGB2 
and VCAM1 are injected in the mammary gland of recipient mice, followed by CTC targeted 
barcode sequencing to reveal selective sgRNA dropouts, highlighting genes whose knockout 
does not allow CTC-neutrophil clusters formation (Fig. 4b). Importantly, we observed no 
differences in primary tumor growth and no selective sgRNA dropouts in primary tumor cells 
(Extended Data Fig. 10c,d), suggesting that knockout of F11R, ICAM1, ITGB2 or VCAM1 does 
not affect proliferation in the primary tumor. Yet, we found that 4/4 VCAM1 sgRNAs selectively 
dropped out in CTCs from CTC-neutrophil clusters, while they were still present in CTCs alone 
(Fig. 4c), highlighting a possible VCAM1 requirement for CTC-neutrophil clusters formation. 
We further validated this finding using individual sgRNAs (Fig. 4d and Extended Data Fig. 
10e). Thus, VCAM1 functionally mediates the interaction between CTCs and neutrophils, and 
its inhibition does not allow the formation of CTC-neutrophil clusters.  
 
 
 
 
 
 
 
 
Figure 4. Identification of vulnerabilities of CTC-neutrophil clusters. a, Pie charts displaying the mean 
percentage of single CTCs (grey), CTC clusters (green) and CTC–neutrophil clusters (gold) in NSG-4T1-GFP mice 
treated with anti-Ly-6G antibodies or G-CSF overexpression (top). W, weeks upon tumour development. The 
number of independent biological replicates (n) is shown for each condition. The plots show the mean fold change  
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of CTC ratios from NSG-4T1-GFP mice treated with anti-Ly-6G antibodies or G-CSF overexpression (bottom). 
Error bars, s.e.m.; P values by two-sided Student’s t-test are shown. b, Schematic of the experimental design. 4T1-
Cas9-GFP cells are transduced with a pool of sgRNAs targeting cell–cell junctions and injected in NSG mice. 
Upon tumour development, spontaneously generated CTC–neutrophil clusters, CTC clusters and single CTCs are 
sequenced to identify sgRNA dropouts. c, Bar plot showing the fold change (log2) of individual sgRNAs (numbered 
1 to 4) found in CTCs from CTC–neutrophil clusters versus CTCs alone. sgRNAs with a representation that was 
reduced in CTCs from CTC–neutrophil clusters are shown in dark red (n = 3). d, Pie charts displaying the mean 
percentage of single CTCs (grey), CTC clusters (green) and CTC–neutrophil clusters (gold) in NSG mice carrying 
4T1-Cas9-GFP tumours expressing a control sgRNA or individual sgRNAs targeting Vcam1 (Vcam1-KO) (top). 
The number of independent biological replicates (n) is shown for each condition. The plot shows the mean fold 
change of CTC ratios from mice carrying 4T1-Cas9-GFP tumours expressing a control sgRNA or individual 
sgRNAs targeting Vcam1 (bottom). Error bars, s.e.m., P value by two-sided Student’s t-test is shown. 
 
Altogether, our data provide new insights into the processes that define the interaction between 
cancer cells and immune cells during blood-borne dissemination (Fig. 5) We propose a model 
whereby neutrophils directly interact with CTCs to support cell cycle progression in circulation 
and to accelerate metastasis seeding. This mechanism of metastatic spread and the possibility 
that CTC-neutrophil clusters may be targeted therapeutically provides an opportunity to reduce 
the spread of breast cancer.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Graphic representation of key findings. Image from ‘Sticking together helps cancer to spread’ by 
Egeblad and de Visser, Nature 2019 [87].  
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Extended Data Figure 1. CTC capture in breast cancer patients and mouse models. a, Schematic of the CTC 
capture strategy with the Parsortix device. b, Schematic of the experimental design. 50 single CTCs and 50 CTC 
clusters are spiked into blood to assess capture rate. c, Representative pictures of CTCs and WBCs captured on the 
Parsortix device and stained for EpCAM, HER2, EGFR (green) and CD45 (red) (left); n=3. The plot shows the 
mean CTC capture efficiency (right); n=3; error bars represent S.E.M. d, Schematic of the experimental design. 50  
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single CTCs are spiked into blood to evaluate artificial CTC aggregation rate during processing. e, Representative 
picture of captured CTCs (left); n=3. The plot shows the mean percent of captured single CTCs, CTC clusters and 
CTC-WBC clusters (right); n=3; error bars represent S.E.M. f, Representative pictures of CTCs from patients and 
mouse models. n=34 for patients; n=8 for NSG-LM2-GFP and NSG-4T1-GFP; n=7 for Balb/c-4T1-GFP; n=5 for 
MMTV-PyMT. g, The plot shows mean CTC counts in patients. n=34; error bars represent S.E.M. h, The plot 
shows the number of CTCs in each patient-derived CTC-WBC cluster. The red line represents the mean. i, The 
plots show mean CTC counts in mouse models. n=8 for NSG-CDX-BR16-GFP, NSG-LM2-GFP and NSG-4T1-
GFP; n=7 for Balb/c-4T1-GFP; n=5 for MMTV-PyMT. Error bars represent S.E.M. j, The plot shows the number 
of CTCs in each mouse model-derived CTC-WBC cluster. The red line represents the mean. k, Pie charts 
displaying the mean percentage of single CTCs (grey), CTC clusters (green) and CTC-WBC clusters (red) in mice 
upon blood draw via heart puncture (HP) or tumor-draining vessel (TDV) (left). The plots show the mean number 
of CTCs from the same experiment (right). Error bars represent S.E.M.; n=5 for NSG-CDX-BR16-GFP, n=3 for 
NSG-LM2-GFP; P values by two-sided Student’s t test are shown. l, The plots show fold change of CTC counts, 
comparing HP versus TDV blood draw. Error bars represent S.E.M.; n=5 for NSG-CDX-BR16-GFP, n=3 for NSG-
LM2-GFP; P values by two-sided Student’s t test are shown. m, The plots show the number of CTCs in each 
mouse model-derived CTC-WBC cluster, isolated via HP or TDV. The red lines represent the mean. P values by 
two-sided Student’s t test are shown. n, The plot shows the mean number of CTCs at day 10 after tumor 
inoculation, collected from HP, TDV or peripheral circulation (i.e. tail vein; PC). Error bars represent S.E.M.; n=3; 
P values by two-sided Student’s t test are shown.  
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Extended Data Figure 2. Characterization of CTC-associated WBCs. a, Bar plot showing the expression levels 
of white blood cell (WBC) marker CD45 in patient samples, including CTC-associated WBCs (red), free-floating 
peripheral WBCs (blue) and CTCs alone (green). b, Principal component analysis (PCA) of CTC-associated WBCs  
LETTER RESEARCH
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of patients and five reference WBC populations. n=50. c, Bar plot showing the expression levels of CD45 in mouse 
samples, including CTC-associated WBCs (red) and CTCs alone (green). d, PCA of CTC-associated WBCs from 
all mouse models and five reference WBC populations. n=47. e, Reference component analysis clustering of CTC-
associated WBCs (red) and reference WBCs from mouse models, displaying projection scores of cells (columns; 
n=47) on the immune reference panel (rows). f, Representative immunofluorescence images of mouse immune 
cells stained for CD45, Ly-6G and CD11b. Mouse lymphocytes (CD45+/Ly-6G-/CD11b-), mouse monocytes 
(CD45+/Ly-6G-/CD11b+), and mouse granulocytes (CD45+/Ly-6G+/CD11blow) are shown (top). Representative 
immunofluorescence images of mouse lymphocytes and macrophages (peritoneum-derived) stained for F4/80 are 
shown (bottom). Mouse macrophages display a F4/80+ phenotype, while lymphocytes display a F4/80- phenotype. 
n=3 for all. g, Representative images of human and mouse T cells, B cells, NK cells, monocytes and granulocytes 
stained with the Wright-Giemsa protocol to highlight nuclear morphology (left). Wright-Giemsa staining of the 
human CTC-derived cell line BR16 is also shown (right). n=3 for all. h, Representative immunofluorescence 
images of CTC-neutrophil clusters and CTC-monocyte clusters isolated from mouse models and stained for Ly-6G 
(gold) and CD11b (blue). CTCs stably express GFP (green). n=8 for NSG-CDX-BR16-GFP, NSG-LM2-GFP and 
NSG-4T1-GFP; n=7 for Balb/c-4T1-GFP. i, Representative images of CTC-neutrophil clusters stained with the 
Wright-Giemsa protocol to highlight nuclear morphology. n=8 for NSG-CDX-BR16-GFP, NSG-LM2-GFP and 
NSG-4T1-GFP. j, Bar graph showing the mean number of CTC-neutrophil clusters and CTC-monocyte clusters in 
mouse models. Error bars represent S.E.M.; n=8 for NSG-CDX-BR16-GFP, NSG-LM2-GFP, NSG-4T1-GFP and 
n=7 for Balb/c-4T1-GFP. k, Heatmaps showing the projection scores of mouse-derived (left) and patient-derived 
(right) CTC-associated neutrophils (columns) on pro-tumoral (N2) neutrophil markers (rows). 
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Extended Data Figure 3. Progression-free survival analysis in breast cancer patients and mouse models. a, 
Kaplan-Meier progression-free survival (PFS) analysis comparing patients with ≥1 CTC-neutrophil cluster per 
7.5ml of peripheral blood (n=9) versus all patients with no CTC-neutrophil clusters (n=48); P value by two-sided 
Log-Rank test is shown. b, Kaplan-Meier PFS analysis comparing patients with ≥1 CTC-neutrophil cluster per 
7.5ml of peripheral blood (n=9) versus patients with ≥1 CTC per 7.5ml of peripheral blood but no CTC-neutrophil 
clusters (n=21); P value by two-sided Log-Rank test is shown. c, Kaplan-Meier PFS analysis comparing patients 
with ≥1 CTC-neutrophil cluster per 7.5ml of peripheral blood (n=9), patients with ≥1 single CTC per 7.5ml of 
peripheral blood  but  without  CTC-neutrophil  clusters  (n=14),  and  patients  with ≥1  CTC  cluster  per  7.5ml of  
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peripheral blood but without CTC-neutrophil clusters (n=7).; P value by two-sided Log-Rank test is shown. Of 
note, these results are consistent with our previous observations whereby PFS differences in patients with single 
CTCs versus CTC-clusters were visible only when CTC clusters were present for multiple time points along disease 
progression. d, Schematic of the experimental design. 100 CTCs from CTC-neutrophil clusters, CTC clusters or 
single CTCs are injected in the tail vein of tumor-free recipient mice to measure their metastatic potential. e, The 
plot shows normalized bioluminescence signal from the lungs of injected mice. n=5 for all; Error bars represent 
S.E.M.; *P< 0.05 by two-sided Student’s t test. f, Kaplan-Meier plot showing overall survival of injected mice. n=5 
for all; P values by two-sided Log-Rank test are shown. g, Representative picture of a metastatic lesion in NSG 
mice injected intravenously with either with CTC-neutrophil clusters, CTC clusters or single CTCs from NSG-
BR16-GFP mice. Metastases are stained for pan-cytokeratin (pCK; green) and DAPI (nuclei; blue) (left); n=3. The 
plot shows the mean number of metastatic foci per field of view (right). n=3; Error bars represent S.E.M; P values 
by two-sided Student’s t test are shown. h, Representative picture of a metastatic lesion in the lungs of Balb/c mice 
injected intravenously with either with CTC-neutrophil clusters, CTC clusters or single CTCs from Balb/c-4T1-
GFP mice. Metastases are stained for pan-cytokeratin (pCK; green) and DAPI (nuclei; blue) (left); n=3. The plot 
shows the mean number of metastatic foci per field of view (right). n=3; Error bars represent S.E.M; P values two-
sided Student’s t test are shown. 
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Extended Data Figure 4. Gene expression analysis of single-cell RNA sequencing data. a, t-distributed 
stochastic neighbor embedding (t-SNE) analysis of CTCs from CTC-neutrophil clusters and CTCs alone using the 
500 most variable genes. t-SNE plots for Balb/c-4T1-GFP samples are colored by number of detected genes (left) 
and number of reads per sample (right). n=29. b, t-SNE plots for patient samples colored by number of detected 
genes (left) and number of reads per sample (right). n=68.  c, Heatmap showing the projection scores of mouse 
model-derived CTCs from CTC-neutrophil clusters and CTCs alone in relation to epithelial and mesenchymal 
genes. n=59. d, Heatmap showing the projection scores of patient-derived CTCs from CTC-neutrophil clusters and     
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Extended Data Fig. 4 | Gene expression analysis of scRNA-seq data.  
a, t-SNE analysis of CTCs from CTC–neutrophil clusters and CTCs alone 
using the 500 most variable genes. t-SNE plots for BALB/c-4T1-GFP 
samples are coloured by number of detected genes (left) and number 
of reads per sample (right) (n = 29). b, t-SNE plots for patient samples 
coloured by number of detected genes (left) and number of reads per 
sampl  (right) (n = 68). c, Heat map showing the projection scores of 
mouse-model-derived CTCs from CTC–neutrophil clusters and CTCs 
alone in relatio  to epithelial and mese chymal genes (n = 59).  
d, Heat map showing the projection scores of patient-derived CTCs from 
CTC–neutrophil clusters and CTCs alone in relation to epithelial and 
mesenchymal genes (n = 68). e, Heat map showing the projection scores 
of mouse-model-derived CTCs from CTC–neutrophil clusters and CTCs 
alone in relation to cancer stem-cell genes (n = 59). f, Heat map showing 
the projection scores of patient-derived CTCs from CTC–neutrophil 
clusters and CTCs alone in relation to cancer stem-cell genes (n = 68).  
g, Heat map showing the projection scores of mouse-model-derived CTCs 
from CTC–neutrophil clusters and CTCs alone in relation to platelet g nes 
(n = 59). h, Heat map showing the projection scores of patient-derived 
CTCs from CTC–neutrophil cl ters and CT s alone in relation to platelet 
genes (n = 68).
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CTCs alone in relation to epithelial and mesenchymal genes. n=68. e, Heatmap showing the projection scores of 
mouse model-derived CTCs from CTC-neutrophil clusters and CTCs alone in relation to cancer stem cell genes. 
n=59. f, Heatmap showing the projection scores of patient-derived CTCs from CTC-neutrophil clusters and CTCs 
alone in relation to cancer stem cell genes. n=68. g, Heatmap showing the projection scores of mouse model-
derived CTCs from CTC-neutrophil clusters and CTCs alone in relation to platelet genes. n=59. h, Heatmap 
showing the projection scores of patient-derived CTCs from CTC-neutrophil clusters and CTCs alone in relation to 
platelet genes. n=68. 
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Extended Data Figure 5. Proliferation of tumor cells adjacent to neutrophils in primary and metastatic 
tissues. a, Representative immunofluorescence images of NSG-LM2-GFP primary tumor and matched lung 
metastasis, stained for pan cytokeratin (pCK; green), MPO (gold), Ki67 (purple) and DAPI (nuclei; blue). n=3. b, 
The plots show the mean percent of Ki67-positive cancer cells in the primary tumor and metastatic sites (lung or 
brain) of mouse models, both overall and when considering only those cells that are adjacent to neutrophils. n=3 for 
all; error bars represent S.E.M; ns= not significant by two-sided Student’s t test. c, Representative 
immunofluorescence images of BR57 primary tumor and matched liver metastasis, stained for pan cytokeratin 
(pCK; green), MPO (gold), Ki67 (purple) and DAPI (nuclei; blue). n=3. d, The plots show the mean percent of 
Ki67-positive cancer cells, both overall and when considering only those cells that are adjacent to neutrophils, in 
matched primary and metastatic sites of nine breast cancer patients. Error bars represent S.E.M.; ns= not significant 
by two-sided Student’s t test. e, Schematic of the experimental design. 100 CTCs from CTC-neutrophil clusters or 
CTC alone are injected in the tail vein of recipient mice to measure disseminated tumor cells (DTC) proliferation. f, 
Representative pictures of DTCs stained for pan-cytokeratin (pCK; green), Ki67 (purple) and DAPI (nuclei; blue) 
(left). The plot shows the mean percent of Ki67-positive DTCs (right). n=3. Error bars represent S.E.M; *P=0.001 
by two-sided Student’s t test.  
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Extended Data Figure 6. Characterization of cytokine-mediated crosstalk within CTC-neutrophil clusters. a, 
Schematic of the experimental design (top). The heatmap shows the transcriptional landscape of cytokines and 
corresponding receptors expressed in at least 20% of CTC-neutrophil clusters (bottom). The cytokine-receptor pairs 
that are most frequently expressed in human cells are shown in red. b, Schematic of the experimental design (top). 
The heatmap shows the transcriptional landscape of cytokine receptors and corresponding cytokines expressed in at 
least 20% of CTC-neutrophil clusters (bottom). The cytokine-receptor pairs that are expressed in at least 40% of 
CTC-neutrophil clusters are shown in red. c, The plot shows the mean 4T1-GFP cell number upon starvation and 
stimulation with IL6, IL1β, TNFα, OSM or all four cytokines together (cytokine pool). n=3; error bars represent 
S.E.M.; *P< 0.05 by two-sided Student’s t test. d, Plots showing the mean percentage of Ki67-positive 
disseminated tumor cells (DTCs) in the bone marrow of injected mice. n=3 for all; error bars represent S.E.M.; 
*P<0.05 by two-sided Student’s t test. e, The plots show normalized bioluminescence signal from the lungs of 
injected mice. n=4 for all; error bars represent S.E.M; *P<0.05 by two-sided Student’s t test. f, Tumor growth 
curves of NSG mice injected with 4T1-Cas9-GFP cells expressing a control vector (Ctrl sgRNA) or sgRNAs 
targeting Il1r1 or Il6st. n=3; Error bars represent S.E.M.; ns= not significant by two-sided Student’s t test. g, Pie 
charts displaying the mean percentage of single CTCs (grey), CTC clusters (green) and CTC-neutrophil clusters 
(gold) of injected mice (left); n=3. The plots show the mean fold change of CTC ratios from injected mice (right); 
n=3; error bars represent S.E.M.; ns= not significant by two-sided Student’s t test. h, The plot shows the mean 
percent of Ki67-positive CTCs from injected mice. n=3; error bars represent S.E.M.; *P=0.001 by two-sided 
Student’s t test. 
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Extended Data Figure 7. Mutation analysis of single-cell whole exome sequencing data. a, Somatic mutation 
rate (mutations/Mb) of CTCs from CTC-neutrophil clusters (n=14) versus CTCs alone (n=56), normalized by 
donor.  Lines  within  the  violin  plots  show  the  25th,  50th  and  75th  percentile, respectively, while dots represent  
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individual CTCs. P value by two-sided Wilcoxon sign-ranked test is shown. b, Somatic mutation rate 
(mutations/Mb) in all CTCs isolated from donors with CTC-neutrophil clusters (Donors (+); n=6) and donors 
without CTC-neutrophil clusters (Donors (-); n=5). Lines within the violin plots show the 25th, 50th and 75th 
percentile, respectively, while dots represent individual CTCs. ns= not significant by two-sided Wilcoxon sign-
ranked test. c, Nucleotide substitution pattern among putative somatic mutations in CTCs isolated from donors with 
CTC-neutrophil clusters (Donors (+)) versus donors without CTC-neutrophil clusters (Donors (-)). n=6 for Donors 
(+) and n=5 for Donors (-). Lines within the violin plots show the 25th, 50th and 75th percentile, respectively, while 
dots represent individual CTCs. P value by two-sided Wilcoxon sign-ranked test is shown. d, The bar plots show 
the nucleotide context of given mutations in CTCs alone versus CTCs from CTC-neutrophil clusters. e, Plot 
showing the age distribution of Donors (+) (n=10) and Donors (-) (n=24). The red lines represent the mean. ns= not 
significant by two-sided Student’s t test. f, The tile plot represent genes (columns) containing predicted high-impact 
mutations in at least two Donors (+) and in none of the Donors (-). g, The plots show the mean fold change for 
MERTK and TLE1 (WT or mutated) transcripts compared to control (Ctrl) cells. n=3; error bars represent S.E.M.; 
*P<0.004 by two-sided Student’s t test. h, Tumor growth curves representing mean tumor volume measurements of 
NSG mice injected with 4T1 cells carrying an empty vector (pLOC), WT or mutated MERTK (left) or TLE1 (right). 
n=3; error bars represent S.E.M. ns= not significant by two-sided Student’s t test. i, Representative images of the 
primary tumor of injected mice, stained for pan cytokeratin (pCK, green), myeloperoxidase (MPO, gold) and DAPI 
(nuclei, blue) (top); n=3. The plot shows the mean number of infiltrated neutrophils per field of view within the 
primary tumor (bottom). Error bars represent S.E.M. n=3; ns= not significant by two-sided Student’s t test. j, 
Representative images of the primary tumor of injected mice, stained for pan cytokeratin (pCK, green), 
myeloperoxidase (MPO, gold) and DAPI (nuclei, blue) (top); n=3. The plot shows the mean number of infiltrated 
neutrophils per field of view within the primary tumor (bottom). Error bars represent S.E.M. n=3; *P=0.002 
**P=0.0007 by two-sided Student’s t test. k, Pie charts displaying the mean percentage of single CTCs (grey), CTC 
clusters (green) and CTC-neutrophil clusters (gold) in injected mice. The number of independent biological 
replicates (n) is shown for each condition. 
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Extended Data Fig. 8 | Co-culture of cancer cells and neutrophils does 
not lead to the accumulation of key mutational events. a, Schematic of 
the experimental design. Neutrophils were purified from healthy donor 
blood and cultured with either CTC-derived cell lines (BR16, Brx50) or 
LM2 cells for 72 h. Tumour cells were collected, and isolated gDNA was 
processed for WES. b, Tile plot showing the mutation status of all key loci 
found mutated in patients with CTC–neutrophil clusters. None of the 
CTC–neutrophil-cluster-associated mutations were detected upon  
co-culture of cancer cells with neutrophils.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Extended Data Figure 8. Co-culture of cancer cells and neutrophils does not lead to the accumulation of key 
mutational events. a, Schematic of the experimental design. Neutrophils were purified from healthy donor blood 
and cultured with either CTC-derived cell lines (BR16, Brx50) or LM2 cells for 72h. Tumor cells were harvested, 
and isolated gDNA was processed for whole exome sequencing (WES). b, Tile plot showing the mutation status of 
all key loci found mutated in patients with CTC-neutrophil clusters. None of the CTC-neutrophil clusters-
associated mutations were detected upon co-culture of cancer cells with neutrophils. 
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Extended Data Figure 9. Effects of neutrophil depletion or augmentation in mice. a, The plots show the mean 
number  of  neutrophils  in  the  circulation  of  mice  treated  with Ly-6G neutralizing antibodies (αLy-6G) (left), or  
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carrying G-CSF overexpressing tumors (right). Error bars represent S.E.M.; the number of independent biological 
replicates (n) is provided for simplicity directly within the source data. NA=not available; *P<0.03, **P<0.0001 by 
two-sided Student’s t test. b, Representative images of the primary tumor of NSG-LM2-GFP mice stained for pan 
cytokeratin (pCK, green), myeloperoxidase (MPO, gold) and DAPI (nuclei, blue) (left); n=3. The plots show the 
mean number of infiltrated neutrophils per field of view within the tumor (right). W= weeks upon tumor 
development. Error bars represent S.E.M. n=3, *P<0.03, **P<0.0001 by two-sided Student’s t test. c, Tumor 
growth curves representing mean tumor volume measurements in the presence or absence of αLy-6G antibodies or 
G-CSF overexpression. Error bars represent S.E.M. The number of independent biological replicates (n) is provided 
for simplicity directly within the source data. ns= not significant by two-sided Student’s t test. d, The plots show 
the mean counts of single CTCs, CTC clusters and CTC-neutrophil clusters in mice. Error bars represent S.E.M. 
The number of independent biological replicates (n) is provided for simplicity directly within the source data. ns= 
not significant; ND=not detected; *P<0.05 by two-sided Student’s t test. e, Pie charts displaying the mean 
percentage of single CTCs (grey), CTC clusters (green) and CTC-neutrophil clusters (gold) in NSG-LM2-GFP and 
NSG-CDX-BR16-GFP mice treated with αLy-6G antibodies or G-CSF overexpression. W= weeks upon tumor 
development; the number of independent biological replicates (n) is shown for each condition. f, The plots show the 
mean fold change of CTC ratios from NSG-LM2-GFP and NSG-CDX-BR16-GFP mice treated with αLy-6G 
antibodies or G-CSF overexpression. Error bars represent S.E.M. The number of independent biological replicates 
(n) is provided for simplicity directly within the source data. *P=0.045, **P=0.01, ***P=0.004 by two-sided 
Student’s t test. g, Representative bioluminescence images of lungs from mice treated with αLy-6G antibodies or 
G-CSF overexpression (left); the number of independent biological replicates (n) is provided for simplicity directly 
within the source data. W = weeks upon tumor development. The plots show the mean metastatic index of mice 
treated with αLy-6G antibodies or G-CSF overexpression (right). The number of independent biological replicates 
(n) is provided for simplicity directly within the source data; error bars represent S.E.M.; *P<0.03 **P<0.01 by 
two-sided Student’s t test. h, Kaplan-Meier survival plots showing overall survival rates of mice. The number of 
independent biological replicates (n) is provided for simplicity directly within the source data; *P<0.02 by two-
sided Log-rank test. i, Schematic of the experiment. NSG, FVB and Balb/c mice were pre-treated with αLy-6G 
antibodies or control IgG. 4T1-GFP cells or Py2T-GFP cells were then injected into the tail vein to assess 
metastasis development. j, The plots show mean normalized bioluminescence signal in the lungs of injected mice. 
n=3; error bars represent S.E.M.; ns= not significant by two-sided Student’s t test. k, Kaplan-Meier survival plot of 
injected mice. n=3; ns= not significant by two-sided Student’s t test. l, The plots show the mean percentage of 
Ki67-positive disseminated tumor cells (DTCs) collected from the bone marrow of injected mice. n=3; error bars 
represent S.E.M.; ns= not significant by two-sided Student’s t test. m, The bar graph shows the proportion of breast 
cancer patients that were treated with G-CSF, related to their CTC status. n=42 for no CTCs, n=23 for CTCs, n=9 
for CTC-neutrophil clusters. P value by two-sided Fisher’s exact test is shown. 
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Extended Data Figure 10. Expression of cell-adhesion molecules (CAMs)-receptor pairs on CTC-neutrophil 
clusters. a, Schematic of the experimental design (top). The heatmap shows the expression landscape of cell-
adhesion molecules (CAMs) and corresponding receptors that are expressed in at least 20% of CTC-neutrophil 
clusters (bottom). The CAM-receptor pairs that are expressed in at least 50% of CTC-neutrophil clusters are shown 
in red. b, Schematic of the experiment (top). The heatmap shows the expression landscape of CAM receptors and 
corresponding  CAMs  that  are  expressed  in at least 20% of CTC-neutrophil clusters (bottom). The CAM-receptor  
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Extended Data Fig. 10 | Expression of cell-adhesion molecules–
receptor pairs on CTC–neutrophil clusters. a, Schematic of the 
experimental design (top). The heat map shows the expression landscape 
of cell-adhesion molecules (CAMs) and corresponding receptors that 
are expressed in at least 20% of CTC–neutrophil clusters (bottom). 
The CAM–receptor pairs that are expressed in at least 50% of CTC–
neutrophil clusters are shown in red. b, Schematic of the experiment 
(top). The heatmap shows the expression landscape of CAM receptors and 
corresponding CAMs that are expressed in at least 20% of CTC–neutrophil 
clusters (bottom). The CAM–receptor pairs that are expressed in at least 
50% of CTC–neutrophil clusters are shown in red. c, Tumour growth 
curves representing mean tumour volume measurements of mice injected 
with 4T1-Cas9-GFP cells expressing a control vector (CTRL sgRNA) or 
sgRNA pools targeting F11r, Icam1, Itgb2 and Vcam1 (CRISPR pool).  
d, Plot showing the proportion of reads derived from sgRNAs targeting 
F11r, Icam1, Itgb2 and Vcam1 (4 sgRNAs each) in the 4T1-Cas9-GFP cell 
line upon library transduction as well as in three primary tumours from 
NSG-4T1-Cas9-GFP mice. All sgRNAs were represented in the tumour 
until the end of the experiment. e, Tumour growth curves representing 
mean tumour volume measurements of mice injected with 4T1-Cas9-GFP 
cells expressing a control vector (CTRL sgRNA) or individual sgRNAs 
targeting Vcam1. n = 3; error bars, s.e.m.; ns, not significant by two-sided 
Student’s t-test (c, e).
- 62 - 
 
 
 
pairs that are expressed in at least 50% of CTC-neutrophil clusters are shown in red. c, Tumor growth curves 
representing mean tumor volume measurements of mice injected with 4T1-Cas9-GFP cells expressing a control 
vector (CTRL sgRNA) or sgRNA pools targeting F11r, Icam1, Itgb2 and Vcam1 (CRISPR pool). n=3; error bars 
represent S.E.M.; ns= not significant by two-sided Student’s t test. d, The plot shows the proportion of reads 
derived from sgRNAs targeting F11r, Icam1, Itgb2 and Vcam1 (4 sgRNAs each) in the 4T1-Cas9-GFP cell line 
upon library transduction as well as in three primary tumors from NSG-4T1-Cas9-GFP mice. All sgRNAs were 
represented in the tumor until the end of the experiment. e, Tumor growth curves representing mean tumor volume 
measurements of mice injected with 4T1-Cas9-GFP cells expressing a control vector (CTRL sgRNA) or individual 
sgRNAs targeting Vcam1. n=3; error bars represent S.E.M.; ns= not significant by two-sided Student’s t test. 
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5.1.2. “DENOSUMAB TREATMENT IS ASSOCIATED WITH THE ABSENCE OF 
CIRCULATING TUMOR CELLS IN PATIENTS WITH BREAST CANCER” [88] 
 
Circulating tumor cells (CTCs) are derivatives of solid tumor lesions that detach from the tumor 
and enter the bloodstream [26]. In patients with breast cancer, CTCs have been shown to be 
predictive of a shorter disease-free survival and overall survival, with a worse prognosis in 
patients that present with a count of at least five CTCs per 7.5ml of blood [76, 89]. Generally, 
high CTC counts have been associated to a poor prognosis in multiple settings, including those 
patients that were newly diagnosed with metastatic breast cancer and were about to start a 
therapy [76, 90]. At the morphological level, breast CTCs occur in the blood of patients as 
single CTCs or as CTC clusters, with the latter being associated with a shorter metastasis-free 
survival, compared to patients in whom only single CTCs are found [21]. While the association 
between CTCs and bad prognosis is well established in breast cancer, CTCs are only detectable 
in a subset (~20-40%) of patients [21, 89]. To date, no parameters have been found that could 
explain CTC abundance in patients, leading to difficulties in enabling patient stratification prior 
to CTC-related investigations [68, 91], as well as limiting our understanding of those factors that 
may influence the spread of cancer. In this study, we aimed to investigate a number of 
clinicopathological variables, blood counts at the time of CTC isolation and detailed treatment 
history prior to blood sampling in a cohort of 73 consecutive patients with invasive breast 
cancer characterized by progressive disease, high tumor load and treatment discontinuation (or 
without any pre-treatment) at the time of CTC isolation, before the next line of therapy. 
Additionally, we did not only investigate parameters that are associated with the presence of 
CTCs, but we also specifically interrogated our datasets to identify features that are associated 
with CTC clusters. The rationale of our study was therefore to identify, in an unbiased manner 
(i.e. not driven by pre-existing hypotheses), clinical parameters that correlate with CTC 
presence in patients with progressive breast cancer. 
 
Given previously reported correlations between number of CTCs and tumor load [92], and the 
findings that CTC counts predict poor prognosis in breast cancer [76, 90, 93], we focused on a 
group of 73 consecutive patients with invasive breast cancer that featured the following 
characteristics: 1) high tumor load, 2) detailed treatment history available, 3) progressive disease 
associated  with  treatment  discontinuation  at  the time of CTC isolation (before the next line of  
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therapy) and 4) availability of comprehensive blood counts performed at CTC collection. 
Selected patients were ranging from 36 to 85 years of age and carrying either invasive ductal, 
lobular or inflammatory carcinoma, with a broad expression range of estrogen receptor (ER), 
progesterone receptor (PR), HER2 and Ki67 protein levels, as well as tumor grade varying from 
1-3. Detailed characteristics for patients, therapies and statistical tests used for the analysis are 
listed in Extended Data Tables 1-3. Blood samples were drawn in EDTA vacutainers and 
processed directly with the Parsortix microfluidic device [74], with a dedicated protocol 
enabling the isolation of >99% of breast CTCs from unlabeled blood samples (Extended Data 
Figure 1A). Upon enrichment, CTCs were stained with an antibody cocktail against EpCAM, 
EGFR and HER2, and counterstained for the while blood cell marker CD45 (Extended Data 
Figure 1A and 1B). With this approach, we detected at least one CTC per 7.5ml of peripheral 
blood in 34 (46.6%) patients. Among these, we observed that 22 (64.7%) patients were 
characterized by the presence of single CTCs and that 12 (35.3%) patients had both single CTCs 
and CTC clusters (Extended Data Figure 1C). 
 
We investigated a number of clinicopathological variables to identify features associated to 
patients in whom either single CTCs or CTC-clusters were found, compared to patients with no 
detectable CTCs. We first observed that previous treatments with targeted therapy (including 
but not limited to hormonal, anti-HER2, anti-CDK4/6 treatments), chemotherapy or 
radiotherapy did not correlate with the presence of CTCs (Extended Data Table 4). Yet, we 
found that treatment with the anti-bone resorption antibody Denosumab (received by 21/73 
patients) was associated with the absence of CTCs (OR, 0.25; 95%CI, 0.06-0.86; P= 0.019). 
Namely, the prevalence of CTCs was 14.7% (5/21) among treated patients with Denosumab and 
55.8% (29/52) among non-treated (Table 1). Further, when considering only those patients in 
whom CTCs were detected, the average CTC number was 9.8 for patients treated with 
Denosumab (n=5) versus 24.79 for nontreated patients (n=29). Despite its role as anti-bone 
resorption agent, the same association was not seen for bisphosphonates (P=0.784). Importantly, 
anti-bone resorption treatment with either Denosumab or bisphosphonates was decided based on 
treatment initiation date (Denosumab was approved in Switzerland in December 2011, and 
given as the preferred treatment option to eligible patients after that date), while patients that 
started receiving bisphosphonates (i.e. prior to December 2011) continued receiving 
bisphosphonates unless major side effects occurred (Extended Data Table 5). When restricting 
the analysis to the 44  patients  with  bone metastasis,  Denosumab was administered to 20/44 of  
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them, and it also correlated with a reduction in CTC number compared to the remaining 24 
patients with bone metastasis but no Denosumab treatment (OR, 0.22; 95%CI, 0.04-0.96; P= 
0.03) (Table 2). These results were confirmed using logistic regression adjusting by age at 
primary diagnosis, tumor stage at diagnosis, tumor grade and histologic subtype (OR, 0.25; 
95%CI, 0.06-0.82; P= 0.03). When comparing clinicopathological variables in patients that were 
treated or not with Denosumab, as expected, we observed a correlation with bone metastasis 
(OR, 22.53; 95%CI, 3.14-995.64; P= 5.6e-05; adjusted P= 0.01) (Extended Data Table 6), yet 
no effect in progression-free survival (Extended Data Figure 2). Together, our data show that 
Denosumab treatment is associated with a marked reduction of CTC counts in breast cancer 
patients. 
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Table 1. Clinical Features of Patients with Circulating Tumor Cells. The table shows clinical features of 
patients with and without circulating tumor cells (CTCs). Abbreviations: ER, estrogen receptor; HER2, human 
epidermal growth factor receptor 2; PR, progesterone receptor; SD, standard deviation. 
 
	 9/23 
Table 1: Clinical Features of Patients with Circulating Tumor Cells.  
  
No CTC 
(n = 39) 
CTC 
(n = 34) P Estimate (95%CI) 
Age at primary diagnosis, mean (SD) 58.38 (11.85) 55.1 (11.04) 0.444 -2.76 (-8.49 - 2.84) 
Age at first CTC evaluation, mean (SD) 63.53 (11.69) 59.58 (10.7) 0.163 -4.11 (-9.27 - 1.63) 
Stage at Diagnosis   0.679 - 
I (%) 4 (10.53%) 5 (14.71%)   
IA (%) 1 (2.63%) 0 (0%)   
II (%) 5 (13.16%) 4 (11.76%)   
IIA (%) 1 (2.63%) 4 (11.76%)   
III (%) 11 (28.95%) 7 (20.59%)   
IIIA (%) 2 (5.26%) 0 (0%)   
IIIC (%) 0 (0%) 2 (5.88%)   
IV (%) 14 (36.84%) 11 (32.35%)   
Lymphocyte node involvement   0.881 - 
N0 (%) 11 (31.43%) 8 (25.81%)   
N1 (%) 11 (31.43%) 14 (45.16%)   
N2 (%) 6 (17.14%) 0 (0%)   
N3 (%) 6 (17.14%) 9 (29.03%)   
Histologic subtype   0.964 - 
Invasive lobular (%) 6 (15.38%) 4 (11.76%)   
Invasive ductal (%) 31 (79.49%) 29 (85.29%)   
Inflammatory invasive lobular (%) 1 (2.56%) 1 (2.94%)   
Inflammatory (%) 2 (5.13%) 2 (5.88%)   
% of ER+ cells, mean (SD) 65.82 (42.48) 59.79 (40.93) 0.386 0 (-10 - 0) 
% of PR+ cells, mean (SD) 38.97 (40.04) 26.35 (33.78) 0.171 -4 (-20 - 0) 
% of KI67+ cells, mean (SD) 27.08 (17.13) 31.59 (21.55) 0.514 5 (-5 - 10) 
HER2+ (%) 7 (17.95%) 7 (22.58%) 0.766 1.33 (0.35 - 5.11) 
Triple - (%) 4 (10.81%) 3 (9.68%) 1.000 0.89 (0.12 - 5.73) 
Tumor grade   0.985 - 
1 (%) 4 (10.53%) 4 (12.12%)   
2 (%) 17 (44.74%) 14 (42.42%)   
3 (%) 17 (44.74%) 15 (45.45%)   
Bisphosphonates (%) 9 (23.68%) 7 (20.59%) 0.784 0.84 (0.23 - 2.94) 
Denosumab (%) 16 (41.03%) 5 (14.71%) 0.019 0.25 (0.06 - 0.86) 
Radiotherapy (%) 22 (56.41%) 13 (38.24%) 0.160 0.48 (0.17 - 1.35) 
Relapse     
Any (%) 31 (79.49%) 25 (73.53%) 0.589 0.72 (0.21 - 2.45) 
Local (%) 3 (7.69%) 4 (11.76%) 0.698 1.59 (0.25 - 11.72) 
Metastasis (%) 26 (66.67%) 19 (55.88%) 0.470 0.64 (0.22 - 1.82) 
Days between primary diagnosis and relapse, mean (SD) 1954.08 (2042.25) 1893.48 (1853.86) 0.966 -9.37 (-1000 - 756) 
Established metastatic disease at CTC evaluation (%) 35 (89.74%) 30 (88.24%) 1.000 0.86 (0.15 - 5.04) 
Number of metastatic sites, mean (SD) 2.09 (1.01) 1.9 (0.94) 0.473 0 (-1 - 0) 
Metastasis site     
Bone (%) 27 (69.23%) 17 (51.52%) 0.150 0.45 (0.15 - 1.28) 
Liver (%) 10 (25.64%) 12 (36.36%) 0.447 1.57 (0.51 - 4.9) 
Lymphnode (%) 9 (23.08%) 10 (30.3%) 0.599 1.38 (0.43 - 4.54) 
Pleural (%) 7 (17.95%) 2 (6.06%) 0.162 0.29 (0.03 - 1.68) 
Peritoneal (%) 3 (7.69%) 4 (12.12%) 0.698 1.59 (0.25 - 11.72) 
Lung (%) 4 (10.26%) 4 (12.12%) 1.000 1.16 (0.2 - 6.83) 
Skin (%) 3 (7.69%) 0 (0%) 0.243 0 (0 - 2.74) 
Brain (%) 2 (5.13%) 2 (6.06%) 1.000 1.15 (0.08 - 16.76) 
Uterus (%) 1 (2.56%) 1 (3.03%) 1.000 1.15 (0.01 - 92.67) 
Muscular (%) 1 (2.56%) 2 (6.06%) 0.595 2.35 (0.12 - 143.61) 
The table shows clinical features of patients with and without circulating tumor cells 
(CTCs). Abbreviations: ER, estrogen recepto ; HER2, human pid rmal growth 
factor receptor 2; PR, progesterone receptor; SD, standard deviation. 
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Table 2: Circulating Tumor Cells Detection According to Denosumab Treatment and 
Bone Metastasis.  
  Number of samples No CTCs CTCs P Estimate (95%CI) P Estimate (95%CI) 
Reference 28 12 (43%) 16 (57%) ref  - - 
Bone metastasis 24 11 (46%) 13 (54%) 1.000 0.89 (0.26-3.05) ref  
Bone metastasis and Denosumab 20 16 (80%) 4 (20%) 0.017 0.19 (0.04-0.81) 0.030 0.22 (0.04-0.96) 
The table shows the number of patients with and without circulating tumor cells 
(CTCs) among individuals with bone metastasis that were treated or not with 
Denosumab. 
 
 
Features of patients with CTC-clusters 
 
We further asked whether any clinicopathological variables might be associated 
specifically to the presence of CTC clusters, compared to patients in whom CTC 
clusters were not found (i.e. having either single CTCs or no CTCs). We found that 
both younger age at primary diagnosis as well as younger age at first CTC evaluation 
were associated to the presence of CTC clusters (Table 3). Particularly, we observed 
an average age at primary diagnosis of 50.63 years (SD, 12.60) for patients with CTC 
clusters and 58.08 years (SD, 10.99) for patients with no CTC clusters (P= 0.033), as 
well as a average age at first CTC evaluation of 54.87 years (SD, 12.14) for patients 
with CTC clusters and 63.03 years (SD, 10.77) for patients with no CTC clusters (P= 
0.025). We also observed that while HER2 is expressed in 22% (13/61) of patients 
with no CTC clusters (7/39, i.e. 17.95% of patients with no CTCs and 6/22, i.e. 30% 
of patients with single CTCs only), it is only expressed in one patient (9.09%) with 
CTC clusters (OR, 0.36; 95% CI, 0.01-2.97; P = 0.44); even though the relationship 
between HER2 negativity and CTC-clusters did not reach statistical significance 
(Table 3).  
 When considering only patients with CTCs, and comparing those with CTC 
clusters versus those with single CTCs, we found that also in this context younger age 
at primary diagnosis (P= 0.044) and younger age at first CTC evaluation (P= 0.058) 
are associated with the presence of CTC-clusters (Additional File 9: Table S7).  
 
 
 
 
 
 
 
Table 2. Circulating Tumor Cells Detection According to Denosumab Treatment and Bone Metastasis. The 
table shows the number of patients with and without circulating tumor cells (CTCs) among individuals with bone 
metastasis that were treated or not with Denosumab. 
 
 
We further asked whether any clinicopathological variables might be associated specifically to 
the presence of CTC clusters, compared to patients in whom CTC clusters were not found (i.e. 
having either single CTCs or no CTCs). We found that both younger age at primary diagnosis as 
well as younger age at first CTC evaluation were associated to the presence of CTC clusters 
(Table 3). Particularly, we observed an average age at primary diagnosis of 50.63 years (SD, 
12.60) for patients with CTC clusters and 58.08 years (SD, 10.99) for patients with no CTC 
clusters (P= 0.033), as well as a average age at first CTC evaluation of 54.87 years (SD, 12.14) 
for patients with CTC clusters a d 63.03 years (SD, 10.77) for patients with no CTC clusters 
(P=0.025). W lso observed that while HER2 is expressed in 22% (13/61) of patients with no
CTC clusters (7/39, i.e. 17.95% of patients with no CTCs and 6/22, i.e. 30% of patients with 
single CTCs only), it is only expressed in one patient (9.09%) with CTC clusters (OR, 0.36; 
95% CI, 0.01-2.97; P = 0.44); even though the relationship between HER2 negativity and CTC 
clusters did not reach statistical significance (Table 3). When considering only patients with 
CTCs, and comparing those with CTC clusters versus those with single CTCs, we found that 
also in this context younger age at primary diagnosis (P= 0.044) and younger age at first CTC 
evaluation (P= 0.058) are associated with the presence of CTC-clusters (Extended Data Table 
7). 
 
Additionally, to investigating the clinical parameters summarized above, for each patient we 
also evaluated comprehensive blood counts performed at CTC collection. We first asked 
whether blood-related parameters were associated with the presence of CTCs (either single or 
clustered), compared to patients in whom CTCs were not detected. We observed that patients 
with detectable CTCs had a lower red blood cell (RBC) count (OR, -0.42; 95% CI, -0.8 - -0.08; 
P= 0.019) compared to patients with no CTCs (Table 4).  
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Table 3: Clinical Features of Patients with Circulating Tumor Cell Clusters.  
  
No CTC clusters 
(n = 61) 
CTC clusters 
(n = 12) P Estimate (95%CI) 
Age at primary diagnosis, mean (SD) 58.08 (10.99) 50.63 (12.6) 0.033 -8.26 (-15.3 - -0.44) 
Age at first CTC evaluation, mean (SD) 63.03 (10.77) 54.87 (12.14) 0.025 -8.3 (-16.06 - -1.04) 
Stage at Diagnosis   0.726 - 
I (%) 7 (11.67%) 2 (16.67%)   
IA (%) 1 (1.67%) 0 (0%)   
II (%) 7 (11.67%) 2 (16.67%)   
IIA (%) 4 (6.67%) 1 (8.33%)   
III (%) 16 (26.67%) 2 (16.67%)   
IIIA (%) 2 (3.33%) 0 (0%)   
IIIC (%) 1 (1.67%) 1 (8.33%)   
IV (%) 21 (35%) 4 (33.33%)   
Lymphocyte node involvement   0.855 - 
N0 (%) 15 (27.27%) 4 (36.36%)   
N1 (%) 22 (40%) 3 (27.27%)   
N2 (%) 6 (10.91%) 0 (0%)   
N3 (%) 11 (20%) 4 (36.36%)   
Histologic subtype   0.679 - 
Invasive lobular (%) 9 (14.75%) 1 (8.33%)   
Invasive ductal (%) 49 (80.33%) 11 (91.67%)   
Inflammatory invasive lobular (%) 1 (1.64%) 1 (8.33%)   
Inflammatory (%) 3 (4.92%) 1 (8.33%)   
% of ER+ cells, mean (SD) 62.34 (41.8) 66.42 (42.1) 0.675 0 (-10 - 20) 
% of PR+ cells, mean (SD) 32.71 (37.79) 34 (37.3) 0.888 0 (-10 - 20) 
% of KI67+ cells, mean (SD) 30 (19.65) 23 (16.43) 0.384 -5 (-20 - 10) 
HER2+ (%) 13 (22.03%) 1 (9.09%) 0.442 0.36 (0.01 - 2.97) 
Triple - (%) 7 (12.28%) 0 (0%) 0.588 0 (0 - 3.7) 
Tumor grade   0.093 - 
1 (%) 5 (8.33%) 3 (27.27%)   
2 (%) 26 (43.33%) 5 (45.45%)   
3 (%) 29 (48.33%) 3 (27.27%)   
Bisphosphonates (%) 14 (23.33%) 2 (16.67%) 1.000 0.66 (0.06 - 3.68) 
Denosumab (%) 19 (31.15%) 2 (16.67%) 0.489 0.45 (0.04 - 2.41) 
Radiotherapy (%) 30 (49.18%) 5 (41.67%) 0.756 0.74 (0.17 - 3.06) 
Relapse     
Any (%) 47 (77.05%) 9 (75%) 1.000 0.9 (0.19 - 5.83) 
Local (%) 4 (6.56%) 3 (25%) 0.082 4.61 (0.58 - 32.62) 
Metastasis (%) 40 (65.57%) 5 (41.67%) 0.193 0.38 (0.08 - 1.59) 
Days between primary diagnosis and relapse, mean (SD) 1969.49 (2003.96) 1636.67 (1538.48) 0.633 -236.86 (-1643 - 1203) 
Established metastatic disease at CTC evaluation (%) 54 (88.52%) 11 (91.67%) 1.000 1.42 (0.15 - 70.01) 
Number of metastatic sites, mean (SD) 1.96 (0.98) 2.18 (0.98) 0.452 0 (0 - 1) 
Metastasis site     
Bone (%) 37 (61.67%) 7 (58.33%) 1.000 0.91 (0.22 - 4.08) 
Liver (%) 19 (31.67%) 3 (25%) 1.000 0.74 (0.12 - 3.42) 
Lymphnode (%) 15 (25%) 4 (33.33%) 0.497 1.52 (0.29 - 6.74) 
Pleural (%) 9 (15%) 0 (0%) 0.339 0 (0 - 2.57) 
Peritoneal (%) 5 (8.33%) 2 (16.67%) 0.323 2.21 (0.19 - 16.05) 
Lung (%) 7 (11.67%) 1 (8.33%) 1.000 0.7 (0.01 - 6.47) 
Skin (%) 3 (5%) 0 (0%) 1.000 0 (0 - 12.81) 
Brain (%) 3 (5%) 1 (8.33%) 0.521 1.74 (0.03 - 24.14) 
Uterus (%) 1 (1.67%) 1 (8.33%) 0.304 5.27 (0.06 - 433.34) 
Muscular (%) 2 (3.33%) 1 (8.33%) 0.421 2.63 (0.04 - 54.78) 
The table shows clinical features of patients with and without circulating tumor cell 
clusters (CTC clusters). Abbreviations: ER, estrogen receptor; HER2, human 
epidermal growth factor receptor 2; PR, progesterone receptor; SD, standard 
deviation. 
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Blood parameters associated with CTCs 
 
Additionally to investigating the clinical parameters summarized above, for each 
patient we also evaluated comprehensive blood counts performed at CTC collection. 
We first asked whether blood-related parameters were associated with the presence of 
CTCs (either single or clustered), compared to patients in whom CTCs were not 
detected. We observed that patients with detectable CTCs had a lower red blood cell 
(RBC) count (OR, -0.42; 95% CI, -0.8 - -0.08; P= 0.019) compared to patients with 
no CTCs (Table 4).   
 
Table 4: Complete Blood Counts in Patients with Circulating Tumor Cells.  
  
No CTC 
(n = 39) 
CTC 
(n = 34) P Estimate (95%CI) 
CA 15-3, mean (SD) 223.71 (384.68) 1084.15 (4136.87) 0.658 6.7 (-19.2 - 87.6) 
Alkaline phosphatase, mean (SD) 105.47 (103.98) 198.15 (365.58) 0.401 6 (-12 - 27) 
Calcium (korr), mean (SD) 2.34 (0.15) 2.32 (0.25) 0.145 -0.06 (-0.13 - 0.02) 
CRP, mean (SD) 31.92 (47.56) 26.87 (47.69) 0.982 0 (-8.8 - 3.8) 
LDH, mean (SD) 281.61 (118.18) 300.15 (228.57) 0.772 -5 (-36 - 23) 
RBC 10^12/L, mean (SD) 4.37 (0.56) 3.85 (0.77) 0.019 -0.42 (-0.8 - -0.08) 
HGB g/L, mean (SD) 130.14 (19.85) 118.15 (24.11) 0.051 -11 (-21 - 0) 
HCT L/L, mean (SD) 0.38 (0.06) 0.35 (0.06) 0.053 -0.03 (-0.06 - 0) 
MCV fL, mean (SD) 87.46 (5.68) 89.73 (5.26) 0.227 2 (-1 - 4) 
MCH pg, mean (SD) 29.62 (2.52) 30.66 (1.96) 0.157 0.8 (-0.3 - 1.8) 
MCHC g/L, mean (SD) 339.03 (13.98) 341.19 (12.79) 0.667 2 (-6 - 8) 
WBC 10^9/L, mean (SD) 7.35 (2.13) 7.24 (3.53) 0.334 -0.6 (-1.88 - 0.81) 
Neutrophile 10^9/L, mean (SD) 5.33 (1.87) 5.12 (2.87) 0.239 -0.63 (-1.65 - 0.56) 
Lymphocyte10^9/L, mean (SD) 1.37 (0.67) 1.41 (0.85) 0.941 -0.02 (-0.38 - 0.38) 
Monocyte 10^9/L, mean (SD) 0.42 (0.12) 0.44 (0.2) 0.843 -0.01 (-0.08 - 0.07) 
Eosinophil 10^9/L, mean (SD) 0.16 (0.18) 0.17 (0.12) 0.423 0.02 (-0.03 - 0.09) 
Basophil 10^9/L, mean (SD) 0.04 (0.07) 0.04 (0.03) 0.256 0.01 (-0.01 - 0.02) 
LUC 10^9/L, mean (SD) 0.15 (0.22) 0.12 (0.08) 0.912 0 (-0.03 - 0.02) 
PLT 10^9/L, mean (SD) 289.92 (139.86) 249.93 (91.52) 0.277 -30 (-84 - 24) 
MPV fL, mean (SD) 8.2 (1.51) 8.68 (1.52) 0.109 0 (0 - 1) 
The table shows complete blood counts in patients with and without circulating tumor 
cells (CTCs). Abbreviations: CA 15-3, cancer antigen 15-3; CRP, C-reactive protein; 
HCT, hematocrit; HGB, hemoglobin; LDH, lactate dehydrogenase; LUC, large 
unstained cells; MCH, mean corpuscular hemoglobin; MCHC, mean corpuscular 
hemoglobin concentration; MCV, mean corpuscular volume; MPV, Mean platelet 
volume; PLT, platelets; RBC, red blood cells; WBC, white blood cells. 
 
 
Blood parameters associated with CTC-clusters 
 
We then asked whether specific blood-related parameters could be associated to the 
presence of CTC clusters, compared to patients with no CTC clusters (i.e. having 
either no CTCs or single CTCs only). In this case, we found that patients with CTC 
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We then asked whether specific blood-related parameters could be associated to the presence of 
CTC clusters, compared to patients with no CTC clusters (i.e. having either no CTCs or single 
CTCs only).  In this case, we found that patients with CTC 13/23 clusters have 14-fold higher 
levels of CA 15-3 tumor marker (P=0.021), higher mean corpuscular volume (MCV) (P=0.033), 
higher white blood cells counts (WBC) (P=0.03) and higher mean platelet volume (MPV) 
(P=0.032) compared to patients in whom CTC clusters are not found (Table 5). We also 
restricted this  analysis  to  patients   with   CTCs   and  compared  patients   with  CTC  clusters   
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clusters have 14-fold higher levels of CA 15-3 tumor marker (P= 0.021), higher mean 
corpuscular volume (MCV) (P= 0.033), higher white blood cells counts (WBC) (P= 
0.03) and higher mean platelet volume (MPV) (P= 0.032) compared to patients in 
whom CTC clusters are not found (Table 5). We also restricted this analysis to 
patients with CTCs and compared patients with CTC clusters to patients with only 
single CTCs. In this setting, we further confirmed that patients with CTC clusters 
have 38-fold higher CA 15-3 tumor antigen (P= 0.0089), as well as nearly two-fold 
higher total white blood cell (WBC) counts (P= 0.0045) and higher neutrophil counts 
(P= 0.03) (Additional File 10: Table S8). 
 
Table 5: Complete Blood Counts in Patients with Circulating Tumor Cell Clusters.  
  
No CTC clusters 
(n = 61) 
CTC clusters 
(n = 12) P Estimate (95%CI) 
CA 15-3, mean (SD) 172.5 (324.45) 2554.6 (6387.64) 0.021 204.16 (9.7 - 515) 
Alkaline phosphatase, mean (SD) 106.4 (104.27) 310.25 (525.57) 0.301 10 (-12 - 74.58) 
Calcium (korr), mean (SD) 2.33 (0.14) 2.36 (0.35) 0.698 -0.02 (-0.16 - 0.14) 
CRP, mean (SD) 27.76 (44.47) 37.25 (58.6) 0.279 2.9 (-4 - 21.4) 
LDH, mean (SD) 271 (102.59) 363.33 (329.24) 0.463 17 (-26 - 76) 
RBC 10^12/L, mean (SD) 4.26 (0.6) 3.66 (0.93) 0.078 -0.51 (-1.16 - 0.06) 
HGB g/L, mean (SD) 127.52 (20.18) 114.18 (29.19) 0.183 -12 (-30 - 6) 
HCT L/L, mean (SD) 0.38 (0.05) 0.34 (0.08) 0.159 -0.03 (-0.09 - 0.01) 
MCV fL, mean (SD) 87.7 (5.58) 91.73 (4.41) 0.033 4 (0 - 7) 
MCH pg, mean (SD) 29.8 (2.42) 31.24 (1.51) 0.064 1.1 (0 - 2.3) 
MCHC g/L, mean (SD) 339.8 (13.38) 340.64 (14.25) 0.646 2 (-10 - 10) 
WBC 10^9/L, mean (SD) 6.87 (2.25) 9.38 (3.99) 0.030 2.54 (0.26 - 4.68) 
Neutrophile 10^9/L, mean (SD) 4.94 (1.87) 6.65 (3.6) 0.177 1.22 (-0.52 - 3.68) 
Lymphocyte10^9/L, mean (SD) 1.38 (0.69) 1.42 (1) 0.756 -0.11 (-0.62 - 0.6) 
Monocyte 10^9/L, mean (SD) 0.41 (0.13) 0.5 (0.24) 0.336 0.06 (-0.08 - 0.26) 
Eosinophil 10^9/L, mean (SD) 0.16 (0.16) 0.17 (0.14) 0.974 0 (-0.07 - 0.1) 
Basophil 10^9/L, mean (SD) 0.04 (0.06) 0.04 (0.04) 0.983 0 (-0.02 - 0.02) 
LUC 10^9/L, mean (SD) 0.14 (0.19) 0.12 (0.11) 0.471 -0.01 (-0.05 - 0.02) 
PLT 10^9/L, mean (SD) 278.02 (125.8) 251.5 (109.99) 0.667 -15.84 (-94 - 47) 
MPV fL, mean (SD) 8.32 (1.62) 8.82 (0.87) 0.032 1 (0 - 1) 
The table shows complete blood counts in patients with and without circulating tumor 
cell clusters (CTC clusters). Abbreviations: CA 15-3, cancer antigen 15-3; CRP, C-
reactive protein; HCT, hematocrit; HGB, hemoglobin; LDH, lactate dehydrogenase; 
LUC, large unstained cells; MCH, mean corpuscular hemoglobin; MCHC, mean 
corpuscular hemoglobin concentration; MCV, mean corpuscular volume; MPV, 
Mean platelet volume; PLT, platelets; RBC, red blood cells; WBC, white blood cells. 
 
 
 
 
 
 
 
 
to patients with only single CTCs. In this setting, we further confirmed that patients with CTC 
clusters have 38-fold higher CA 15-3 tumor antigen (P=0.0089), as well as nearly two-fold 
higher total white blo d cell (WBC) counts (P=0.0045) and higher neutrophil counts (P=0.03) 
(Extended Data Table 8). 
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blood counts in patients with and without circulating tumor cell clusters (CTC clusters). Abbreviations: CA 15-3, 
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In a selected cohort of 73 patients with progressive invasive breast cancer, we provide a detailed 
description of a number of clinicopathological parameters and blood counts at the time of CTC 
isolation that correlate with the presence of single CTCs and CTC clusters. Interestingly, we 
observe that treatment with the monoclonal antibody Denosumab in patients with bone 
metastasis strongly correlates with the absence of CTCs from their peripheral circulation, 
suggesting a  scenario  whereby  the  treatment  itself might influence CTC spread from the bone  
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tissue. Importantly, this correlation is not seen for treatment with the anti-bone resorption drug 
bisphosphonate, possibly because of different administration routes or dosing schedules [94] or 
alternatively, potential off-target binding of Denosumab to proteins other than RANKL.  
 
While focusing on clinical parameters, our study does not provide molecular insights into the 
mechanism of action of Denosumab in the context of its role in inhibiting CTC generation. Yet, 
considering that most Denosumab-treated patients are characterized by bone metastatic disease 
but no primary breast tumor (which has been surgically removed prior to Denosumab 
treatment), CTCs represent derivatives of their bone metastatic lesions. In this setting, we 
speculate that the effect of Denosumab in suppressing CTC generation could be the result of 
RANKL inhibition within the bone, preventing the maturation of pre-osteoclasts into osteoclasts 
[95] and protecting the bone from degradation, leading to a lower likelihood of a bone 
metastatic lesion to shed CTCs. However, we cannot exclude an action of Denosumab on breast 
cancer cells themselves, which have been previously shown to express high RANK levels [96, 
97] and may be susceptible to its inhibition. Prospective studies and molecular assays will be 
needed to specifically dissect the role and mechanism of action of Denosumab in CTC 
generation.  
 
Recently, a phase 3 clinical trial designed to determine the long-term effects of Denosumab 
treatment (D-CARE; NCT01077154) showed no benefits in metastasis-free survival and overall 
survival of breast cancer patients. While individuals within this study mainly comprised patients 
with early breast cancer, i.e. stage IIB to IIIC, our patient cohort was largely dominated by 
patients with stage IV disease. While we are not aware of CTC enumeration data being 
evaluated within the D-CARE study, it is possible that Denosumab might play a different role in 
the intravasation of bone metastasis-derived CTCs (as seen in our study) as opposed to primary 
tumor-derived CTCs (D-CARE).  
 
Among other correlations, we observe an intriguing association between the absence of HER2 
expression in the primary tumor and the presence of CTC clusters. While this result did not 
reach statistical significance, our observation regarding HER2 does not seem to be influenced by 
the metastatic tropism of HER2-positive breast cancers, and it might reveal important insights 
into the signaling networks involving CTC clusters formation, also considering HER2 
expression  fluctuations  in  CTCs  and  breast  cancer  metastasis  [98, 99].  In  other words,  we  
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speculate that HER2 signaling might influence cancer cells to intravasate as single CTCs, while 
its absence might poise them towards collective invasion into the bloodstream. This hypothesis 
will require experimental testing to be addressed.  
 
We also found that CTC clusters, but not CTCs in general, are more prevalent in younger 
patients. Both CTC clusters and younger age have been associated with worse prognosis and 
reduced survival rates [21, 89, 100-103]. In this case, it is unlikely that younger age represents 
an independent risk factor for CTC clusters formation, but rather it may reflect an association to 
tumor aggressiveness [104].  
 
Lastly, blood counts at the time of CTC collection provide evidence for applying well-
established, cost-effective and widespread blood testing strategies to stratify patients with higher 
likelihood to present with detectable CTCs. For instance, we find that lower RBC count is a 
good correlate with the presence of CTCs. Additionally, CA 15-3 tumor antigen is highly 
increased in patients with CTC clusters, possibly reflecting a higher tumor load but also tumors 
that are characterized by an elevated shedding of MUC-1-containing cells into the bloodstream 
[105]. A functional relationship between MUC-1 and CTC clusters remains to be investigated. 
We also observe that higher MCV, higher MPV and higher WBC counts correlate with the 
presence of CTC clusters. We envision these parameters to be used to stratify patient 
populations to conduct CTC-related studies in the setting of advanced breast cancer.  
 
Altogether, our study is meant as an exploratory analysis to evaluate the association of multiple 
clinical predictors with the presence of CTCs. Given the high number of hypotheses tested and 
the relatively low number of patient samples enrolled in the study (n=73), none of the 
associations reported show a P value lower than 0.05 after adjustment for multiple comparisons, 
with the exception of the correlation between Denosumab treatment and the presence of bone 
metastasis (adjusted P = 0.01). For this reason, subsequent prospective and experimental studies 
should be conducted to validate the associations that are presented in this work, including the 
role of Denosumab in CTC shedding.  
 
Our data provide evidence of the association between treatment with the monoclonal antibody 
Denosumab and the absence of CTCs from the peripheral circulation of breast cancer patients.  
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This finding suggests that Denosumab treatment may be beneficial to reduce cancer spread in 
patients that are diagnosed with bone metastasis.  
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Supplementary Figure 1: Circulating tumor cell (CTC) capture strategy. (A) Schematic drawing 
showing the size-based capturing principle of the Parsortix microfluidic device (left). Plot showing
the capture efficiency of the Parsortix microfluidic device for MCF7 cells spiked in healthy blood
samples (right). Representative images of a captured MCF7 single cell, a cell cluster (green) and a
contaminant white blood cell (WBC; red) in the Parsortix microfluidic cassette (bottom). 
(B) Representative images of a captured single CTC, a CTC cluster (green) and a contaminant WBC 
(red) from a breast cancer patient sample. (C) Bar graph showing the number of patients in whom 
no CTCs, single CTCs or CTC clusters were found.
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Extended Data Figure 1. C rculating tumor cell (CTC) capture strategy. A. Schematic drawing showing the 
size-based capturing principle of the Parsortix microfluidic device (left). Plot showing the capture efficiency of the 
Parsortix microfluidic device for MCF7 cells spiked in healthy blood samples (right). Representative images of a 
captured MCF7 s gle cell, a ce l clust r (green) and a contaminant white blood cell (WBC; red) in the Parsortix 
microfluidic cassette (bottom). B. Representative images of a captured single CTC, a CTC cluster (green) and a 
contaminant WBC (red) from a breast cancer patient sample. C. Bar graph showing the number of patients in 
whom no CTCs, single CTCs or CTC clusters were found. 
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Supplementary Figure 2: Progression-free survival of patients that were treated or not 
with Denosumab. Kaplan-Meier curve showing the progression-free survival probability of 
patients that were treated (red) or not (green) with Denosumab (top). P=0.95 by paiwise Log-Rank 
test. The table shows the number of patients at each timepoint (bottom). 
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Extended Data Figure 2. Progression-free survival of patients who were treated or not with denosumab. 
Kaplan-Meier curve showing the progression-free survival probability of patients who were treated (red) or not 
(green) with denosumab (top). P = 0.95 by pairwise log-rank test. The table shows the number of patients at each 
time point (bottom). 
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Drug Action Group Other names
afinitor mTOR inhibitor Targeted therapy afinitor
abemaciclib CDK4 and CDK6 inhibitor Targeted therapy abemaciclib
adjuvant tcbx6 *taxol+carbo) chemotherapy Chemotherapy adjuvant tcbx6 *taxol+carbo)
afinitor mTOR inhibitor Targeted therapy everolimus;afinitor
anastrozol aromatase inhibitor Hormone therapy anastrozol;arimidex
arimidex aromatase inhibitor Hormone therapy anastrozol;arimidex
aromasin aromatase inhibitor Hormone therapy aromasin;exemestan
atezolizumab PD-L1 inhibitor Immunotherapy atezolizumab
avastin VEGF inhibitor Targeted therapy avastin
caelyx chemotherapy Chemotherapy caelyx;pld
carboplatin chemotherapy Chemotherapy carboplatin
decapeptyl anti-estrogen Hormone therapy decapeptyl
depocyte intrathekal chemotherapy Chemotherapy depocyte intrathekal
ec chemotherapy Chemotherapy ec
epirubicin chemotherapy Chemotherapy epirubicin
eribulin chemotherapy Chemotherapy halaven;eribulin
everolimus mTOR inhibitor Targeted therapy everolimus;afinitor
exemestan aromatase inhibitor Hormone therapy aromasin;exemestan
farlutal Synthetic progesteron Hormone therapy farlutal
faslodex anti-estrogen Hormone therapy fulvestrant;faslodex
femara aromatase inhibitor Hormone therapy letrozol;femara
fulvestrant anti-estrogen Hormone therapy faslodex;fulvestrant
gemzar chemotherapy Chemotherapy gemzar
gnrh anti-estrogen Hormone therapy gnrh;zoladex
halaven chemotherapy Chemotherapy eribulin;halaven
herceptin Her2 inhibitor Targeted therapy herceptin
il-dox chemotherapy Chemotherapy il-dox
kadcyla Her2+tubulin blocker Targeted therapy kadcyla;tdm1
l-pld chemotherapy Chemotherapy l-pld
lapatinib Her2+EGFR blocker Targeted therapy lapatinib
letrozol aromatase inhibitor Hormone therapy femara;letrozol
lucrin anti-estrogen Hormone therapy lucrin
nab-paclitaxel chemotherapy Chemotherapy nab-paclitaxel
navelbine chemotherapy Chemotherapy navelbine;vinorelbin
ofs estrogen blocker Hormone therapy ofs
paclitaxel chemotherapy Chemotherapy paclitaxel;taxol
palbociclib CDK4 and CDK6 inhibitor Targeted therapy palbociclib
perjeta Her2 inhibitor Targeted therapy perjeta
pld chemotherapy Chemotherapy caelyx;pld
tam anti-estrogen Hormone therapy tam;tamoxifen
tamoxifen anti-estrogen Hormone therapy tam;tamoxifen
taxol chemotherapy Chemotherapy paclitaxel;taxol
taxotere chemotherapy Chemotherapy taxotere
tdm1 Her2+tubulin blocker Targeted therapy kadcyla;tdm1
vinorelbin chemotherapy Chemotherapy navelbine;vinorelbin
xeloda chemotherapy Chemotherapy xeloda
zoladex anti-estrogen Hormone therapy gnrh;zoladex
adriamycin-cyclophosphamide chemotherapy Chemotherapy adriamycin-cyclophosphamide;ac
carboplatin-docetaxel chemotherapy Chemotherapy carboplatin-docetaxel;tcb
tcb chemotherapy Chemotherapy carboplatin-docetaxel;tcb
cisplatin chemotherapy Chemotherapy cisplatin
adriblastin chemotherapy Chemotherapy adriblastin
endoxan chemotherapy Chemotherapy endoxan
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Extended Data Table 1. Drug classification. The table shows the drug classification used for the analysis, 
grouping drugs into targeted therapy, chemotherapy, hormone therapy and immunotherapy.  
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Type of Variable Statistical Test
Age at primary diagnosis, mean (SD) Numerical
two-sided Wilcoxon rank-
sum test
Age at first CTC evaluation, mean (SD) Numerical
two-sided Wilcoxon rank-
sum test
Stage at Diagnosis Ordinal Kruscal Wallis
I (%)
IA (%)
II (%)
IIA (%)
III (%)
IIIA (%)
IIIC (%)
IV (%)
Lymphocyte node involvement Ordinal Kruscal Wallis
N0 (%)
N1 (%)
N2 (%)
N3 (%)
Histologic subtype Categorical >2-level Fisher test
Invasive lobular (%)
Invasive ductal (%)
Inflammatory invasive lobular (%)
Inflammatory (%)
% of ER+ cells, mean (SD) Numerical
two-sided Wilcoxon rank-
sum test
% of PR+ cells, mean (SD) Numerical
two-sided Wilcoxon rank-
sum test
% of KI67+ cells, mean (SD) Numerical
two-sided Wilcoxon rank-
sum test
HER2+ (%) Categorical 2-level Fisher test
Triple - (%) Categorical 2-level Fisher test
Tumor grade Ordinal Kruscal Wallis
1 (%)
2 (%)
3 (%)
Bisphosphonates (%) Categorical 2-level Fisher test
Denosumab (%) Categorical 2-level Fisher test
Radiotherapy (%) Categorical 2-level Fisher test
Relapse
Any (%) Categorical 2-level Fisher test
Local (%) Categorical 2-level Fisher test
Metastasis (%) Categorical 2-level Fisher test
Days between primary diagnosis and 
relapse, mean (SD)
Numerical
two-sided Wilcoxon rank-
sum test
Established metastatic disease at CTC 
evaluation (%)
Categorical 2-level Fisher test
Number of metastatic sites, mean (SD) Numerical
two-sided Wilcoxon rank-
sum test
Metastasis site
Bone (%) Categorical 2-level Fisher test
Liver (%) Categorical 2-level Fisher test
Lymphnode (%) Categorical 2-level Fisher test
Pleural (%) Categorical 2-level Fisher test
Peritoneal (%) Categorical 2-level Fisher test
Lung (%) Categorical 2-level Fisher test
Skin (%) Categorical 2-level Fisher test
Brain (%) Categorical 2-level Fisher test
Uterus (%) Categorical 2-level Fisher test
Muscular (%) Categorical 2-level Fisher test
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Extended Data Table 2. Variable classification and statistical test applied. The table shows the type of variable 
and statistical test used for the analysis of individual clinicopathological parameters.  
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Patient
Age at 
primary 
diagnosis
Age at 
first CTC 
evaluation
% of ER+ 
cells
% of PR+ 
cells
% of 
KI67+ 
cells
HER2+
Histologic 
subtype
Tumor 
grade
Established 
metastatic 
disease at 
CTC 
evaluation
ECOG at 
CTC 
evaluation
Therapy at 
CTC 
evaluation
Accumulated 
Therapy at 
CTC 
evaluation
Br1 47.69 54.18 90 90 NA 0 ID 3 yes 1 none none
Br2 57.6 72.39 1 1 NA NA IL 3 yes 1 Hormone
Hormone; 
Chemotherapy
Br3 56.77 57.54 35 0 40 1 ID 3 yes 1
Targeted; 
Chemotherapy
Targeted; 
Chemotherapy
Br4 53.48 54.96 80 5 30 0 IL 3 yes 1 Chemotherapy Chemotherapy
Br6 74.74 81.68 70 80 NA 0 IL 2 yes 3 none none
Br7 41.88 41.92 90 90 25 0
ID 
inflammatory
2 yes 1 none none
Br8 64.51 69.5 70 30 10 0 ID 2 yes 1 Hormone Hormone
Br9 60.16 62.67 70 30 60 0 ID 3 yes 1 Hormone
Chemotherapy
; Hormone
Br10 48.45 64.72 100 0 NA 0 ID 1 yes 0-1 Hormone
Hormone; 
Chemotherapy
Br11 53.81 56.31 0 0 50 0 ID 3 yes 1 Chemotherapy Chemotherapy
Br12 60.1 67.11 90 70 NA 0 IL 2 yes NA Chemotherapy
Hormone; 
Chemotherapy
; Targeted
Br13 56.02 61.47 100 5 5 0 IL 2 yes 0-1
Targeted; 
Hormone
Hormone; 
Targeted
Br14 72.68 74.76 100 10 NA 0 ID 2 yes 1 none
Hormone; 
none
Br15 38.05 42.9 100 75 NA NA ID 1 yes 1 Hormone
Hormone; 
Targeted
Br16 38.71 49.04 100 75 NA 0 ID 2 yes 2 Chemotherapy
Hormone; 
Chemotherapy
Br17 54.82 66.94 1 1 NA 0 ID 1 yes 2 Hormone
Chemotherapy
; Hormone
Br18 59.89 63.61 80 0 NA 0 ID 3 yes 0-1 Chemotherapy
Hormone; 
Chemotherapy
Br19 40.05 42.48 0 0 NA 1 ID 2 yes 1 Targeted
Targeted; 
Chemotherapy
Br20 40.86 45.26 80 80 35 0 ID 3 yes 0-1 none none
Br21 55.47 69.23 100 70 NA 0 IL 2 yes 1 none none
Br22 53.35 66.15 100 90 NA 0 ID 2 yes 01.Feb Hormone Hormone
Br23 63.02 63.05 100 0 NA 0 IL 2 yes 1 Hormone Hormone
Br25 39.02 45.84 70 15 NA 0 ID 2 yes 0-1 Hormone Hormone
Br27 62.22 64.26 100 5 20 1 ID 2 yes 1
Targeted; 
Chemotherapy
Targeted; 
Chemotherapy
Br29 53.22 54.32 0 0 70 0 ID 3 yes 02.Mar none none
Br30 48.99 50.64 80 70 25 0 ID 3 yes 1 none
Chemotherapy
; none
Br31 81.68 81.92 100 5 25 0 ID 3 yes 1 Hormone Hormone
Br32 68.32 68.43 90 100 20 1 ID 3 yes NA
Hormone; 
Targeted
Hormone; 
Targeted
Br33 53.18 68.71 0 0 NA 1 ID 3 yes 1 Targeted
Targeted; 
Chemotherapy
Br34 49.93 65.51 1 1 NA 0 IL 2 yes 0 Hormone Hormone
Br35 71.97 78.42 70 50 15 0 IL 2 yes 1 Chemotherapy Chemotherapy
Br36 59.84 59.89 50 0 50 1 ID 3 no 0-1 Hormone Hormone
Br37 67.19 67.25 70 0 27.5 1 ID 3 yes 0
Targeted; 
Chemotherapy
Targeted; 
Chemotherapy
Br38 36.12 36.16 90 50 50 0 ID 2 no 0-1 none none
Br39 47.38 53.28 60 30 10 0 ID 3 yes 2 Chemotherapy
Hormone; 
Chemotherapy
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Extended Data Table 3. Patient characteristics. The table shows the characteristics of the 73 patients included in 
the study. Abbreviations: ER Estrogen receptor, HER2 Human epidermal growth factor receptor 2, ID Invasive 
ductal, IL Invasive lobular, NA Not available, PR Progesterone receptor, ECOG Eastern Cooperative Oncology 
Group (as defined by Oken et al. [106]v). 
  
Br40 79.82 79.87 100 100 5 0 ID 1 yes 3 Hormone Hormone
Br41 49.9 61.54 100 100 NA 0 ID 2 yes 1 Hormone Hormone
Br42 78.76 78.83 80 10 20 0 ID 2 yes 01.Feb Hormone Hormone
Br43 69.87 74.73 100 70 25 0 ID 2 yes 2 none none
Br44 46.84 50.22 100 80 30 1 ID 2 yes 0-1 none none
Br45 44.68 49.06 100 80 10 0 ID 1 yes 1 none none
Br46 49.27 49.29 0 0 80 0 ID 3 no 0 none none
Br47 74.53 77.16 0 0 10 0 ID 3 yes 02.Mar
Targeted; 
Chemotherapy
Targeted; 
Chemotherapy
Br48 60.93 65.38 100 100 10 0 ID 1 yes 0 none none
Br49 77.33 77.37 100 10 20 0 ID 3 no 0 none none
Br50 52.19 52.22 90 90 5 0 ID 1 no NA none none
Br51 54.13 55.65 0 0 27.5 NA ID 3 yes NA none none
Br52 48.66 68.15 100 50 35 0 ID 3 yes 1 none none
Br53 48.22 58.81 1 0 NA 0 ID NA yes 1 Hormone Hormone
Br54 56.91 58.06 100 50 20 0
ID 
inflammatory
2 yes 1 Chemotherapy
Hormone; 
Chemotherapy
Br55 62.56 62.63 0 0 15 1 ID 2 yes 0 none none
Br56 70.09 73.19 50 0 35 0 ID 3 no 3 Chemotherapy Chemotherapy
Br57 55.39 55.41 95 5 NA 0 ID 3 yes 3 none none
Br58 66.44 66.48 90 50 30 0 IL 3 yes 0 none none
Br59 46.32 49.95 100 5 50 1 ID 2 yes 0 Targeted
Targeted; 
Chemotherapy
Br60 53.88 72.05 100 50 NA 0 NA NA yes 1 Hormone Hormone
Br61 59.82 62.39 60 0 NA 0 ID 2 yes 0-1 Chemotherapy
Br62 80.44 85.61 100 1 20 0 ID 2 yes 01.Feb Hormone Hormone
Br63 57.92 60.85 0 0 90 0 ID 3 no 0 Chemotherapy Chemotherapy
Br64 40.33 50.62 90 2 NA 1 ID 3 yes 1 none none
Br65 70.02 70.02 0 0 20 0 inflammatory 3 yes 1 none none
Br66 57.76 74.59 1 NA NA 0 ID 3 yes 1
Targeted; 
Hormone
Hormone; 
Targeted
Br67 56.72 69.65 90 90 NA 0 ID 1 yes 0
Hormone; 
Targeted
Hormone; 
Targeted
Br68 46.04 54.13 95 90 NA 0 ID 2 yes 0 none none
Br69 45.78 45.84 0 NA 10 1 inflammatory 2 yes 0 none none
Br70 44.61 46.13 100 5 NA 0 ID 2 yes 1 Chemotherapy
Chemotherapy
; Hormone
Br71 61.18 61.16 90 80 30 0 ID 2 yes NA none none
Br72 41.46 42.95 10 0 15 1 ID 3 no 0-1
Chemotherapy; 
Targeted
Chemotherapy
; Targeted
Br73 79.43 79.49 0 2 20 1 ID 3 yes 0
Targeted; 
Chemotherapy
Targeted; 
Chemotherapy
Br74 65.36 68.02 0 70 50 0 ID 2 yes 0-1 Hormone Hormone
Br75 55.48 60.72 20 0 25 0 ID 2 yes NA none none
Br76 55.4 57.02 0 0 30 0 ID 3 yes 1
Targeted; 
Chemotherapy
Chemotherapy
; Targeted
Br77 54.63 55.75 100 20 40 0 ID 3 yes 0-1 Hormone Hormone
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Extended Data Table 4. Therapy evaluation in patients with circulating tumor cells. The table shows the types 
of therapy that patients with and without circulating tumor cells (CTCs) underwent. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
No CTC CTC
(n = 39) (n = 34)
Bisphosphonates (%) 9 (23.68%) 7 (20.59%) 0.784 0.84 (0.23 - 2.94)
Denosumab (%) 16 (41.03%) 5 (14.71%) 0.019 0.25 (0.06 - 0.86)
Radiotherapy (%) 22 (56.41%) 13 (38.24%) 0.16 0.48 (0.17 - 1.35)
Therapy at CTC evaluation
Targeted therapy (%) 8 (20.51%) 6 (17.65%) 1 0.83 (0.21 - 3.13)
Chemotherapy (%) 9 (23.08%) 9 (26.47%) 0.79 1.2 (0.36 - 4)
Hormone therapy (%) 15 (38.46%) 9 (26.47%) 0.324 0.58 (0.19 - 1.74)
Cumulative therapy at CTC 
evaluation
Targeted therapy (%) 9 (23.08%) 7 (20.59%) 1 0.87 (0.24 - 3.03)
Chemotherapy (%) 13 (33.33%) 14 (41.18%) 0.628 1.39 (0.48 - 4.05)
Hormone therapy (%) 19 (48.72%) 12 (35.29%) 0.343 0.58 (0.2 - 1.63)
P Estimate (95%CI)
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Patient Bisphosphonates Denosumab None
Br1 no no yes
Br2 yes no no
Br3 no no yes
Br4 yes no no
Br6 no no yes
Br7 no yes no
Br8 no no yes
Br9 no no yes
Br10 yes yes no
Br11 no no yes
Br12 yes no no
Br13 yes no no
Br14 yes yes no
Br15 no no yes
Br16 no no yes
Br17 no no yes
Br18 no no yes
Br19 no yes no
Br20 no no yes
Br21 no yes no
Br22 no no yes
Br23 no no yes
Br25 no no yes
Br27 no no yes
Br29 no no yes
Br30 no no yes
Br31 no yes no
Br32 yes yes no
Br33 yes no no
Br34 no yes no
Br35 yes no no
Br36 no no yes
Br37 no no yes
Br38 no no yes
Br39 yes yes no
Br40 no no yes
Br41 no no yes
Br42 no no yes
Br43 no no yes
Br44 no no yes
Br45 no no yes
Br46 no no yes
Br47 yes yes no
Br48 no yes no
Br49 NA no NA
Br50 no no yes
Br51 no no yes
Br52 no yes no
Br53 no no yes
Br54 yes yes no
Br55 no no yes
Br56 no no yes
Br57 no no yes
Br58 yes yes no
Br59 yes yes no
Br60 no yes no
Br61 yes no no
Br62 no no yes
Br63 yes no no
Br64 no no yes
Br65 no no yes
Br66 no yes no
Br67 no no yes
Br68 no no yes
Br69 no no yes
Br70 no yes no
Br71 no yes no
Br72 no no yes
Br73 no no yes
Br74 no yes no
Br75 no no yes
Br76 no no yes
Br77 no yes no
Br38 no no yes
Br39 yes yes no
Br40 no no yes
Br41 no no yes
Br42 no no yes
Br43 no no yes
Br44 no no yes
Br45 no no yes
Br46 no no yes
Br47 yes yes no
Br48 no yes no
Br49 NA no NA
Br50 no no yes
Br51 no no yes
Br52 no yes no
Br53 no no yes
Br54 yes yes no
Br55 no no yes
Br56 no no yes
Br57 no no yes
Br58 yes yes no
Br59 yes yes no
Br60 no yes no
Br61 yes no no
Br62 no no yes
Br63 yes no no
Br64 no no yes
Br65 no no yes
Br66 no yes no
Br67 no no yes
Br68 no no yes
Br69 no no yes
Br70 no yes no
Br71 no yes no
Br72 no no yes
Br73 no no yes
Br74 no yes no
Br75 no no yes
Br76 no no yes
Br77 no yes no
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Extended Data Table 5. Bisphosphonates or denosumab treatment. The table shows whether bisphosphonates 
or denosumab was administered to each of the patients included in the study.   
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Control Treated
(n = 52) (n = 21)
Age at primary diagnosis, mean (SD) 56.79 (11.7) 57 (11.33) 0.918 -0.31 (-6.34 - 6.01)
Age at first CTC evaluation, mean (SD) 61.12 (11.41) 63.1 (11.3) 0.411 -2.8 (-9 - 3.92)
Stage at Diagnosis 0.213 -
I (%) 7 (13.46%) 2 (10%)
IA (%) 0 (0%) 1 (5%)
II (%) 7 (13.46%) 2 (10%)
IIA (%) 4 (7.69%) 1 (5%)
III (%) 16 (30.77%) 2 (10%)
IIIA (%) 0 (0%) 2 (10%)
IIIC (%) 2 (3.85%) 0 (0%)
IV (%) 15 (28.85%) 10 (50%)
Lymphocyte node involvement 0.065 -
N0 (%) 14 (29.17%) 5 (27.78%)
N1 (%) 15 (31.25%) 10 (55.56%)
N2 (%) 4 (8.33%) 2 (11.11%)
N3 (%) 14 (29.17%) 1 (5.56%)
Histologic subtype 0.077 -
Invasive lobular (%) 7 (13.46%) 3 (14.29%)
Invasive ductal (%) 43 (82.69%) 17 (80.95%)
Inflammatory invasive lobular (%) 0 (0%) 2 (9.52%)
Inflammatory (%) 2 (3.85%) 2 (9.52%)
% of ER+ cells, mean (SD) 59.19 (41.11) 72.48 (42.25) 0.06 -10 (-20 - 0)
% of PR+ cells, mean (SD) 30.43 (37.99) 39.3 (36.19) 0.168 -5 (-29 - 0)
% of KI67+ cells, mean (SD) 30 (21.2) 27.31 (13.79) 0.941 0 (-10 - 10)
HER2+ (%) 11 (22.45%) 3 (14.29%) 0.52917 0.58 (0.09 - 2.58)
Triple - (%) 6 (12.5%) 1 (5%) 0.66441 0.37 (0.01 - 3.42)
Tumor grade 0.704 -
1 (%) 6 (11.76%) 2 (10%)
2 (%) 21 (41.18%) 10 (50%)
3 (%) 24 (47.06%) 8 (40%)
Bisphosphonates (%) 8 (15.69%) 8 (38.1%) 0.05952 3.24 (0.87 - 12.27)
Radiotherapy (%) 24 (46.15%) 11 (52.38%) 0.79635 1.28 (0.41 - 4.02)
Relapse
Any (%) 40 (76.92%) 16 (76.19%) 1 0.96 (0.26 - 4.06)
Local (%) 4 (7.69%) 3 (14.29%) 0.40264 1.98 (0.26 - 12.99)
Metastasis (%) 33 (63.46%) 12 (57.14%) 0.79082 0.77 (0.24 - 2.49)
Days between primary diagnosis and relapse, mean 
(SD)
1560.57 (1491.24) 2995.75 (2680.45) 0.213 -1017.31 (-3417 - 359)
Established metastatic disease at CTC evaluation 
(%)
44 (84.62%) 21 (100%) 0.09526 Inf (0.73 - Inf)
Number of metastatic sites, mean (SD) 1.96 (0.9) 2.1 (1.14) 0.777 0 (-1 - 0)
Metastasis site
Bone (%) 24 (47.06%) 20 (95.24%) 5.60E-05 22.53 (3.14 - 995.64)
Liver (%) 14 (27.45%) 8 (38.1%) 0.40326 1.66 (0.49 - 5.49)
Lymphnode (%) 12 (23.53%) 7 (33.33%) 0.38892 1.65 (0.46 - 5.72)
Pleural (%) 7 (13.73%) 2 (9.52%) 1 0.68 (0.06 - 4.03)
Peritoneal (%) 7 (13.73%) 0 (0%) 0.18165 0 (0 - 1.65)
Lung (%) 3 (5.88%) 5 (23.81%) 0.03927 4.97 (0.86 - 35.61)
Skin (%) 3 (5.88%) 0 (0%) 0.55229 0 (0 - 6.05)
Brain (%) 3 (5.88%) 1 (4.76%) 1 0.82 (0.01 - 10.92)
Uterus (%) 2 (3.92%) 0 (0%) 1 0 (0 - 13.31)
Muscular (%) 3 (5.88%) 0 (0%) 0.55229 0 (0 - 6.05)
P Estimate (95%CI)
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Extended Data Table 6. Clinical features of patients in regard to denosumab treatment. The table shows 
clinical features of patients who were treated or not with denosumab. Abbreviations: ER Estrogen receptor, HER2 
Human epidermal growth factor receptor 2, PR Progesterone receptor. 
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CTC single cell CTC clusters
(n = 22) (n = 12)
Age at primary diagnosis, mean (SD) 57.54 (9.52) 50.63 (12.6) 0.04 -8.6 (-16.08 - -0.31)
Age at first CTC evaluation, mean 
(SD)
62.15 (9.11) 54.87 (12.14) 0.06 -7.73 (-15.37 - 0.42)
Stage at Diagnosis 0.85 -
I (%) 3 (13.64%) 2 (16.67%)
IA (%) 0 (0%) 0 (0%)
II (%) 2 (9.09%) 2 (16.67%)
IIA (%) 3 (13.64%) 1 (8.33%)
III (%) 5 (22.73%) 2 (16.67%)
IIIA (%) 0 (0%) 0 (0%)
IIIC (%) 1 (4.55%) 1 (8.33%)
IV (%) 7 (31.82%) 4 (33.33%)
Lymphocyte node involvement 0.9 -
N0 (%) 4 (20%) 4 (36.36%)
N1 (%) 11 (55%) 3 (27.27%)
N2 (%) 0 (0%) 0 (0%)
N3 (%) 5 (25%) 4 (36.36%)
Histologic subtype 0.7 -
Invasive lobular (%) 3 (13.64%) 1 (8.33%)
Invasive ductal (%) 18 (81.82%) 11 (91.67%)
Inflammatory invasive lobular (%) 0 (0%) 1 (8.33%)
Inflammatory (%) 1 (4.55%) 1 (8.33%)
% of ER+ cells, mean (SD) 56.18 (40.82) 66.42 (42.1) 0.36 1 (-10 - 30)
% of PR+ cells, mean (SD) 22.18 (31.81) 34 (37.3) 0.36 1 (-4 - 40)
% of KI67+ cells, mean (SD) 34.12 (22.64) 23 (16.43) 0.21 -10 (-25 - 10)
HER2+ (%) 6 (30%) 1 (9.09%) 0.37 0.24 (0 - 2.52)
Triple - (%) 3 (15%) 0 (0%) 0.54 0 (0 - 4.4)
Tumor grade 0.07 -
1 (%) 1 (4.55%) 3 (27.27%)
2 (%) 9 (40.91%) 5 (45.45%)
3 (%) 12 (54.55%) 3 (27.27%)
Bisphosphonates (%) 5 (22.73%) 2 (16.67%) 1 0.69 (0.06 - 5.25)
Denosumab (%) 3 (13.64%) 2 (16.67%) 1 1.26 (0.09 - 12.99)
Radiotherapy (%) 8 (36.36%) 5 (41.67%) 1 1.24 (0.23 - 6.52)
Relapse
Any (%) 16 (72.73%) 9 (75%) 1 1.12 (0.18 - 8.63)
Local (%) 1 (4.55%) 3 (25%) 0.12 6.57 (0.46 - 383.48)
Metastasis (%) 14 (63.64%) 5 (41.67%) 0.29 0.42 (0.08 - 2.14)
Days between primary diagnosis and 
relapse, mean (SD)
1996.2 (2006.19) 1636.67 (1538.48) 0.62 -291.5 (-1975 - 1591)
Established metastatic disease at 
CTC evaluation (%)
19 (86.36%) 11 (91.67%) 1 1.71 (0.12 - 99.29)
Number of metastatic sites, mean 
(SD)
1.75 (0.91) 2.18 (0.98) 0.21 0 (0 - 1)
Metastasis site
Bone (%) 10 (47.62%) 7 (58.33%) 0.72 1.65 (0.33 - 8.94)
Liver (%) 9 (42.86%) 3 (25%) 0.47 0.49 (0.07 - 2.77)
Lymphnode (%) 6 (28.57%) 4 (33.33%) 0.71 1.32 (0.21 - 7.67)
Pleural (%) 2 (9.52%) 0 (0%) 0.53 0 (0 - 9.85)
Peritoneal (%) 2 (9.52%) 2 (16.67%) 0.6 1.96 (0.12 - 30.79)
Lung (%) 3 (14.29%) 1 (8.33%) 1 0.58 (0.01 - 8.36)
Skin (%) 0 (0%) 0 (0%) 1 0.58 (0.01 - 8.36)
Brain (%) 1 (4.76%) 1 (8.33%) 1 1.87 (0.02 - 156.66)
Uterus (%) 0 (0%) 1 (8.33%) 0.35 Inf (0.05 - Inf)
Muscular (%) 1 (4.76%) 1 (8.33%) 1 1.87 (0.02 - 156.66)
P Estimate (95%CI)
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Extended Data Table 7. Clinical features of patients with single circulating tumor cell and circulating tumor 
cell clusters. The table shows clinical features of patients in whom only single circulating tumor cells (CTC single 
cell) or also clustered circulating tumor cells (CTC clusters) were found. Abbreviations: ER Estrogen receptor, 
HER2 Human epidermal growth factor receptor 2, PR Progesterone receptor.  
 
 
  
- 88 - 
 
 
Single CTC CTC clusters
(n = 22) (n = 12)
CA 15-3, mean (SD) 66.15 (57.74) 2554.6 (6387.64) 0.0089 234.2 (17.4 - 540.4)
Alkaline phosphatase, mean (SD) 108.47 (108.56) 310.25 (525.57) 0.4941 9 (-18 - 109)
Calcium (korr), mean (SD) 2.29 (0.11) 2.36 (0.35) 0.8835 0.01 (-0.14 - 0.21)
CRP, mean (SD) 17.96 (35.81) 37.25 (58.6) 0.1497 4.99 (-2 - 31.5)
LDH, mean (SD) 246 (43.64) 363.33 (329.24) 0.3035 30.66 (-20 - 96)
RBC 10^12/L, mean (SD) 3.99 (0.63) 3.66 (0.93) 0.4996 -0.22 (-1.08 - 0.31)
HGB g/L, mean (SD) 121.07 (20.19) 114.18 (29.19) 0.6777 -5 (-29 - 14)
HCT L/L, mean (SD) 0.36 (0.04) 0.34 (0.08) 0.7204 -0.02 (-0.09 - 0.03)
MCV fL, mean (SD) 88.27 (5.48) 91.73 (4.41) 0.081 4 (-2 - 8)
MCH pg, mean (SD) 30.23 (2.19) 31.24 (1.51) 0.1608 1 (-0.6 - 2.6)
MCHC g/L, mean (SD) 341.6 (12.12) 340.64 (14.25) 0.8557 1 (-13 - 12)
WBC 10^9/L, mean (SD) 5.68 (2.15) 9.38 (3.99) 0.0045 3.48 (1.15 - 6.42)
Neutrophile 10^9/L, mean (SD) 4.03 (1.57) 6.65 (3.6) 0.0306 2.02 (0.11 - 4.9)
Lymphocyte10^9/L, mean (SD) 1.4 (0.76) 1.42 (1) 0.8859 -0.07 (-0.76 - 0.9)
Monocyte 10^9/L, mean (SD) 0.4 (0.15) 0.5 (0.24) 0.2918 0.07 (-0.08 - 0.32)
Eosinophil 10^9/L, mean (SD) 0.17 (0.1) 0.17 (0.14) 0.7844 -0.02 (-0.13 - 0.11)
Basophil 10^9/L, mean (SD) 0.04 (0.03) 0.04 (0.04) 0.6197 -0.01 (-0.03 - 0.02)
LUC 10^9/L, mean (SD) 0.11 (0.04) 0.12 (0.11) 0.4379 -0.02 (-0.06 - 0.02)
PLT 10^9/L, mean (SD) 248.67 (77.76) 251.5 (109.99) 0.9809 2.5 (-77 - 73)
MPV fL, mean (SD) 8.59 (1.89) 8.82 (0.87) 0.153 1 (0 - 1)
P Estimate (95%CI)
 
 
 
 
 
 
 
 
 
 
 
Extended Data Table 8. Complete blood counts in patients with single circulating tumor cells and circulating 
tumor cell clusters. The table shows complete blood counts in patients in whom only single circulating tumor cells 
(single CTC) or also clustered circulating tumor cells (CTC clusters) were found. Abbreviations: CA 15-3 Cancer 
antigen 15-3, CRP C-reactive protein, HCT Hematocrit, HGB Hemoglobin, LDH Lactate dehydrogenase, LUC 
Large unstained cells, MCH Mean corpuscular hemoglobin, MCHC Mean corpuscular hemoglobin concentration, 
MCV Mean corpuscular volume, MPV Mean platelet volume, PLT Platelets, RBC Red blood cells, WBC White 
blood cells. 
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5.2. UNPUBLISHED RESULTS 
5.2.1 SINGLE CELL RNA AND DNA SEQUENCING OF INDIVIDUAL CTCS 
 
In order to apply parallel DNA and RNA isolation and amplification from single cells, several 
protocols were tested. The base for method validations was parallel Genome and Transcriptome 
sequencing (G&T-Seq) [65], (which combined MDA (Multiple Displacement Amplification) for 
the genome and SMART-Seq2 method for the transcriptome processing. In order to proceed 
with the most efficient sample preparation, the published protocol was compared side-to-side 
with two newly introduced commercial methods – AMPLI1 WTA (whole transcriptome 
amplification) method and MALBAC (Multiple Annealing and Looping Based Amplification 
Cycles) for the genome amplification. Of note, two whole genome amplification (WGA) kits 
from the same manufacturer were tested (V3 vs single cell-specific). Interestingly, V3 yielded 
better results (higher concentrations) for individual cells and was used in further steps.  
 
Based on the final sample concentration and amplified fragments sizes, the original G&T-Seq 
protocol, including few minor modifications, was chosen for further sample preparation. RNA 
content was amplified at least 1’000-fold (from around 2 pg to 10-40 ng).  Moreover, as 
opposed to the alternative methods, improved MDA protocol provided over 1ug total gDNA 
(from starting 6.6 pg), amount necessary for the library construction, and yielded consistent 
fragment sizes of amplified transcriptome (Figure 1).  
 
 
Figure 1. Quality control of single-cell WGA. Representative distribution of fragment sizes for SMART-Seq2 
and AMPLI1 (left). Concentrations of gDNA obtained after the amplification with either SMART-Seq2 and 
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MALBAC approaches (right). Green check mark indicates results that were necessary for further protocol steps. 
Red crosses point towards poor quality data.  
 
Initial exome and transcriptome (E&T) validation sequencing with HiSeq 2500 was performed 
on CTC-derided cell line (Brx68-GFP) and resulted in high quality data (Figure 2 and Table 1).  
 
Figure 2. First attempts in isolation of individual cells. Pictures captured during the manipulation of cells used 
for E&T-seq protocol validation. Courtesy of Dr. Stefan Arnold. 
 
There were on average 9832 transcripts detected from 7 different single cells, with a minimum 
of 10 reads per each transcript (depth). In addition, protocol included two positive controls of 
15-cell pools (to ensure the presence of deposited cell), and RNA sequencing of these samples 
resulted in the mean of 13333 transcripts (10x depth).  
 
Table 1. E&T-Seq validation. Number of genes detected with 1,10 or 20 reads are shown for 15-cell pools (in 
duplicate) and 6 single cells. Note: Computational analysis performed by Dr. Robert Ivanek. 
 
The quality of amplified transcriptome has been assessed with AMPLI1 quality control (QC) kit 
(Figure 3). 
Sample ID Genes With 1 Read Genes With 10 reads Genes With 20 reads 
15 cells 1 15611 13536 12950 
15 cells 2 15718 13130 12570 
Single cell 1 11943 10554 10205 
Single cell 2 10564 9052 8803 
Single cell 3 10782 9350 9001 
Single cell 4 11399 9974 9610 
Single cell 5 12153 10782 10429 
Single cell 6 10336 9098 8821 
Single cell 7 11356 10019 9726 
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Figure 3. Whole transcriptome amplification QC. An 
agarose gel visualizing QC PCR product. Three bands represent 
good quality amplification products and are recommended for 
samples submitted to RNA sequencing. Samples 1-6 represent 
six individual CTCs (mouse-derived), N = negative control (no 
template), P = positive control (spiked gDNA).  
 
 
 
 
Correlation analysis of transcripts shared between all sequenced samples proved high protocol 
reproducibility (74-90% identical sequences detected between samples). Importantly, the 
additional of internal RNA control (ERCC spike-in) enabled more precise sample analysis and 
the concentration of tested spike-in was approved for all the future samples (Figure 4).  
 
 
Figure 4. RNA-seq data quality. Correlation plot showing proportion of shared sequences between samples (left). 
Sensitivity of the detection of RNA expression across different samples is analyzed by evaluating the expression of 
both ERCC spike-in control transcripts (right). Note: Computational analysis performed by Dr. Robert Ivanek. 
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On the other hand, whole exome sequencing from matched samples resulted in 33-63% of 
exome coverage for single cells and 80-85% for 15-cell pools at 5x depth (Figure 5).  
 
Figure 5. DNA Data quality. Fraction of exome 
coverage at different number of reads shown for 
multiple samples ranging between single cell and 
300’000 cells. Note: Computational analysis 
performed by Dr. Robert Ivanek. 
 
 
 
 
 
 
 
 
Interestingly, mouse (xenograft)-derived CTCs provided better quality DNA-seq data compared 
to patient CTCs, as evaluated based on the % coverage of the exome. Taken together, these data 
confirm a proper protocol execution for E&T-Seq (Figure 6). 
 
 
 
 
 
 
 
 
Figure 6. Mouse-derived CTCs provide better quality DNA-Seq data. Boxplots showing the percentage of 
exome coverage distribution between patient- and xenograft (mouse)– derived CTCs, at either 1x (left) or 5x depth. 
Note: Computational analysis performed by Dr. Francesc Castro-Giner. 
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5.2.2 PATIENT AND MOUSE-DERIVED CTC ISOLATION 
 
Circulating tumor cells were isolated from freshly drawn blood of cancer patients and mouse 
models using two-step procedure.  
 
 
 
Firstly, blood was passed through a microfluidic system (Parsortix) in order to enrich large 
tumor cells and remove the majority of unwanted red and white blood cells. Secondly, collected 
CTCs were deposited into ultra-low attachment and individual cells of interest were 
micromanipulated (CellCelector) to allow downstream analyses (Figure 7). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Precision of cell micromanipulation with CellCelector. Representative pictures form before (top) 
and after (bottom) cell cluster micromanipulation are shown. Red blood cell in proximity of isolated CTC 
cluster is indicated with an arrow. 
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Figure 8. Representative images of patient-derived CTCs. 
CTC clusters (top left) or single CTCs (top right and both 
bottom) were imaged before micromanipulation. Cells 
originated from either breast (Br), prostate (Pr), lung (Lu) or 
ovarian (Ov) cancers. Patient ID is shown after the cancer 
type.  
 
 
 
 
 
 
Occasionally, cell distress was detected based on the morphology (e.g. in Figure 8, Lu2 and 
Ov1), probably due to the ongoing chemotherapy. On the other hand, CTCs from drug naive 
mouse models displayed a healthier phenotype (Figure 9). 
 
 
Figure 9. Representative images of mouse-derived CTCs. 
Single CTCs (top) and CTC clusters were isolated at the time 
of an overt metastatic disease from NSG mice injected with 
either LM2 (left) or 4T1 (right) cells.  
 
 
 
 
 
 
 
 
In case of clustered cells, micromanipulation was used to mechanically dissociate attached cells 
using aspiration and immediate release into the capillary, performed sequentially around ten 
times. This procedure did not induce any visible changes in cell morphology (Figure 10).  
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Figure 10. Isolation of cells from CTC clusters. Individual cells were subsequently removed from a 5-cell cluster 
from NSG-BR16 mouse model. Note: 3-cell cluster from this example was unmanageable to dissociate further and 
was sequenced as a bulk of three cells. 
 
A total number of CTCs collected over the course of the study is shown in Table 2 for patients 
and Table 3 for mouse models. 
 
 Breast  Lung Prostate Ovarian 
Donor # 18 2 5 2 
     
Single CTCs 156 28 41 5 
CTC clusters 52 0 6 2 
CTC-WBC cluster 25 0 4 0 
 
Table 2. Summary of CTC collection from cancer patients. Single and clustered CTCs were collected from 
breast, lung, prostate and ovarian cancer patients. Numbers of donors from each cancer type are shown in bold. A 
sum of collected single CTCs, CTC clusters and CTC-WBC clusters are given below each patient group. 
 
 
 NSG-BR16 NSG-BRx50 NSG-LM2 NSG-4T1 BALB/c-4T1 PyMT 
Single CTCs 32 43 51 57 16 1 
CTC clusters 40 25 44 58 6 18 
CTC-WBC cluster 7 3 24 15 11 6 
 
Table 3. Summary of CTCs collected from mouse models. Table shows total numbers of collected single CTCs, 
CTC clusters and CTC-WBC clusters for different mouse models used in the study. 
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CTCs obtained from different mouse models were consistent in respect of cell size. An 
exception was a transgenic MMTV-PyMT model with spontaneous cancer in multiple 
mammary fat pads. Isolated cells were found much smaller compared to other models (15-20 µm in diameter for BR16 vs. 7-10	 µm for MMTV-PyMT), which perhaps can explain low 
capture rate in Parsortix system (only one single CTC found among 24 CTC clusters). 
Interestingly, PyMT-derived clusters formed “tight” multicellular spheres, as opposed to “string-
like” clusters of BR16-model (Figure 11). 
 
 
Figure 11. CTC clusters display morphological differences 
between mouse models. Representative images of CTC 
clusters from NSG-BR16 and MMTV-PyMT mice captured in 
the microfluid cassette (left). Images taken at the same 
magnification (40x). Multiple “string-like” clusters of BR16 
model were visualized with anti-EpCAM antibody (right). 
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5.2.3 SINGLE CELL VS. CELL CLUSTERS PROLIFERATION AND SURVIVAL 
POTENTIAL 
 
The role of cell-cell connection in survival and proliferation was studied in vitro in CTC-derived 
cell lines (Brx50, Brx68 and BR16). The growth of over 1000 single cells and cell clusters (2-14 
cells) was monitored during 8-week period in 384-well format (Figure 12).  
 
 
Figure 12. Proliferation of single vs. clustered cells. Representative images of Brx50 cells seeded either 
individually (top) or as clusters (bottom). Significant improvement in survival and proliferation was observed for 
clustered cells.  
 
Obtained data was normalized by a total number of cells included in the experiment. This 
experiment showed clear survival advantage of cell clusters, with 18% (clusters) vs. 4% (single 
cells) survival rate for Brx50. Similar results were observed for Brx68, approximately 90% of 
clusters and only 40% of single cell survived over 56 days (Figure 13).  
 
 
Figure 13. Distinct morphology of Brx68 cells. Single-cell derived colony shows dramatic difference after the 
first division: dormant “giant” cell vs. proliferating progeny of a sister cell (left). “Egg-like” viable cells present in 
the culture (middle). Similar structures were found also among NSG-4T1 (right) and NSG-LM2 CTCs. 
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Rare single-cell derived colonies exhibited much lower total cell numbers when compared to 
normalized (i.e. final cell number was divided by the number of cells at the time of seeding) 
colonies originating from cell clusters (Figure 14). 
 
Figure 14. Survival advantage of CTC clusters. Proportions of successful wells (i.e. with live cells at day 56) are 
shown for the cell lines (BR16, Brx68 and Brx50) (top). The same experiment was summarized with Kaplan-Meier 
survival analysis (bottom). 
 
Cells with the highest proliferation were used to create clone-derived sublines (26 cluster-
derived and one single cell-derived for Brx50 and 24 each for BR16) and tested in mice for 
metastatic potential (study not yet concluded). Moreover, this experiment enabled identification 
of quiescent cells defined by no cell division for 56 days. These cells were isolated and 
preserved for further analysis. Morphological abnormality was observed (Figure 15). 
 
Figure 15. Atypical BR16 cells. Representative 
pictures showing granular surface (left) and 
incomplete division (right) found among some 
proliferating BR16 colonies. 
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Figure 16. Size difference between single cell- and clustered cell-derived colonies. Representative images of 
Brx50 colonies. 
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5.2.3 PROLIFERATION EFFICIENCY OF CTC-DERIVED CELL LINE UNDER 
DIFFERENT CONCENTRATION OF OXYGEN 
 
 
Establishment of a patient CTC-derived cell line is known to be challenging due to lack of 
proliferation or immediate cell death. Even existing protocols have multiple limitations and 
struggle with low culture efficiency [68, 107], noted also during culturing trials of patient 
samples from the “CTC-study” (e.g. unsuccessful Br7, Ov10, Lu2, Pr2 cultures). Since hypoxia 
is a known regulator of metastasis [108], one of the characteristic features in CTC-specific 
culture is a decrease of oxygen supply to 1-5%. In order to test how CTC-derived cell line 
(Brx50) will react to changes in oxygen, equal number of cells was cultured at either standard 
condition (5% oxygen) vs. significant hypoxia (1% oxygen) or normoxia (21% oxygen) shown 
in Figure 17.  
 
 
 
 
Figure 17. Schematic of experimental design. Brx50 cells were transferred from standard culture conditions into 
lower oxygen concentration or normoxia. Experient was performed in triplicates.  
 
 
After 21 days of culture results indicated that previously maintained oxygen concentration was 
optimal for cell proliferation. Although cells tended to cluster more at 20% oxygen, their total 
numbers were lower than at previous hypoxic conditions. Interestingly, further limitation of 
oxygen down to 1% slowed down the cell cycle the most. Cells did not proliferate, but at the 
same time they did not exhibit any morphological signs of distress over the three-week culture. 
This could be the result of intrinsic or acquired in vitro oxygen-dependency for Brx50 cell line.  
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Further studies are required to decipher the influence of oxygen levels on physiology of CTC-
derived cell lines (Figure 18). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18. Oxygen dependence for CTC growth. Pictures of Brx50 cells cultured at different oxygen levels were 
taken after 21 days. All technical replicates are shown (lines). Pictures were taken and stitched using the 
CellCelector software.  
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5.2.4 COMPLETE BLOOD COUNTS (CBCS) ACROSS DIFFERENT MOUSE MODELS 
 
 
Significant changes in the total number of blood cells are known to occur in cancer patients, 
especially due to the chemotherapy [109]. However, pre-therapy blood counts are known for 
decades for their prognostic significant in cancer field, e.g. high white blood cell counts corelate 
with worse survival [110-113].  
 
To address the impact of cancer on CBC changes, the blood was taken from either naïve or 
tumor-bearing mice, at the time of experiment termination (Figure 19). 
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Figure 19. CBCs among breast cancer mouse models. Blood counts were measured for control mouse strains 
(naïve NSG and BALB/c) or tumor-bearing mice at the time of an overt metastatic disease. WBC – white blood 
cell, RBC – red blood cell, PLT – platelet, MCV – mean corpuscular volume, MPV – mean platelet volume, NEU – 
neutrophil, LYMPH – lymphocyte, MONO – monocyte, EOS – eosinophil. Significant differences with naïve mice 
were marked with red star.  
 
 
Across mice with NSG background Brx50 model had no significant impact on CBCs. Notably, 
this CTC-derived cell line although tumorigenic, rarely causes metastatic disease. Similarly, 
NSG-BR16 mice did not stand out except lower red blood cell numbers and smaller platelet 
size. Mice injected with LM2 cells exhibited the biggest differences. Namely, higher count of 
WBCs, seen across all measured leukocytes (neutrophils, monocytes and eosinophils), lower red 
blood cell and platelet counts and bigger corpuscular volume. Importantly, higher counts of 
lymphocytes detected upon LM2 tumor growth are the result of an inaccurate cell assignment by 
the CBC enumeration system, counting most likely abnormal monocytes and granulocytes. In 
case of BALB/c background only one parameter (number of RBCs) was not changed indicating 
dramatic changes induces by 4T1 cancer growth in these immunocompetent mice. 
 
These findings can be linked to the changes of spleen size in different models, as spleen is a 
known immune cell storage organ (Figure 20). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20. Spleen size across mouse models. Representative pictures of spleens from different breast cancer 
mouse models (top). Graph showing the weight of spleens for each model (bottom). 
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6. CONCLUSIONS 
 
The ability to metastasize to distant sites is a fatal hallmark and possibly one of the least 
understood and most complex features of cancer. Due to the continuous interest and recent 
development of novel technologies our understanding of metastatic mechanisms is rapidly 
broadening, especially in the context of CTC biology. Scientists are now offered a long-
anticipated opportunity to study these rare cells and tackle the key questions in cancer field.  
 
A unique approach applied in the described study allowed simultaneous analyses of 
exome and transcriptome at the single-CTC level. This enabled deeper characterization of 
highly understudied cells leading to the description of pro-metastatic interactions between CTCs 
and neutrophils. The ability of cancer to take such an advantage of immune cells might explain 
why certain tumors are more aggressive than other and how CTC vulnerability might be 
overcome in the circulation. These results are in line with previously reported prognostic value 
of CTC-WBC clusters, showing that cancer cells can carry the tumor “soil” to facilitate 
metastasis and worsen prognosis. Moreover, by focusing on cell clusters (as opposed to single 
CTCs) and highlighting the role of the rarest CTC subtypes, emphasis was placed at the highly 
relevant cell entities, that were previously disregarded. Notably, interaction with other immune 
cells were observed, opening yet another area for exploration (CTC-T cell or CTC-B cell 
clusters).  
 
Findings published in Nature are not restricted only to breast cancer. The same workflow 
can be applied to other metastatic cancers. In fact, multiple samples from lung, prostate and 
ovarian cancers were already collected during this study. Additionally, provided approach can 
be applied to assess the exome and transcriptome profile changes along the therapy, leading to 
identification of new drug resistance mechanisms or prediction of drug responsiveness. In the 
era of personalized medicine, liquid biopsy is bringing hope for non-invasive and precise 
clinical tool. Importantly, collected parallel DNA and RNA sequencing enables future analysis 
of the direct impact of mutational profile on gene expression at a single-cell level.   
 
Data provided in the second manuscript points towards the previously unknown 
association between CTC absence and the treatment with the monoclonal antibody 
(Denosumab) among breast cancer patients.   
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This finding suggests that Denosumab treatment may be beneficial to reduce cancer spread in 
patients that are diagnosed with bone metastasis. Moreover, while factors such as limited blood 
volume and diverse CTC-isolation technologies may influence CTC detection rate in cancer 
patients, the identification of a set of clinical correlatives to CTCs in breast cancer is likely to 
facilitate the identification of those patients that would benefit the most from CTC analysis, 
including genetic profile assessment for patient stratification and testing of drug susceptibility. 
As an added benefit to this analysis, the identification of Denosumab treatment as a strategy to 
reduce CTC intravasation warrants further investigation. 
 
Altogether, tremendous advancements in the CTC field have prepared the ground to 
investigate the functional features of cancer aggressiveness. Presented work profoundly 
extended the focus of CTC research and revealed new means for CTC characterization. Yet, the 
exact processes underlying cancer spread and metastasis vulnerability remain unknown and 
gaining more insights about the cancer perpetrators is still essential.  
  
- 106 - 
 
 
7. REFERENCES 1.	 Tomasetti,	C.	and	B.	Vogelstein,	Cancer	etiology.	Variation	in	cancer	risk	among	
tissues	can	be	explained	by	the	number	of	stem	cell	divisions.	Science,	2015.	
347(6217):	p.	78-81.	2.	 Torre,	L.A.,	et	al.,	Global	cancer	statistics,	2012.	CA	Cancer	J	Clin,	2015.	65(2):	p.	87-108.	3.	 Jemal,	A.,	et	al.,	Global	cancer	statistics.	CA	Cancer	J	Clin,	2011.	61(2):	p.	69-90.	4.	 Talmadge,	J.E.	and	I.J.	Fidler,	AACR	centennial	series:	the	biology	of	cancer	metastasis:	
historical	perspective.	Cancer	Res,	2010.	70(14):	p.	5649-69.	5.	 Massague,	J.	and	A.C.	Obenauf,	Metastatic	colonization	by	circulating	tumour	cells.	Nature,	2016.	529(7586):	p.	298-306.	6.	 Yoo,	B.H.,	et	al.,	Anoikis	of	colon	carcinoma	cells	triggered	by	beta-catenin	loss	can	be	
enhanced	by	tumor	necrosis	factor	receptor	1	antagonists.	Oncogene,	2015.	34(38):	p.	4939-51.	7.	 Wheeler,	L.J.,	et	al.,	CBX2	identified	as	driver	of	anoikis	escape	and	dissemination	in	
high	grade	serous	ovarian	cancer.	Oncogenesis,	2018.	7(11):	p.	92.	8.	 Vayrynen,	S.A.,	et	al.,	Clinical	impact	and	network	of	determinants	of	tumour	necrosis	
in	colorectal	cancer.	Br	J	Cancer,	2016.	114(12):	p.	1334-42.	9.	 Bredholt,	G.,	et	al.,	Tumor	necrosis	is	an	important	hallmark	of	aggressive	
endometrial	cancer	and	associates	with	hypoxia,	angiogenesis	and	inflammation	
responses.	Oncotarget,	2015.	6(37):	p.	39676-91.	10.	 Kitamura,	T.,	B.-Z.	Qian,	and	J.W.	Pollard,	Immune	cell	promotion	of	metastasis.	Nature	reviews.	Immunology,	2015.	15(2):	p.	73-86.	11.	 Chen,	M.-T.,	et	al.,	Comparison	of	patterns	and	prognosis	among	distant	metastatic	
breast	cancer	patients	by	age	groups:	a	SEER	population-based	analysis.	Scientific	reports,	2017.	7(1):	p.	9254-9254.	12.	 Valderrama-Treviño,	A.I.,	et	al.,	Hepatic	Metastasis	from	Colorectal	Cancer.	Euroasian	journal	of	hepato-gastroenterology,	2017.	7(2):	p.	166-175.	13.	 Ellis,	P.M.	and	R.	Vandermeer,	Delays	in	the	diagnosis	of	lung	cancer.	Journal	of	thoracic	disease,	2011.	3(3):	p.	183-188.	14.	 Tivari,	S.,	et	al.,	Reawakening	of	dormant	estrogen-dependent	human	breast	cancer	
cells	by	bone	marrow	stroma	secretory	senescence.	Cell	Commun	Signal,	2018.	16(1):	p.	48.	15.	 Lindstrom,	L.S.,	et	al.,	Clinically	used	breast	cancer	markers	such	as	estrogen	
receptor,	progesterone	receptor,	and	human	epidermal	growth	factor	receptor	2	are	
unstable	throughout	tumor	progression.	J	Clin	Oncol,	2012.	30(21):	p.	2601-8.	16.	 Rybinski,	B.	and	K.	Yun,	Addressing	intra-tumoral	heterogeneity	and	therapy	
resistance.	Oncotarget,	2016.	7(44):	p.	72322-72342.	17.	 Rueda,	O.M.,	et	al.,	Dynamics	of	breast-cancer	relapse	reveal	late-recurring	ER-
positive	genomic	subgroups.	Nature,	2019.	18.	 Criscitiello,	C.,	et	al.,	Biopsy	confirmation	of	metastatic	sites	in	breast	cancer	patients:	
clinical	impact	and	future	perspectives.	Breast	cancer	research	:	BCR,	2014.	16(2):	p.	205-205.	19.	 Toss,	A.,	et	al.,	CTC	enumeration	and	characterization:	moving	toward	personalized	
medicine.	Ann	Transl	Med,	2014.	2(11):	p.	108.	20.	 Fidler,	I.J.,	The	relationship	of	embolic	homogeneity,	number,	size	and	viability	to	the	
incidence	of	experimental	metastasis.	Eur	J	Cancer,	1973.	9(3):	p.	223-7.	
- 107 - 
 
 
21.	 Aceto,	N.,	et	al.,	Circulating	tumor	cell	clusters	are	oligoclonal	precursors	of	breast	
cancer	metastasis.	Cell,	2014.	158(5):	p.	1110-1122.	22.	 Duda,	D.G.,	et	al.,	Malignant	cells	facilitate	lung	metastasis	by	bringing	their	own	soil.	Proc	Natl	Acad	Sci	U	S	A,	2010.	107(50):	p.	21677-82.	23.	 Sarioglu,	A.F.,	et	al.,	A	microfluidic	device	for	label-free,	physical	capture	of	circulating	
tumor	cell	clusters.	Nat	Methods,	2015.	12(7):	p.	685-91.	24.	 Yu,	M.,	et	al.,	Circulating	breast	tumor	cells	exhibit	dynamic	changes	in	epithelial	and	
mesenchymal	composition.	Science,	2013.	339(6119):	p.	580-4.	25.	 Jansson,	S.,	et	al.,	Prognostic	impact	of	circulating	tumor	cell	apoptosis	and	clusters	in	
serial	blood	samples	from	patients	with	metastatic	breast	cancer	in	a	prospective	
observational	cohort.	BMC	cancer,	2016.	16:	p.	433-433.	26.	 Aceto,	N.,	et	al.,	En	Route	to	Metastasis:	Circulating	Tumor	Cell	Clusters	and	
Epithelial-to-Mesenchymal	Transition.	Trends	Cancer,	2015.	1(1):	p.	44-52.	27.	 Zheng,	X.,	et	al.,	Epithelial-to-mesenchymal	transition	is	dispensable	for	metastasis	
but	induces	chemoresistance	in	pancreatic	cancer.	Nature,	2015.	527(7579):	p.	525-530.	28.	 Fischer,	K.R.,	et	al.,	Epithelial-to-mesenchymal	transition	is	not	required	for	lung	
metastasis	but	contributes	to	chemoresistance.	Nature,	2015.	527(7579):	p.	472-6.	29.	 Gkountela,	S.,	et	al.,	Recent	advances	in	the	biology	of	human	circulating	tumour	cells	
and	metastasis.	ESMO	Open,	2016.	1(4):	p.	e000078.	30.	 Maheswaran,	S.,	et	al.,	Detection	of	mutations	in	EGFR	in	circulating	lung-cancer	cells.	N	Engl	J	Med,	2008.	359(4):	p.	366-77.	31.	 Cristofanilli,	M.,	et	al.,	The	clinical	use	of	circulating	tumor	cells	(CTCs)	enumeration	
for	staging	of	metastatic	breast	cancer	(MBC):	International	expert	consensus	paper.	Crit	Rev	Oncol	Hematol,	2019.	134:	p.	39-45.	32.	 Joosse,	S.A.,	T.M.	Gorges,	and	K.	Pantel,	Biology,	detection,	and	clinical	implications	of	
circulating	tumor	cells.	EMBO	Mol	Med,	2015.	7(1):	p.	1-11.	33.	 Riethdorf,	S.,	et	al.,	Detection	of	circulating	tumor	cells	in	peripheral	blood	of	patients	
with	metastatic	breast	cancer:	a	validation	study	of	the	CellSearch	system.	Clin	Cancer	Res,	2007.	13(3):	p.	920-8.	34.	 Nagrath,	S.,	et	al.,	Isolation	of	rare	circulating	tumour	cells	in	cancer	patients	by	
microchip	technology.	Nature,	2007.	450(7173):	p.	1235-9.	35.	 Ozkumur,	E.,	et	al.,	Inertial	focusing	for	tumor	antigen-dependent	and	-independent	
sorting	of	rare	circulating	tumor	cells.	Sci	Transl	Med,	2013.	5(179):	p.	179ra47.	36.	 Chudziak,	J.,	et	al.,	Clinical	evaluation	of	a	novel	microfluidic	device	for	epitope-
independent	enrichment	of	circulating	tumour	cells	in	patients	with	small	cell	lung	
cancer.	Analyst,	2016.	141(2):	p.	669-78.	37.	 Hou,	H.W.,	et	al.,	Isolation	and	retrieval	of	circulating	tumor	cells	using	centrifugal	
forces.	Sci	Rep,	2013.	3:	p.	1259.	38.	 Galanzha,	E.I.	and	V.P.	Zharov,	Circulating	Tumor	Cell	Detection	and	Capture	by	
Photoacoustic	Flow	Cytometry	in	Vivo	and	ex	Vivo.	Cancers	(Basel),	2013.	5(4):	p.	1691-738.	39.	 Tauriello,	D.V.F.,	et	al.,	TGFbeta	drives	immune	evasion	in	genetically	reconstituted	
colon	cancer	metastasis.	Nature,	2018.	554(7693):	p.	538-543.	40.	 Quail,	D.F.	and	J.A.	Joyce,	Microenvironmental	regulation	of	tumor	progression	and	
metastasis.	Nature	medicine,	2013.	19(11):	p.	1423-1437.	41.	 Salvatore,	V.,	et	al.,	The	tumor	microenvironment	promotes	cancer	progression	and	
cell	migration.	Oncotarget,	2016.	8(6):	p.	9608-9616.	
- 108 - 
 
 
42.	 Mlecnik,	B.,	et	al.,	The	tumor	microenvironment	and	Immunoscore	are	critical	
determinants	of	dissemination	to	distant	metastasis.	Sci	Transl	Med,	2016.	8(327):	p.	327ra26.	43.	 Wculek,	S.K.	and	I.	Malanchi,	Neutrophils	support	lung	colonization	of	metastasis-
initiating	breast	cancer	cells.	Nature,	2015.	528(7582):	p.	413-7.	44.	 Toor,	S.M.,	et	al.,	Myeloid	cells	in	circulation	and	tumor	microenvironment	of	breast	
cancer	patients.	Cancer	Immunol	Immunother,	2017.	66(6):	p.	753-764.	45.	 Li,	B.,	et	al.,	Landscape	of	tumor-infiltrating	T	cell	repertoire	of	human	cancers.	Nat	Genet,	2016.	48(7):	p.	725-32.	46.	 Soncin,	I.,	et	al.,	The	tumour	microenvironment	creates	a	niche	for	the	self-renewal	of	
tumour-promoting	macrophages	in	colon	adenoma.	Nat	Commun,	2018.	9(1):	p.	582.	47.	 Michea,	P.,	et	al.,	Adjustment	of	dendritic	cells	to	the	breast-cancer	microenvironment	
is	subset	specific.	Nat	Immunol,	2018.	19(8):	p.	885-897.	48.	 Sjodahl,	G.,	et	al.,	Infiltration	of	CD3(+)	and	CD68(+)	cells	in	bladder	cancer	is	subtype	
specific	and	affects	the	outcome	of	patients	with	muscle-invasive	tumors.	Urol	Oncol,	2014.	32(6):	p.	791-7.	49.	 Sideras,	K.,	et	al.,	PD-L1,	Galectin-9	and	CD8(+)	tumor-infiltrating	lymphocytes	are	
associated	with	survival	in	hepatocellular	carcinoma.	Oncoimmunology,	2017.	6(2):	p.	e1273309.	50.	 Hotta,	K.,	et	al.,	Magnitude	of	the	benefit	of	progression-free	survival	as	a	potential	
surrogate	marker	in	phase	3	trials	assessing	targeted	agents	in	molecularly	selected	
patients	with	advanced	non-small	cell	lung	cancer:	systematic	review.	PLoS	One,	2015.	10(3):	p.	e0121211.	51.	 He,	G.,	et	al.,	Peritumoural	neutrophils	negatively	regulate	adaptive	immunity	via	the	
PD-L1/PD-1	signalling	pathway	in	hepatocellular	carcinoma.	J	Exp	Clin	Cancer	Res,	2015.	34:	p.	141.	52.	 Feng,	S.,	et	al.,	Myeloid-derived	suppressor	cells	inhibit	T	cell	activation	through	
nitrating	LCK	in	mouse	cancers.	Proc	Natl	Acad	Sci	U	S	A,	2018.	115(40):	p.	10094-10099.	53.	 Su,	S.,	et	al.,	Immune	Checkpoint	Inhibition	Overcomes	ADCP-Induced	
Immunosuppression	by	Macrophages.	Cell,	2018.	175(2):	p.	442-457.e23.	54.	 Multhoff,	G.,	M.	Molls,	and	J.	Radons,	Chronic	inflammation	in	cancer	development.	Front	Immunol,	2011.	2:	p.	98.	55.	 Stockmann,	C.,	et	al.,	Deletion	of	vascular	endothelial	growth	factor	in	myeloid	cells	
accelerates	tumorigenesis.	Nature,	2008.	456(7223):	p.	814-8.	56.	 Wilke,	C.M.,	et	al.,	Prognostic	significance	of	regulatory	T	cells	in	tumor.	Int	J	Cancer,	2010.	127(4):	p.	748-58.	57.	 Wolf,	A.M.,	et	al.,	Increase	of	regulatory	T	cells	in	the	peripheral	blood	of	cancer	
patients.	Clin	Cancer	Res,	2003.	9(2):	p.	606-12.	58.	 Kerkar,	S.P.	and	N.P.	Restifo,	Cellular	constituents	of	immune	escape	within	the	tumor	
microenvironment.	Cancer	Res,	2012.	72(13):	p.	3125-30.	59.	 Gong,	J.,	et	al.,	Development	of	PD-1	and	PD-L1	inhibitors	as	a	form	of	cancer	
immunotherapy:	a	comprehensive	review	of	registration	trials	and	future	
considerations.	J	Immunother	Cancer,	2018.	6(1):	p.	8.	60.	 Rowshanravan,	B.,	N.	Halliday,	and	D.M.	Sansom,	CTLA-4:	a	moving	target	in	
immunotherapy.	Blood,	2018.	131(1):	p.	58-67.	61.	 Du,	W.,	et	al.,	TIM-3	as	a	Target	for	Cancer	Immunotherapy	and	Mechanisms	of	
Action.	Int	J	Mol	Sci,	2017.	18(3).	
- 109 - 
 
 
62.	 Powell,	A.A.,	et	al.,	Single	cell	profiling	of	circulating	tumor	cells:	transcriptional	
heterogeneity	and	diversity	from	breast	cancer	cell	lines.	PLoS	One,	2012.	7(5):	p.	e33788.	63.	 Polzer,	B.,	et	al.,	Molecular	profiling	of	single	circulating	tumor	cells	with	diagnostic	
intention.	EMBO	Mol	Med,	2014.	6(11):	p.	1371-86.	64.	 Suzuki,	A.,	et	al.,	Single-cell	analysis	of	lung	adenocarcinoma	cell	lines	reveals	diverse	
expression	patterns	of	individual	cells	invoked	by	a	molecular	target	drug	treatment.	Genome	Biol,	2015.	16:	p.	66.	65.	 Macaulay,	I.C.,	et	al.,	G&T-seq:	parallel	sequencing	of	single-cell	genomes	and	
transcriptomes.	Nat	Methods,	2015.	12(6):	p.	519-22.	66.	 Schwartzman,	O.	and	A.	Tanay,	Single-cell	epigenomics:	techniques	and	emerging	
applications.	Nat	Rev	Genet,	2015.	16(12):	p.	716-26.	67.	 Wu,	M.	and	A.K.	Singh,	Single-cell	protein	analysis.	Curr	Opin	Biotechnol,	2012.	
23(1):	p.	83-8.	68.	 Yu,	M.,	et	al.,	Cancer	therapy.	Ex	vivo	culture	of	circulating	breast	tumor	cells	for	
individualized	testing	of	drug	susceptibility.	Science,	2014.	345(6193):	p.	216-20.	69.	 Macaulay,	I.C.,	et	al.,	Separation	and	parallel	sequencing	of	the	genomes	and	
transcriptomes	of	single	cells	using	G&T-seq.	Nat	Protoc,	2016.	11(11):	p.	2081-103.	70.	 Chen,	S.,	et	al.,	Genome-wide	CRISPR	screen	in	a	mouse	model	of	tumor	growth	and	
metastasis.	Cell,	2015.	160(6):	p.	1246-60.	71.	 Li,	H.,	et	al.,	Reference	component	analysis	of	single-cell	transcriptomes	elucidates	
cellular	heterogeneity	in	human	colorectal	tumors.	Nat	Genet,	2017.	49(5):	p.	708-718.	72.	 Szczerba,	B.M.,	et	al.,	Neutrophils	escort	circulating	tumour	cells	to	enable	cell	cycle	
progression.	Nature,	2019.	566(7745):	p.	553-557.	73.	 Pantel,	K.	and	M.R.	Speicher,	The	biology	of	circulating	tumor	cells.	Oncogene,	2016.	
35(10):	p.	1216-24.	74.	 Xu,	L.,	et	al.,	Optimization	and	Evaluation	of	a	Novel	Size	Based	Circulating	Tumor	
Cell	Isolation	System.	PLoS	One,	2015.	10(9):	p.	e0138032.	75.	 Fridlender,	Z.G.,	et	al.,	Polarization	of	tumor-associated	neutrophil	phenotype	by	TGF-
beta:	"N1"	versus	"N2"	TAN.	Cancer	Cell,	2009.	16(3):	p.	183-94.	76.	 Cristofanilli,	M.,	et	al.,	Circulating	tumor	cells,	disease	progression,	and	survival	in	
metastatic	breast	cancer.	N	Engl	J	Med,	2004.	351(8):	p.	781-91.	77.	 Labelle,	M.,	S.	Begum,	and	R.O.	Hynes,	Direct	signaling	between	platelets	and	cancer	
cells	induces	an	epithelial-mesenchymal-like	transition	and	promotes	metastasis.	Cancer	Cell,	2011.	20(5):	p.	576-90.	78.	 Rothstein,	G.,	et	al.,	Stimulation	of	neutrophil	production	in	CSF-1-responsive	clones.	Blood,	1988.	72(3):	p.	898-902.	79.	 He,	J.Q.,	et	al.,	Association	of	genetic	variations	in	the	CSF2	and	CSF3	genes	with	lung	
function	in	smoking-induced	COPD.	Eur	Respir	J,	2008.	32(1):	p.	25-34.	80.	 Verri,	W.A.,	Jr.,	et	al.,	IL-15	mediates	antigen-induced	neutrophil	migration	by	
triggering	IL-18	production.	Eur	J	Immunol,	2007.	37(12):	p.	3373-80.	81.	 Kacinski,	B.M.,	et	al.,	FMS	(CSF-1	receptor)	and	CSF-1	transcripts	and	protein	are	
expressed	by	human	breast	carcinomas	in	vivo	and	in	vitro.	Oncogene,	1991.	6(6):	p.	941-52.	82.	 McCracken,	J.M.	and	L.A.	Allen,	Regulation	of	human	neutrophil	apoptosis	and	
lifespan	in	health	and	disease.	J	Cell	Death,	2014.	7:	p.	15-23.	83.	 Canli,	O.,	et	al.,	Myeloid	Cell-Derived	Reactive	Oxygen	Species	Induce	Epithelial	
Mutagenesis.	Cancer	Cell,	2017.	32(6):	p.	869-883	e5.	
- 110 - 
 
 
84.	 Alexandrov,	L.B.,	et	al.,	Signatures	of	mutational	processes	in	human	cancer.	Nature,	2013.	500(7463):	p.	415-21.	85.	 Wellenstein,	M.D.	and	K.E.	de	Visser,	Cancer-Cell-Intrinsic	Mechanisms	Shaping	the	
Tumor	Immune	Landscape.	Immunity,	2018.	48(3):	p.	399-416.	86.	 Ramasamy,	S.,	et	al.,	Tle1	tumor	suppressor	negatively	regulates	inflammation	in	vivo	
and	modulates	NF-kappaB	inflammatory	pathway.	Proc	Natl	Acad	Sci	U	S	A,	2016.	
113(7):	p.	1871-6.	87.	 Egeblad,	M.	and	K.E.	de	Visser,	Sticking	together	helps	cancer	to	spread.	Nature,	2019.	566(7745):	p.	459-460.	88.	 Vetter,	M.,	et	al.,	Denosumab	treatment	is	associated	with	the	absence	of	circulating	
tumor	cells	in	patients	with	breast	cancer.	Breast	Cancer	Res,	2018.	20(1):	p.	141.	89.	 Rack,	B.,	et	al.,	Circulating	tumor	cells	predict	survival	in	early	average-to-high	risk	
breast	cancer	patients.	J	Natl	Cancer	Inst,	2014.	106(5).	90.	 Giuliano,	M.,	et	al.,	Circulating	tumor	cells	as	prognostic	and	predictive	markers	in	
metastatic	breast	cancer	patients	receiving	first-line	systemic	treatment.	Breast	Cancer	Res,	2011.	13(3):	p.	R67.	91.	 Carter,	L.,	et	al.,	Molecular	analysis	of	circulating	tumor	cells	identifies	distinct	copy-
number	profiles	in	patients	with	chemosensitive	and	chemorefractory	small-cell	lung	
cancer.	Nat	Med,	2017.	23(1):	p.	114-119.	92.	 Kaifi,	J.T.,	et	al.,	Circulating	tumor	cell	levels	are	elevated	in	colorectal	cancer	patients	
with	high	tumor	burden	in	the	liver.	Cancer	Biol	Ther,	2015.	16(5):	p.	690-8.	93.	 Cristofanilli,	M.,	et	al.,	Circulating	tumor	cells	in	metastatic	breast	cancer:	biologic	
staging	beyond	tumor	burden.	Clin	Breast	Cancer,	2007.	7(6):	p.	471-9.	94.	 Whitaker,	M.,	et	al.,	Bisphosphonates	for	osteoporosis--where	do	we	go	from	here?	N	Engl	J	Med,	2012.	366(22):	p.	2048-51.	95.	 Hanley,	D.A.,	et	al.,	Denosumab:	mechanism	of	action	and	clinical	outcomes.	Int	J	Clin	Pract,	2012.	66(12):	p.	1139-46.	96.	 Blake,	M.L.,	et	al.,	RANK	expression	on	breast	cancer	cells	promotes	skeletal	
metastasis.	Clin	Exp	Metastasis,	2014.	31(2):	p.	233-45.	97.	 Pfitzner,	B.M.,	et	al.,	RANK	expression	as	a	prognostic	and	predictive	marker	in	breast	
cancer.	Breast	Cancer	Res	Treat,	2014.	145(2):	p.	307-15.	98.	 Jordan,	N.V.,	et	al.,	HER2	expression	identifies	dynamic	functional	states	within	
circulating	breast	cancer	cells.	Nature,	2016.	537(7618):	p.	102-106.	99.	 Houssami,	N.,	et	al.,	HER2	discordance	between	primary	breast	cancer	and	its	paired	
metastasis:	tumor	biology	or	test	artefact?	Insights	through	meta-analysis.	Breast	Cancer	Res	Treat,	2011.	129(3):	p.	659-74.	100.	 Anderson,	W.F.,	et	al.,	Comparison	of	age	distribution	patterns	for	different	
histopathologic	types	of	breast	carcinoma.	Cancer	Epidemiol	Biomarkers	Prev,	2006.	
15(10):	p.	1899-905.	101.	 Adami,	H.O.,	et	al.,	The	relation	between	survival	and	age	at	diagnosis	in	breast	
cancer.	N	Engl	J	Med,	1986.	315(9):	p.	559-63.	102.	 Fredholm,	H.,	et	al.,	Long-term	outcome	in	young	women	with	breast	cancer:	a	
population-based	study.	Breast	Cancer	Res	Treat,	2016.	160(1):	p.	131-143.	103.	 Bleyer,	A.,	et	al.,	The	distinctive	biology	of	cancer	in	adolescents	and	young	adults.	Nat	Rev	Cancer,	2008.	8(4):	p.	288-98.	104.	 Koleckova,	M.,	et	al.,	Age-associated	prognostic	and	predictive	biomarkers	in	patients	
with	breast	cancer.	Oncol	Lett,	2017.	13(6):	p.	4201-4207.	105.	 Duffy,	M.J.,	CA	15-3	and	related	mucins	as	circulating	markers	in	breast	cancer.	Ann	Clin	Biochem,	1999.	36	(	Pt	5):	p.	579-86.	
- 111 - 
 
 
106.	 Oken,	M.M.,	et	al.,	Toxicity	and	response	criteria	of	the	Eastern	Cooperative	Oncology	
Group.	Am	J	Clin	Oncol,	1982.	5(6):	p.	649-55.	107.	 Khoo,	B.L.,	et	al.,	Expansion	of	patient-derived	circulating	tumor	cells	from	liquid	
biopsies	using	a	CTC	microfluidic	culture	device.	Nat	Protoc,	2018.	13(1):	p.	34-58.	108.	 Lu,	X.	and	Y.	Kang,	Hypoxia	and	hypoxia-inducible	factors:	master	regulators	of	
metastasis.	Clin	Cancer	Res,	2010.	16(24):	p.	5928-35.	109.	 Verma,	R.,	et	al.,	Lymphocyte	depletion	and	repopulation	after	chemotherapy	for	
primary	breast	cancer.	Breast	cancer	research	:	BCR,	2016.	18(1):	p.	10-10.	110.	 Grimm,	R.H.,	Jr.,	J.D.	Neaton,	and	W.	Ludwig,	Prognostic	importance	of	the	white	
blood	cell	count	for	coronary,	cancer,	and	all-cause	mortality.	Jama,	1985.	254(14):	p.	1932-7.	111.	 Bruckner,	H.W.,	et	al.,	Absolute	Granulocyte,	Lymphocyte,	and	Monocyte	Counts:	
Useful	Determinants	of	Prognosis	for	Patients	With	Metastatic	Cancer	of	the	Stomach.	JAMA,	1982.	247(7):	p.	1004-1006.	112.	 Aliustaoglu,	M.,	et	al.,	The	effect	of	peripheral	blood	values	on	prognosis	of	patients	
with	locally	advanced	gastric	cancer	before	treatment.	2010.	27(4):	p.	1060-1065.	113.	 Sasaki,	A.,	et	al.,	Prognostic	Value	of	Preoperative	Peripheral	Blood	Monocyte	Count	in	
Patients	with	Colorectal	Liver	Metastasis	after	Liver	Resection.	2007.	11(5):	p.	596-602.	114.	 Gkountela,	S.,	et	al.,	Circulating	Tumor	Cell	Clustering	Shapes	DNA	Methylation	to	
Enable	Metastasis	Seeding.	Cell,	2019.	176(1-2):	p.	98-112	e14.	115.	 Krol,	I.,	et	al.,	Detection	of	circulating	tumour	cell	clusters	in	human	glioblastoma.	Br	J	Cancer,	2018.	119(4):	p.	487-491.	
 
  
- 112 - 
 
 
OTHER SCIENTIFIC CONTRIBUTIONS 
 
Over the course of my studies I had a chance to support multiple other projects, all listed below. 
 
Internal: 
Dr. Sofia Gkountela on “Circulating Tumor Cell Clustering Shapes DNA Methylation to Enable 
Metastasis Seeding”, Cell, 2019 [114] 
 
Ilona Krol on “Detection of circulating tumour cell clusters in human glioblastoma”, British 
Journal of Cancer, 2018 [115] 
 
Cinzia Donato on “Hypoxia Triggers the Intravasation of Clustered Circulating Tumor Cells”, 
ongoing PhD project 
 
Manuel Scheidmann on “Genome-wide CRISPR Screen to Identify Genes Required for CTC 
Cluster Formation and Maintenance”, ongoing PhD project 
 
Aino Alise Paasinen Sohns on “Tracing the regions of origins of various liquid biopsy 
components circulating in blood using barcoded human breast cancer xenograft models”,  
ongoing project 
 
External: 
Prof. Dr. Andrew Ewald on “E-cadherin is an invasion suppressor, survival factor, and 
metastasis promoter across multiple models of breast cancer”, Nature, under revisions 
 
Dr. Marta Cavo on “A novel bioreactor enables spontaneous metastasis modeling in vitro”, 
Biotechnology and Bioengineering, manuscript in preparation 
 
Stefanie Tiede on “Tumor heterogeneity during the progression of metastatic breast cancer”, a 
PhD project 
 
Fabiana Lüönd on “Tracing Epithelial-to-Mesenchymal Transition in Breast Cancer”, a PhD 
project 
- 113 - 
 
 
 
Dr. Nami Matsuda, Dr. Vida Vafaizadeh and Prof. Dr. Maries van den Broek on CTC detection 
from mouse models 
 
Dr. Alessio Zippo on sequencing of CTC and primary tumor in NSG-IMEC-MYC-PIK3CA 
model 
 
Prof. Dr. Luigi Mariani on establishing single cell parallel DNA and RNA sequencing 
 
Armbrecht Lucas on establishing microfluidic chip for CTC capture and characterization 
 
Team of Prof. Dr. Timm Schroeder on hematopoietic cells isolation including semi-adherent 
cells 
 
Dr. Roberta Carbone from Tethis on KRAS sequencing from laser microdissected CTCs 
 
Prof. Dr. Werner Baumgartner on in vivo CTC cluster dissociation 
 
PD Dr. Andrea Banfi on picking fixed tissue from cryosections and RNA-seq 
 
Prof. Tobias Junt from Novartis on his Sjogren’s Syndrome studies 
 
 
Moreover, I have contributed by co-authoring several review articles: 
 
Gkountela S, Szczerba B, Donato C, Aceto N. Recent advances in the biology of human 
circulating tumour cells and metastasis. ESMO Open, 2016 [29] 
 
Marass F, Castro-Giner F, Szczerba B, Jahn K, Kuipers J, Aceto N, Beerenwinkel N. 
Computational analysis of DNA and RNA sequencing data obtained from liquid biopsies. Book 
chapter in ‘Liquid Tumor Biopsies’ by Springer, 2019 (in press) 
 
 
 
 
- 114 - 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CO-AUTHORED PUBLICATIONS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CTC-neutrophil cluster by Aga Jakimiec 
Letter
https://doi.org/10.1038/s41586-019-0915-y
Neutrophils escort circulating tumour cells to 
enable cell cycle progression
 Barbara Maria Szczerba1, Francesc Castro-Giner1,2, Marcus Vetter3,4, Ilona Krol1, Sofia Gkountela1, Julia Landin4,  
Manuel C. Scheidmann1, Cinzia Donato1, ramona Scherrer1, Jochen Singer2,5, Christian Beisel5, Christian Kurzeder3,6,  
Viola Heinzelmann-Schwarz3, Christoph rochlitz4, Walter Paul Weber6, Niko Beerenwinkel2,5 & Nicola Aceto1*
A better understanding of the features that define the interaction 
between cancer cells and immune cells is important for the 
development of new cancer therapies1. However, focus is often 
given to interactions that occur within the primary tumour and 
its microenvironment, whereas the role of immune cells during 
cancer dissemination in patients remains largely uncharacterized2,3. 
Circulating tumour cells (CTCs) are precursors of metastasis in 
several types of cancer4–6, and are occasionally found within the 
bloodstream in association with non-malignant cells such as white 
blood cells (WBCs)7,8. The identity and function of these CTC-
associated WBCs, as well as the molecular features that define 
the interaction between WBCs and CTCs, are unknown. Here 
we isolate and characterize individual CTC-associated WBCs, as 
well as corresponding cancer cells within each CTC–WBC cluster, 
from patients with breast cancer and from mouse models. We use 
single-cell RNA sequencing to show that in the majority of these 
cases, CTCs were associated with neutrophils. When comparing 
the transcriptome profiles of CTCs associated with neutrophils 
against those of CTCs alone, we detect a number of differentially 
expressed genes that outline cell cycle progression, leading to 
more efficient metastasis formation. Further, we identify cell–cell 
junction and cytokine–receptor pairs that define CTC–neutrophil 
clusters, representing key vulnerabilities of the metastatic process. 
Thus, the association between neutrophils and CTCs drives 
cell cycle progression within the bloodstream and expands the 
metastatic potential of CTCs, providing a rationale for targeting 
this interaction in treatment of breast cancer.
CTCs are precursors of metastasis in various solid cancers, including 
breast cancer6, and are occasionally found in association with WBCs7. 
The role of CTC–WBC clusters in the development of metastasis as 
well as the principles that govern the interactions between CTCs and 
WBCs during blood-borne dissemination are largely uncharacterized.
We first sought to determine the number and composition of CTC–
WBC clusters in patients with breast cancer and mouse models. We 
obtained blood samples from 70 patients with invasive breast cancer 
who discontinued their treatment owing to progressive disease, as 
well as from five different breast cancer mouse models, and enriched 
for CTCs using the Parsortix microfluidic device9 (Extended Data 
Fig. 1a–e). We stained CTCs for cancer-associated cell-surface markers 
EpCAM, HER2 and EGFR or imaged directly for the expression of 
GFP, and labelled for CD45 to identify WBCs (Fig. 1a, Extended 
Data Fig. 1f). Among 70 patients, 34 (48.6%) had detectable CTCs, 
with a mean number of 22 CTCs per 7.5 ml of blood (Supplementary 
Tables 1, 2). Whereas the majority of CTCs were single (88.0%), we also 
detected CTC clusters (8.6%) and CTC–WBC clusters (3.4%) (Fig. 1b, 
Extended Data Fig. 1g, h). Similarly, we observed that CTC–WBC clus-
ters were present in all of the mouse models we tested, including those 
with immunodeficient or immunocompetent backgrounds, ranging 
from 0.05% to 61% of the total CTC population (Fig. 1b, Extended 
Data Fig. 1i, j). Of note, CTC abundance and ratios markedly changed 
when drawing blood upstream of capillary beds as opposed to loca-
tions further downstream, which indicates that clustered CTCs are shed 
early yet may be trapped in capillaries before reaching the periphery 
(Extended Data Fig. 1k–n). Thus, CTC–WBC clusters are rare in the 
peripheral circulation yet consistently found in patients with breast 
cancer and in mouse models.
We then determined the type of WBCs found in CTC–WBC clusters. 
We used a robotic micromanipulator to dissociate CTC–WBC clusters 
(Supplementary Video 1), enabling single-cell RNA sequencing analysis 
of cluster-associated WBCs and their comparison to reference WBCs 
from matched donors (Fig. 1c) using reference component analysis10. 
In patients, we found that 75% of CTC-associated WBCs were related 
to the myeloid lineage, whereas the remaining (25%) were similar to 
T cells (Fig. 1d, Extended Data Fig. 2a, b). Likewise, we found that 
93% of CTC-associated WBCs from mouse models were also char-
acterized by a myeloid-cell-like expression profile (Extended Data 
Fig. 2c–e). To determine the proportion of CTC-associated WBCs that 
are neutrophils, monocytes or macrophages, we labelled CTC–WBC 
clusters for Ly-6G, CD11b and F4/80, as well as with Wright–Giemsa 
staining to define nuclear morphology (Extended Data Fig. 2f, g). We 
found that the vast majority (85.5%–91.7%) of CTC-associated WBCs 
were positive for Ly-6G and displayed a nuclear morphology typical 
of neutrophils, whereas a minority (8.3%–14.5%) were monocytes 
(CD11b+F4/80–Ly-6G–), and no F4/80+ macrophages were found 
(Fig. 1e, f, Extended Data Fig. 2h–j). Further, RNA sequencing analysis 
revealed expression of ARG1, CXCL1, CXCL2, CXCL10, CCL2, CXCR2 
and VEGFA in most CTC-associated neutrophils from patients (or their 
orthologues in mouse models) (Extended Data Fig. 2k), which indicates 
that CTC-associated neutrophils have a gene expression profile that is 
similar to that of pro-tumour N2-like cells11.
We next investigated whether the presence of CTC–neutrophil 
clusters in patients with breast cancer could predict disease outcome. 
Of note, patients in whom at least one CTC–neutrophil cluster was 
detected in 7.5 ml of peripheral blood were characterized by a signifi-
cantly worse progression-free survival compared to patients with five 
or more CTCs per 7.5 ml of peripheral blood (previously defined as a 
threshold for adverse outcome12) (Fig. 1g), as well as when compared 
to all patients with no CTC–neutrophil clusters, patients with at least 
one CTC per 7.5 ml of blood or patients in whom either single CTCs 
or CTC clusters were found (Extended Data Fig. 3a–c). In addition, we 
individually micromanipulated equal numbers of CTCs from CTC–
neutrophil clusters, CTC clusters and single CTCs, spontaneously 
generated from tumour-bearing mice, and intravenously injected 100 
CTCs per mouse into tumour-free recipient mice from each of these cat-
egories. We found that mice injected with CTCs from CTC–neutrophil 
clusters developed overt metastasis much faster than those injected 
with CTCs alone and, accordingly, survived for a shorter time (Fig. 1h, 
Extended Data Fig. 3d–h). Thus, CTC–neutrophil clusters represent 
1Department of Biomedicine, Cancer Metastasis Lab, University of Basel and University Hospital Basel, Basel, Switzerland. 2SIB Swiss Institute of Bioinformatics, Lausanne, Switzerland. 
3Gynecologic Cancer Center, University Hospital Basel, Basel, Switzerland. 4Department of Medical Oncology, University Hospital Basel, Basel, Switzerland. 5Department of Biosystems Science  
and Engineering, ETH Zurich, Basel, Switzerland. 6Breast Center, University of Basel and University Hospital Basel, Basel, Switzerland. *e-mail: Nicola.Aceto@unibas.ch
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the most efficient metastasis-forming cell subpopulation among breast 
CTCs, and their presence in the bloodstream of patients is associated 
with a poor prognosis.
We next sought to determine the molecular outcome of the 
interaction between CTCs and neutrophils by dissociating CTC– 
neutrophil clusters and comparing the expression profile of CTCs 
from CTC–neutrophil clusters to that of CTCs alone (Fig. 2a). 
We first determined differential gene expression in the syngeneic 
BALB/c-4T1-GFP model, which provided the highest number of 
CTCs from CTC–neutrophil clusters (n = 25). Compared to CTCs 
that were not associated with neutrophils, we found that CTCs from 
CTC–neutrophil clusters are characterized by differential expression 
of a set of 51 genes, of which 41 are upregulated and 10 are down-
regulated (Fig. 2b, Supplementary Tables 3, 4). Pathway analysis of 
the upregulated genes revealed that CTCs from CTC–neutrophil 
clusters display a marked enrichment in positive regulators of cell 
cycle and DNA replication programs compared to CTCs alone 
(Fig. 2c), independently of the number of detected features or reads 
in each individual sample (Extended Data Fig. 4a). The same results 
were obtained with CTCs from patients with breast cancer (Fig. 2c, 
Extended Data Fig. 4b). Immunofluorescence staining of CTCs 
confirmed higher levels of Ki67 expression in CTCs from CTC– 
neutrophil clusters (Fig. 2d, e), consistent with the RNA sequencing 
results. By contrast, no significant differences were observed for 
genes involved in epithelial-to-mesenchymal transition, cancer stem-
cell markers or platelet-related genes13 (Extended Data Fig. 4c–h). 
We further investigated whether neutrophil proximity confers a 
proliferative advantage to cancer cells at the level of the primary 
tumour, disseminated tumour cells and overt metastasis. We found 
that Ki67 expression does not increase in cancer cells that surround 
tumour-infiltrated neutrophils in the primary tumour or overt 
metastasis (Extended Data Fig. 5a–d). However, higher Ki67 expres-
sion is retained in disseminated tumour cells from CTC–neutrophil 
clusters (Extended Data Fig. 5e, f), that is, when they are deprived 
of other stromal-derived signals that are typical of overt disease.
We then investigated which cytokines are expressed by CTC-
associated neutrophils and paralleled by simultaneous expression of 
matching cytokine receptor(s) in the corresponding cancer cells. We 
found that genes that encode four cytokines (TNF-α, OSM, IL-1β and 
IL-6) are most frequently expressed by CTC-associated neutrophils 
of patients or patient-derived mouse models and matched by expres-
sion of their receptors on the corresponding cancer cells (Extended 
Data Fig. 6a). With a reverse approach, we also found that CTCs from 
CTC–neutrophil clusters most frequently expressed genes that encode 
cytokines such as CSF1, CSF3 (also known as granulocyte colony- 
stimulating factor (G-CSF)), TGF-β3 and IL-15, possibly involved 
in neutrophil stimulation14–17, whereas corresponding neutrophils 
expressed their receptors (Extended Data Fig. 6b). Consistently, we 
observed that a 24-h in vitro treatment (coherent with neutrophil 
lifespan18) with IL6, IL-1β or both was sufficient to confer proliferative 
advantage to 4T1 cells upon dissemination, leading to faster metastasis 
development and shorter overall survival of mice (Fig. 2f, g, Extended 
Data Fig. 6c–e). Further, CRISPR-mediated knockout of IL-6 or IL-1β 
receptors in cancer cells (namely, IL6ST and IL1R1) did not alter the 
frequency of spontaneously generated CTC–neutrophil clusters, but 
did suppress their proliferative advantage (Extended Data Fig. 6f–h).
Given recent findings that highlight that the presence of myeloid 
cells in the primary tumour site leads to accumulation of mutational 
events19, we investigated whether the mutational load of CTCs obtained 
from CTC–neutrophil clusters is different from that of CTCs alone 
in patients (Fig. 3a). Interestingly, we found that the mutational bur-
den is similar between CTCs isolated from CTC–neutrophil clusters 
and CTCs alone, as well as when comparing donors with or without 
CTC–neutrophil clusters (Extended Data Fig. 7a, b). However, we 
observed that the overall frequency of C>T mutations was increased 
in CTCs from CTC–neutrophil clusters compared to CTCs alone, as 
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Fig. 1 | CTC–neutrophil clusters are highly efficient metastatic 
precursors. a, Representative images of a CTC–WBC cluster, a CTC 
cluster and a single CTC from NSG-CDX-BR16-GFP mice. CTCs are 
expressing GFP (green) and CTC-associated WBCs are labelled with 
anti-CD45 antibodies (red) (n = 8). b, Pie charts displaying the mean 
percentage of single CTCs (grey), CTC clusters (green) and CTC–WBC 
clusters (red) in patients with breast cancer and in mouse models. The 
number of independent biological replicates (n) is shown for each 
model. c, Schematic of the experimental design. CTC–WBC clusters 
are dissociated into individual cells and processed for RNA sequencing 
(RNA-seq). The transcriptome of CTC-associated WBCs is then compared 
to reference (ref.) WBCs. d, Reference component analysis clustering of 
CTC-associated WBCs and reference WBCs from patients with breast 
cancer, displaying projection scores of cells (columns; n = 50) on the 
immune reference panel (rows). e, Representative images of CTC–WBC 
clusters stained for Ly-6G (neutrophils, gold) together with GFP (cancer 
cells, green) (top) or processed with the Wright–Giemsa (WG) assay to 
define nuclear morphology (bottom) (n = 8). f, Pie charts showing the 
mean percentage of CTC–neutrophil clusters and CTC–monocyte clusters 
in individual models. The number of independent biological replicates 
(n) is shown for each model. g, Kaplan–Meier plot showing progression-
free survival of patients with breast cancer (n = 9 for patients with one or 
more CTC–neutrophil clusters and n = 10 for patients with five or more 
CTCs); P value by two-sided log-rank test is shown. h, Schematic of the 
experimental design. One hundred CTCs from CTC–neutrophil clusters or 
CTCs alone are injected in the tail vein of recipient mice to measure their 
metastatic potential (left). Kaplan–Meier plot showing overall survival 
of mice (right). n = 5 for CTC–neutrophil clusters and n = 10 for CTCs 
alone; P value by two-sided log-rank test is shown.
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well as in donors with CTC–neutrophil clusters, independent of the 
nucleotide context (that is, the nucleotides surrounding the mutation 
site) (Fig. 3b, Extended Data Fig. 7c, d). Although a general age-related 
accumulation of C>T mutations has previously been reported20, we 
did not observe any age difference between the two groups (Extended 
Data Fig. 7e). Next, considering only high-impact mutations as defined 
by the genomic variant annotations and functional effect prediction 
toolbox (SnpEff), we asked whether specific genes are exclusively 
and recurrently mutated in donors with CTC–neutrophil clusters. 
This scenario is consistent with a model in which particular genetic 
alterations influence the recruitment of immune cells to the primary 
tumour21 and increase the likelihood of generating CTC–neutrophil 
clusters. We found that a number of genes are indeed carrying high- 
impact mutations exclusively in donors with CTC–neutrophil clusters 
(Extended Data Fig. 7f, Supplementary Table 5). We then engineered 
4T1-GFP cells to individually express all of the mutations found in 
two of the most frequently mutated genes (MERTK and TLE1) and 
injected them in the mammary gland of NSG (NOD-scid-Il2rgnull) 
mice. We observed that the introduction of TLE1 mutations G1787A 
or G1509C led to a higher infiltration of neutrophils in the primary 
tumour and a higher proportion of spontaneously generated CTC–
neutrophil clusters (33–41-fold increase), without affecting primary 
tumour size (Fig. 3c, Extended Data Fig. 7g–k). These results are 
consistent with recent observations involving TLE1 function in regu-
lating infiltration of myeloid cells into normal and neoplastic tissues22. 
Conversely, co-culture of cancer cells with neutrophils did not result in 
the acquisition of mutations within the same hotspots (Extended Data 
Fig. 8a, b). Together, our data reveals that although the overall muta-
tional load remains unchanged, donors with CTC–neutrophil clusters 
feature a higher proportion of C>T substitutions and the presence 
of high-impact recurrent mutations in genes that promote neutrophil 
recruitment, such as TLE1.
We next tested whether the depletion or augmentation of the total 
neutrophil population would affect the ratio of spontaneously gener-
ated CTC–neutrophil clusters. We depleted neutrophils through in vivo 
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Fig. 3 | Whole-exome sequencing highlights recurrent mutational 
events in CTCs from CTC–neutrophil clusters. a, Schematic of the 
experimental design. CTC–neutrophil clusters are dissociated and 
then processed for whole-exome sequencing (WES). CTCs that were 
associated to neutrophils are compared to CTCs alone. b, Mutation 
distribution in CTCs from CTC–neutrophil clusters (n = 14) compared 
to CTCs alone (n = 56). Lines within the violin plots show the 25th, 50th 
and 75th percentile, respectively, and dots represent individual CTCs. 
P value by two-sided Wilcoxon sign-ranked test is shown. c, Pie charts 
displaying the mean percentage of single CTCs (grey), CTC clusters 
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(top). The number of independent biological replicates (n) is shown 
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are shown.
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treatment with neutralizing antibodies against Ly-6G (anti-Ly-6G) or, 
conversely, we stably overexpressed G-CSF to stimulate the produc-
tion and recruitment of neutrophils to the tumour site (Extended Data 
Fig. 9a). As expected, treatment with anti-Ly-6G reduced neutrophil 
infiltration to the primary tumour site, whereas G-CSF augmented 
it without altering primary tumour size (Extended Data Fig. 9b, c). 
However, anti-Ly-6G-treated mice completely lacked CTC–neutrophil 
clusters from the circulation and displayed a delayed CTC shedding 
rate compared to control mice, whereas overexpression of G-CSF led 
to earlier CTC release and substantially increased the proportion of 
CTC–neutrophil clusters (more than 88-fold) (Fig. 4a, Extended Data 
Fig. 9d–f). Consequently, neutrophil depletion or augmentation results 
in a delayed or accelerated metastasis development, respectively, mir-
rored by a shorter or longer overall survival of treated mice (Extended 
Data Fig. 9g, h). By contrast, neutrophil depletion with anti-Ly-6G is 
not effective when cancer cells are administered directly through intra-
venous injection of pre-treated mice (Extended Data Fig. 9i–l). Of note, 
in our cohort, G-CSF treatment of patients with breast cancer occurred 
more often in those patients that were positive for CTCs, including 
CTC–WBC clusters (Extended Data Fig. 9m). Thus, overall neutrophil 
abundance affects the likelihood that a tumour has to spontaneously 
shed CTC–neutrophil clusters.
We next sought to identify actionable vulnerabilities of CTC–neutrophil 
clusters without targeting the entire neutrophil population. To this end, 
we investigated cell–cell junction pairs expressed by CTC–neutrophil 
clusters and possibly mediating their heterotypic cell binding (Extended 
Data Fig. 10a, b). We engineered a CRISPR–Cas9-based loss-of- 
function mini-pool screen in vivo, whereby a pool of cells carrying indi-
vidual knockouts for F11r, Icam1, Itgb2 and Vcam1 are injected in the 
mammary gland of recipient mice, followed by CTC-targeted barcode 
sequencing to reveal selective single-guide RNA (sgRNA) dropouts, 
highlighting genes the knockout of which does not allow the formation 
of CTC–neutrophil clusters (Fig. 4b). Of note, we observed no differ-
ences in primary tumour growth and no selective sgRNA dropouts 
in primary tumour cells (Extended Data Fig. 10c, d), suggesting that 
knockout of F11r, Icam1, Itgb2 or Vcam1 does not affect proliferation 
in the primary tumour. However, we found that four out of four Vcam1 
sgRNAs selectively dropped out in CTCs from CTC–neutrophil clusters 
but were still present in CTCs alone (Fig. 4c), highlighting a possible 
VCAM1 requirement for CTC–neutrophil cluster formation. We 
further validated this finding using individual sgRNAs (Fig. 4d, 
Extended Data Fig. 10e). Thus, VCAM1 functionally mediates the 
interaction between CTCs and neutrophils, and its inhibition prevents 
the formation of CTC–neutrophil clusters.
Altogether, our data provide insights into the processes that define 
the interaction between cancer cells and immune cells during blood-
borne dissemination. We propose a model in which neutrophils 
directly interact with CTCs to support cell cycle progression in circu-
lation and to accelerate metastasis seeding. This mechanism of meta-
static spread and the possibility that CTC–neutrophil clusters may be 
targeted therapeutically provides an opportunity to reduce the spread 
of breast cancer.
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biological replicates (n) is shown for each condition. The plots show the 
mean fold change of CTC ratios from NSG-4T1-GFP mice treated with 
anti-Ly-6G antibodies or G-CSF overexpression (bottom). Error bars, 
s.e.m.; P values by two-sided Student’s t-test are shown. b, Schematic 
of the experimental design. 4T1-Cas9-GFP cells are transduced with a 
pool of sgRNAs targeting cell–cell junctions and injected in NSG mice. 
Upon tumour development, spontaneously generated CTC–neutrophil 
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Denosumab treatment is associated with
the absence of circulating tumor cells in
patients with breast cancer
Marcus Vetter1,2†, Julia Landin2†, Barbara Maria Szczerba3†, Francesc Castro-Giner3,4†, Sofia Gkountela3,
Cinzia Donato3, Ilona Krol3, Ramona Scherrer3, Catharina Balmelli2, Alexandra Malinovska2, Alfred Zippelius2,
Christian Kurzeder1,5, Viola Heinzelmann-Schwarz1, Walter Paul Weber5, Christoph Rochlitz2 and Nicola Aceto3*
Abstract
Background: The presence of circulating tumor cells (CTCs) in patients with breast cancer correlates to a bad prognosis.
Yet, CTCs are detectable in only a minority of patients with progressive breast cancer, and factors that influence the
abundance of CTCs remain elusive.
Methods: We conducted CTC isolation and enumeration in a selected group of 73 consecutive patients characterized
by progressive invasive breast cancer, high tumor load and treatment discontinuation at the time of CTC isolation.
CTCs were quantified with the Parsortix microfluidic device. Clinicopathological variables, blood counts at the
time of CTC isolation and detailed treatment history prior to blood sampling were evaluated for each patient.
Results: Among 73 patients, we detected at least one CTC per 7.5 ml of blood in 34 (46%). Of these, 22 (65%)
had single CTCs only, whereas 12 (35%) featured both single CTCs and CTC clusters. Treatment with the monoclonal
antibody denosumab correlated with the absence of CTCs, both when considering all patients and when considering
only those with bone metastasis. We also found that low red blood cell count was associated with the presence of
CTCs, whereas high CA 15-3 tumor marker, high mean corpuscular volume, high white blood cell count and high
mean platelet volume associated specifically with CTC clusters.
Conclusions: In addition to blood count correlatives to single and clustered CTCs, we found that denosumab
treatment associates with most patients lacking CTCs from their peripheral circulation. Prospective studies will
be needed to validate the involvement of denosumab in the prevention of CTC generation.
Keywords: Circulating tumor cells, Circulating tumor cell clusters, Denosumab, Breast cancer, Metastasis
Background
Circulating tumor cells (CTCs) are derivatives of solid
tumor lesions that detach from the tumor and enter the
bloodstream [1]. In patients with breast cancer, CTCs
have been shown to be predictive of a shorter
disease-free survival and overall survival [2, 3], with a
worse prognosis in patients who present with a count of
at least five CTCs per 7.5 ml of blood [2, 3]. Generally,
high CTC counts have been associated with a poor prog-
nosis in multiple settings, including those patients that
are newly diagnosed with metastatic breast cancer and
about to start a therapy [3, 4]. At the morphological
level, breast CTCs occur in the blood of patients as sin-
gle CTCs or as CTC clusters, with the latter being asso-
ciated with a shorter metastasis-free survival than in
patients in whom only single CTCs are found [5].
Although the association between CTCs and bad prog-
nosis is well established in breast cancer, CTCs are de-
tectable only in a subset (~ 20–40%) of patients [2, 5].
To date, no parameters have been found that could ex-
plain CTC abundance in patients, leading to difficulties
in enabling patient stratification prior to CTC-related
* Correspondence: nicola.aceto@unibas.ch
†Marcus Vetter, Julia Landin, Barbara Maria Szczerba and Francesc Castro-
Giner contributed equally to this work.
3Department of Biomedicine, Cancer Metastasis Laboratory, University of
Basel and University Hospital Basel, Mattenstrasse 28, CH-4058 Basel,
Switzerland
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Vetter et al. Breast Cancer Research          (2018) 20:141 
https://doi.org/10.1186/s13058-018-1067-y
investigations [6, 7], as well as limiting our understanding
of those factors that may influence the spread of cancer.
In this study, we aimed to investigate a number of
clinicopathological variables, blood counts at the time of
CTC isolation and detailed treatment history prior to
blood sampling in a cohort of 73 consecutive patients
with invasive breast cancer characterized by progressive
disease, high tumor load and treatment discontinuation
(or without any pretreatment) at the time of CTC isola-
tion, before the next line of therapy. Additionally, we
not only investigated parameters that are associated with
the presence of CTCs but also specifically interrogated
our datasets to identify features that are associated with
CTC clusters. The rationale of our study was therefore
to identify, in an unbiased manner (i.e., not driven by
preexisting hypotheses), clinical parameters that correl-
ate with CTC presence in patients with progressive
breast cancer.
Methods
Patient selection
Seventy-three consecutive patients with invasive breast
cancer, progressive disease, high tumor load, treatment
discontinuation at the time of CTC isolation (before the
next line of therapy) and no preselection for breast can-
cer subtype or specific metastatic sites were enrolled in
the study. Eligible patients were > 18 years old with any
menopausal status and had an Eastern Cooperative On-
cology Group performance status of 0–3. Disease had to
be measurable by Response Evaluation Criteria in Solid
Tumors (RECIST) version 1.1 or nonmeasurable bone-
only disease. Tumor load was defined by either the size
of the primary tumor or the number and size of meta-
static lymph nodes or distant sites, and patients with
higher tumor load were prioritized. All subjects donated
7.5–15 ml of blood in ethylenediaminetetraacetic acid
(EDTA) vacutainers at least once, and each signed an in-
formed consent before joining the study. The study was
performed under the protocols EKNZ BASEC 2016-00067
and EK 321/10, which received ethical and institutional
review board approvals before study initiation (Ethics
Committee northwest/central Switzerland [EKNZ]). This
study was performed in compliance with the Declaration
of Helsinki.
CTC isolation and enumeration strategy
Patient-derived CTCs were captured on the microfluidic
Parsortix Cell Separation Cassette (GEN3D6.5; ANGLE,
Guildford, UK) within 1 h of blood draw, directly from un-
manipulated blood samples. Next, in-cassette staining was
performed with an antibody cocktail comprising antibodies
against epithelial cell adhesion molecule (EpCAM)-Alexa
Fluor 488 (AF488) (#CST5198; Cell Signaling Technology,
Danvers, MA, USA), human epidermal growth factor
receptor 2 (HER2)-AF488 (#324410; BioLegend, San Diego,
CA, USA), epidermal growth factor receptor (EGFR)-fluor-
escein isothiocyanate (FITC) (#GTX11400; GeneTex, Ir-
vine, CA, USA) and CD45-BV605 (#304042; BioLegend).
CTCs were characterized as AF488/FITC-positive and
BV605-negative and enumerated manually by two inde-
pendent operators under a fluorescence microscope at 20×
magnification.
Clinical parameter assessment
Primary tumor samples were collected at the initial diag-
nosis, and IHC was performed for estrogen receptor
(ER), progesterone receptor (PR), HER2 and Ki-67. If the
patient had primary metastatic disease, a biopsy from
the metastatic site was obtained when possible, including
marker assessment: ER, PR and HER2. Histopathological
diagnosis was conducted by two independent patholo-
gists from the breast cancer unit at the University Hos-
pital Basel. All patients were treated at the Breast
Cancer Unit University Hospital Basel according to local
standard operating procedures and National Compre-
hensive Cancer Network and European Society for Med-
ical Oncology guidelines by senior breast oncologists. If
a patient had a progression within new distant sites, a
new biopsy from that site was taken, when possible, to
determine ER, PR and HER2. Patients under systemic
treatment had tumor assessment at least every 12 weeks
with computed tomographic scans or earlier if tumor
progression was anticipated. CTC collection was per-
formed at progression and prior to the next line of ther-
apy or before any treatment was conducted. The
patients’ data was retrieved by detailed retrospective
chart review. Data collection included demographics and
disease-specific and treatment-specific data including
age, gender, primary stage, histologic subtype, ER/PR/
HER2 status, grading, Ki-67, date of primary diagnosis
and relapse, type of relapse (localized, metastatic), site of
distant disease, bone-modifying agents (bisphosphonates,
denosumab), palliative irradiation, and type of systemic
treatment, including time on treatment and time to next
subsequent treatment. Data was correlated with CTC
counts.
Blood parameter assessment
Complete blood counts were measured with the ADVIA
120 Hematology Analyzer (Siemens Healthcare Diagnos-
tics, Tarrytown, NY, USA) using Multispecies version
5.9.0-MS software (Bayer Diagnostics, Tarrytown, NY,
USA). Blood samples were taken before each new therapy
cycle or at least every month, including cancer antigen 15-3
(CA 15-3), alkaline phosphatase, Ca2+, C-reactive protein,
lactate dehydrogenase, red blood cells (RBC), hemoglobin,
hematocrit, mean corpuscular volume (MCV), mean cor-
puscular hemoglobin concentration, white blood cells
Vetter et al. Breast Cancer Research          (2018) 20:141 Page 2 of 11
(WBC), neutrophils, lymphocytes, monocytes, eosinophils,
basophils, large unstained cells, platelets and mean platelet
volume (MPV). In the vast majority of cases, blood samples
were taken simultaneously with the CTC sample or within
7 days after CTCs were taken. Eight of 73 patients had only
partial data available, whereas no blood counts were re-
ported at the time of CTC detection for nine of 73 patients.
Statistical analysis
We first screened our data to exclude variables and pa-
tients with high content of missing information, as well as
observations with implausible values. Cancer therapies
were simplified into three main nonexclusive categories
(targeted therapy, chemotherapy and hormone therapy)
(Additional file 1: Table S1). Some patients had undergone
multiple lines of therapy. For this reason, we assessed the
effects of accumulated therapies and the therapy at CTC
evaluation separately.
We investigated the association between the different
variables of interest and the presence of CTCs using Fish-
er’s exact test for categorical variables, two-sided Wilcoxon
rank-sum test for continuous variables (e.g., complete
blood counts) and Kruskal-Wallis test for ordinal variables
with more than two levels (e.g., stage at diagnosis). A list of
the statistical tests used for each variable can be found in
Additional file 2: Table S2. For each test, we present the
nominal P value. An estimate and 95% CI are also provided
for continuous and two-level categorical variables. The es-
timate corresponds to the OR in Fisher’s exact test and to
the estimated median of the difference between samples
from both groups in the Wilcoxon rank-sum test. To ac-
count for potential confounding variables, logistic regres-
sion analysis was conducted, adjusting by age at primary
diagnosis, tumor stage at diagnosis, tumor grade and histo-
logic subtype. Adjusted P values were calculated following
the Benjamini-Hochberg method, combining all tests per-
formed in this work. Associations with an adjusted P value
≤ 0.05 are highlighted in the text. We conducted the data
wrangling and statistical analysis in R (version 3.4.0; R
Foundation for Statistical Computing, Vienna, Austria).
Results
Patient characteristics
Given previously reported correlations between number
of CTCs and tumor load [8], as well as the findings that
CTC counts predict poor prognosis in breast cancer [3,
4, 9], we focused on a group of 73 consecutive patients
with invasive breast cancer with the following character-
istics: high tumor load, detailed treatment history avail-
able, progressive disease associated with treatment
discontinuation at the time of CTC isolation (before the
next line of therapy), and availability of comprehensive
blood counts performed at CTC collection. Selected pa-
tients ranged from 36 to 85 years of age and carried
either invasive ductal, lobular or inflammatory carcin-
oma, with a broad expression range of ER, PR, HER2
and Ki-67 protein levels, as well as tumor grade varying
from 1 to 3. Detailed characteristics of patients, therap-
ies and statistical tests used for the analysis are listed in
Additional file 1: Table S1, Additional file 2: Table S2,
and Additional file 3: Table S3.
CTC isolation and enumeration
Blood samples were drawn in EDTA vacutainers and
processed directly with the Parsortix microfluidic device
[10], with a dedicated protocol enabling the isolation of
> 99% of breast CTCs from unlabeled blood samples
(Additional file 4: Figure S1A). Upon enrichment, CTCs
were stained with an antibody cocktail against EpCAM,
EGFR and HER2 and counterstained for the WBC
marker CD45 (Additional file 4: Figure S1A and B).
With this approach, we detected at least one CTC per
7.5 ml of peripheral blood in 34 (46.6%) patients. Among
these, we observed that 22 (64.7%) patients were charac-
terized by the presence of single CTCs and that 12
(35.3%) patients had both single CTCs and CTC clusters
(Additional file 4: Figure S1C).
Features of patients with CTCs
We investigated a number of clinicopathological vari-
ables to identify features associated with patients in
whom either single CTCs or CTC clusters were found,
compared with patients with no detectable CTCs. We
first observed that previous treatments with targeted
therapy (including but not limited to hormonal,
anti-HER2, anti-CDK4/6 treatments), chemotherapy or
radiotherapy did not correlate with the presence of
CTCs (Additional file 5: Table S4). Yet, we found that
treatment with the anti-bone resorption antibody deno-
sumab (received by 21 of 73 patients) was associated
with the absence of CTCs (OR, 0.25; 95% CI, 0.06–0.86;
P = 0.019). Namely, the prevalence of CTCs was 14.7%
(5 of 21) among patients treated with denosumab and
55.8% (29 of 52) among nontreated patients (Table 1).
Further, when considering only those patients in whom
CTCs were detected, the average CTC number was 9.8
for patients treated with denosumab (n = 5) versus 24.79
for nontreated patients (n = 29). Despite their role as
anti-bone resorption agents, the same association was
not seen for bisphosphonates (P = 0.784). Importantly,
anti-bone resorption treatment with either denosumab
or bisphosphonates was decided on the basis of treat-
ment initiation date (denosumab was approved in
Switzerland in December 2011 and given as the pre-
ferred treatment option to eligible patients after that
date), whereas patients who started receiving bispho-
sphonates (i.e., prior to December 2011) continued
receiving bisphosphonates unless major side effects
Vetter et al. Breast Cancer Research          (2018) 20:141 Page 3 of 11
Table 1 Clinical features of patients with circulating tumor cells
No CTC (n = 39) CTC (n = 34) P value Estimate (95% CI)
Age at primary diagnosis, years, mean (SD) 58.38 (11.85) 55.1 (11.04) 0.444 − 2.76 (− 8.49, 2.84)
Age at first CTC evaluation, years, mean (SD) 63.53 (11.69) 59.58 (10.7) 0.163 − 4.11 (− 9.27, 1.63)
Stage at diagnosis, n (%) 0.679 –
I 4 (10.53%) 5 (14.71%)
IA 1 (2.63%) 0 (0%)
II 5 (13.16%) 4 (11.76%)
IIA 1 (2.63%) 4 (11.76%)
III 11 (28.95%) 7 (20.59%)
IIIA 2 (5.26%) 0 (0%)
IIIC 0 (0%) 2 (5.88%)
IV 14 (36.84%) 11 (32.35%)
Lymphocyte node involvement, n (%) 0.881 –
N0 11 (31.43%) 8 (25.81%)
N1 11 (31.43%) 14 (45.16%)
N2 6 (17.14%) 0 (0%)
N3 6 (17.14%) 9 (29.03%)
Histologic subtype, n (%) 0.964 –
Invasive lobular 6 (15.38%) 4 (11.76%)
Invasive ductal 31 (79.49%) 29 (85.29%)
Inflammatory invasive lobular 1 (2.56%) 1 (2.94%)
Inflammatory 2 (5.13%) 2 (5.88%)
% of ER+ cells, mean (SD) 65.82 (42.48) 59.79 (40.93) 0.386 0 (− 10, 0)
% of PR+ cells, mean (SD) 38.97 (40.04) 26.35 (33.78) 0.171 − 4 (− 20, 0)
% of Ki-67+ cells, mean (SD) 27.08 (17.13) 31.59 (21.55) 0.514 5 (− 5, 10)
HER2+ 7 (17.95%) 7 (22.58%) 0.766 1.33 (0.35–5.11)
Triple-negative 4 (10.81%) 3 (9.68%) 1.000 0.89 (0.12–5.73)
Tumor grade 0.985 –
1 4 (10.53%) 4 (12.12%)
2 17 (44.74%) 14 (42.42%)
3 17 (44.74%) 15 (45.45%)
Bisphosphonates 9 (23.68%) 7 (20.59%) 0.784 0.84 (0.23–2.94)
Denosumab 16 (41.03%) 5 (14.71%) 0.019 0.25 (0.06–0.86)
Radiotherapy 22 (56.41%) 13 (38.24%) 0.160 0.48 (0.17–1.35)
Relapse
Any 31 (79.49%) 25 (73.53%) 0.589 0.72 (0.21–2.45)
Local 3 (7.69%) 4 (11.76%) 0.698 1.59 (0.25–11.72)
Metastasis 26 (66.67%) 19 (55.88%) 0.470 0.64 (0.22–1.82)
Days between primary diagnosis and relapse, mean (SD) 1954.08 (2042.25) 1893.48 (1853.86) 0.966 − 9.37 (− 1000, 756)
Established metastatic disease at CTC evaluation 35 (89.74%) 30 (88.24%) 1.000 0.86 (0.15–5.04)
Number of metastatic sites, mean (SD) 2.09 (1.01) 1.9 (0.94) 0.473 0 (− 1, 0)
Metastasis site, n (%)
Bone 27 (69.23%) 17 (51.52%) 0.150 0.45 (0.15–1.28)
Liver 10 (25.64%) 12 (36.36%) 0.447 1.57 (0.51–4.9)
Lymph node 9 (23.08%) 10 (30.3%) 0.599 1.38 (0.43–4.54)
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occurred (Additional file 6: Table S5). When we re-
stricted the analysis to the 44 patients with bone metas-
tasis, denosumab was administered to 20 of 44 of them,
and it also correlated with a reduction in CTC numbers
compared with the remaining 24 patients with bone me-
tastasis but no denosumab treatment (OR, 0.22; 95% CI,
0.04–0.96; P = 0.03) (Table 2). These results were con-
firmed using logistic regression adjusting by age at pri-
mary diagnosis, tumor stage at diagnosis, tumor grade
and histologic subtype (OR, 0.25; 95% CI, 0.06–0.82;
P = 0.03). When comparing clinicopathological variables
in patients who were treated or not with denosumab, as
expected, we observed a correlation with bone metasta-
sis (OR, 22.53; 95% CI, 3.14–995.64; P = 5.6e-05; ad-
justed P = 0.01) (Additional file 7: Table S6), but no
effect on progression-free survival was seen (Add-
itional file 8: Figure S2). Together, our data show that
denosumab treatment is associated with a marked re-
duction of CTC counts in patients with breast cancer.
Features of patients with CTC clusters
We further asked whether any clinicopathological vari-
ables might be associated specifically with the presence
of CTC clusters, compared with patients in whom CTC
clusters were not found (i.e., having either single CTCs
or no CTCs). We found that both younger age at pri-
mary diagnosis and younger age at first CTC evaluation
were associated with the presence of CTC clusters
(Table 3). Particularly, we observed average ages at pri-
mary diagnosis of 50.63 years (SD, 12.60) for patients
with CTC clusters and 58.08 years (SD, 10.99) for pa-
tients with no CTC clusters (P = 0.033), as well as aver-
age ages at first CTC evaluation of 54.87 years (SD,
12.14) for patients with CTC clusters and 63.03 years
(SD, 10.77) for patients with no CTC clusters (P =
0.025). We also observed that although HER2 was
expressed in 22% (13 of 61) of patients with no CTC
clusters (7 of 39) (i.e., 17.95% of patients with no CTCs
and 6 of 22 [30%] of patients with single CTCs only), it
was expressed in only 1 patient (9.09%) with CTC clus-
ters (OR, 0.36; 95% CI, 0.01–2.97; P = 0.44), even though
the relationship between HER2 negativity and CTC clus-
ters did not reach statistical significance (Table 3).
When considering only patients with CTCs and com-
paring those with CTC clusters versus those with single
CTCs, we found that also in this context younger age at
primary diagnosis (P = 0.044) and younger age at first
CTC evaluation (P = 0.058) were associated with the
presence of CTC clusters (Additional file 9: Table S7).
Blood parameters associated with CTCs
In addition to investigating the clinical parameters sum-
marized above, for each patient, we also evaluated com-
prehensive blood counts performed at CTC collection.
We first asked whether blood-related parameters were
associated with the presence of CTCs (either single or
clustered), compared with patients in whom CTCs were
not detected. We observed that patients with detectable
CTCs had a lower RBC count (OR, − 0.42; 95% CI, − 0.8
- -0.08; P = 0.019) than patients with no CTCs (Table 4).
Blood parameters associated with CTC clusters
We then asked whether specific blood-related parame-
ters could be associated with the presence of CTC clus-
ters, compared with patients with no CTC clusters (i.e.,
having either no CTCs or single CTCs only). In this
Table 1 Clinical features of patients with circulating tumor cells (Continued)
No CTC (n = 39) CTC (n = 34) P value Estimate (95% CI)
Pleural 7 (17.95%) 2 (6.06%) 0.162 0.29 (0.03–1.68)
Peritoneal 3 (7.69%) 4 (12.12%) 0.698 1.59 (0.25–11.72)
Lung 4 (10.26%) 4 (12.12%) 1.000 1.16 (0.2–6.83)
Skin 3 (7.69%) 0 (0%) 0.243 0 (0–2.74)
Brain 2 (5.13%) 2 (6.06%) 1.000 1.15 (0.08–16.76)
Uterus 1 (2.56%) 1 (3.03%) 1.000 1.15 (0.01–92.67)
Muscular 1 (2.56%) 2 (6.06%) 0.595 2.35 (0.12–143.61)
Abbreviations: ER Estrogen receptor, HER2 Human epidermal growth factor receptor 2, PR Progesterone receptor
The table shows clinical features of patients with and without circulating tumor cells (CTCs)
Table 2 Circulating tumor cells detection according to denosumab treatment and bone metastasis
Number of samples No CTCs CTCs P value Estimate (95% CI) P value Estimate (95% CI)
Reference 28 12 (43%) 16 (57%) Reference – –
Bone metastasis 24 11 (46%) 13 (54%) 1.000 0.89 (0.26–3.05) Reference
Bone metastasis and denosumab 20 16 (80%) 4 (20%) 0.017 0.19 (0.04–0.81) 0.030 0.22 (0.04–0.96)
The table shows the number of patients with and without circulating tumor cells (CTCs) among individuals with bone metastasis who were treated or not
with denosumab
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Table 3 Clinical features of patients with circulating tumor cell clusters
No CTC clusters (n = 61) CTC clusters (n = 12) P value Estimate (95% CI)
Age at primary diagnosis, years, mean (SD) 58.08 (10.99) 50.63 (12.6) 0.033 − 8.26 (− 15.3, − 0.44)
Age at first CTC evaluation, years, mean (SD) 63.03 (10.77) 54.87 (12.14) 0.025 − 8.3 (− 16.06, − 1.04)
Stage at diagnosis, n (%) 0.726 –
I 7 (11.67%) 2 (16.67%)
IA 1 (1.67%) 0 (0%)
II 7 (11.67%) 2 (16.67%)
IIA 4 (6.67%) 1 (8.33%)
III 16 (26.67%) 2 (16.67%)
IIIA 2 (3.33%) 0 (0%)
IIIC 1 (1.67%) 1 (8.33%)
IV 21 (35%) 4 (33.33%)
Lymphocyte node involvement, n (%) 0.855 –
N0 15 (27.27%) 4 (36.36%)
N1 22 (40%) 3 (27.27%)
N2 6 (10.91%) 0 (0%)
N3 11 (20%) 4 (36.36%)
Histologic subtype, n (%) 0.679 –
Invasive lobular 9 (14.75%) 1 (8.33%)
Invasive ductal 49 (80.33%) 11 (91.67%)
Inflammatory invasive lobular 1 (1.64%) 1 (8.33%)
Inflammatory 3 (4.92%) 1 (8.33%)
% of ER+ cells, mean (SD) 62.34 (41.8) 66.42 (42.1) 0.675 0 (− 10, 20)
% of PR+ cells, mean (SD) 32.71 (37.79) 34 (37.3) 0.888 0 (− 10, 20)
% of Ki-67+ cells, mean (SD) 30 (19.65) 23 (16.43) 0.384 − 5 (− 20, − 10)
HER2+, n (%) 13 (22.03%) 1 (9.09%) 0.442 0.36 (0.01–2.97)
Triple-negative, n (%) 7 (12.28%) 0 (0%) 0.588 0 (0–3.7)
Tumor grade, n (%) 0.093 –
1 5 (8.33%) 3 (27.27%)
2 26 (43.33%) 5 (45.45%)
3 29 (48.33%) 3 (27.27%)
Bisphosphonates, n (%) 14 (23.33%) 2 (16.67%) 1.000 0.66 (0.06–3.68)
Denosumab, n (%) 19 (31.15%) 2 (16.67%) 0.489 0.45 (0.04–2.41)
Radiotherapy, n (%) 30 (49.18%) 5 (41.67%) 0.756 0.74 (0.17–3.06)
Relapse, n (%)
Any 47 (77.05%) 9 (75%) 1.000 0.9 (0.19–5.83)
Local 4 (6.56%) 3 (25%) 0.082 4.61 (0.58–32.62)
Metastasis 40 (65.57%) 5 (41.67%) 0.193 0.38 (0.08–1.59)
Days between primary diagnosis and relapse, mean (SD) 1969.49 (2003.96) 1636.67 (1538.48) 0.633 − 236.86 (− 1643, 1203)
Established metastatic disease at CTC evaluation, n (%) 54 (88.52%) 11 (91.67%) 1.000 1.42 (0.15–70.01)
Number of metastatic sites, mean (SD) 1.96 (0.98) 2.18 (0.98) 0.452 0 (0–1)
Metastasis site, n (%)
Bone 37 (61.67%) 7 (58.33%) 1.000 0.91 (0.22–4.08)
Liver 19 (31.67%) 3 (25%) 1.000 0.74 (0.12–3.42)
Lymph node 15 (25%) 4 (33.33%) 0.497 1.52 (0.29–6.74)
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case, we found that patients with CTC clusters have
14-fold higher levels of the CA 15-3 tumor marker (P =
0.021), higher MCV (P = 0.033), higher WBC (P = 0.03)
and higher MPV (P = 0.032) than patients in whom CTC
clusters were not found (Table 5). We also restricted this
analysis to patients with CTCs and compared patients
with CTC clusters with patients with only single CTCs.
In this setting, we further confirmed that patients with
CTC clusters have 38-fold higher CA 15-3 tumor anti-
gen (P = 0.0089), as well as nearly twofold higher total
WBC counts (P = 0.0045) and higher neutrophil counts
(P = 0.03) (Additional file 10: Table S8).
Discussion
In a selected cohort of 73 patients with progressive inva-
sive breast cancer, we provide a detailed description of a
number of clinicopathological parameters and blood
counts at the time of CTC isolation that correlate with
the presence of single CTCs and CTC clusters. Interest-
ingly, we observed that treatment with the monoclonal
Table 3 Clinical features of patients with circulating tumor cell clusters (Continued)
No CTC clusters (n = 61) CTC clusters (n = 12) P value Estimate (95% CI)
Pleural 9 (15%) 0 (0%) 0.339 0 (0–2.57)
Peritoneal 5 (8.33%) 2 (16.67%) 0.323 2.21 (0.19–16.05)
Lung 7 (11.67%) 1 (8.33%) 1.000 0.7 (0.01–6.47)
Skin 3 (5%) 0 (0%) 1.000 0 (0–12.81)
Brain 3 (5%) 1 (8.33%) 0.521 1.74 (0.03–24.14)
Uterus 1 (1.67%) 1 (8.33%) 0.304 5.27 (0.06–433.34)
Muscular 2 (3.33%) 1 (8.33%) 0.421 2.63 (0.04–54.78)
Abbreviations: ER Estrogen receptor, HER2 Human epidermal growth factor receptor 2, PR Progesterone receptor
The table shows clinical features of patients with and without circulating tumor cell clusters (CTC clusters)
Table 4 Complete blood counts in patients with circulating tumor cells
No CTC (n = 39) CTC (n = 34) P value Estimate (95% CI)
CA 15-3, mean (SD) 223.71 (384.68) 1084.15 (4136.87) 0.658 6.7 (− 19.2, 87.6)
Alkaline phosphatase, mean (SD) 105.47 (103.98) 198.15 (365.58) 0.401 6 (− 12, 27)
Calcium (korr), mean (SD) 2.34 (0.15) 2.32 (0.25) 0.145 − 0.06 (− 0.13, 0.02)
CRP, mean (SD) 31.92 (47.56) 26.87 (47.69) 0.982 0 (− 8.8, 3.8)
LDH, mean (SD) 281.61 (118.18) 300.15 (228.57) 0.772 − 5 (− 36, 23)
RBC, 1012/L, mean (SD) 4.37 (0.56) 3.85 (0.77) 0.019 − 0.42 (− 0.8, − 0.08)
HGB, g/L, mean (SD) 130.14 (19.85) 118.15 (24.11) 0.051 − 11 (− 21, 0)
HCT, L/L, mean (SD) 0.38 (0.06) 0.35 (0.06) 0.053 − 0.03 (− 0.06, 0)
MCV, fl, mean (SD) 87.46 (5.68) 89.73 (5.26) 0.227 2 (− 1, 4)
MCH, pg, mean (SD) 29.62 (2.52) 30.66 (1.96) 0.157 0.8 (− 0.3, 1.8)
MCHC, g/L, mean (SD) 339.03 (13.98) 341.19 (12.79) 0.667 2 (− 6, 8)
WBC, 109/L, mean (SD) 7.35 (2.13) 7.24 (3.53) 0.334 − 0.6 (− 1.88, 0.81)
Neutrophils, 109/L, mean (SD) 5.33 (1.87) 5.12 (2.87) 0.239 − 0.63 (− 1.65, 0.56)
Lymphocytes, 109/L, mean (SD) 1.37 (0.67) 1.41 (0.85) 0.941 − 0.02 (− 0.38, 0.38)
Monocytes, 109/L, mean (SD) 0.42 (0.12) 0.44 (0.2) 0.843 − 0.01 (− 0.08, 0.07)
Eosinophils, 109/L, mean (SD) 0.16 (0.18) 0.17 (0.12) 0.423 0.02 (− 0.03, 0.09)
Basophils, 109/L, mean (SD) 0.04 (0.07) 0.04 (0.03) 0.256 0.01 (− 0.01, 0.02)
LUC, 109/L, mean (SD) 0.15 (0.22) 0.12 (0.08) 0.912 0 (− 0.03, 0.02)
PLT, 109/L, mean (SD) 289.92 (139.86) 249.93 (91.52) 0.277 − 30 (− 84, 24)
MPV, fl, mean (SD) 8.2 (1.51) 8.68 (1.52) 0.109 0 (0–1)
Abbreviations: CA 15-3 Cancer antigen 15-3, CRP C-reactive protein, HCT Hematocrit, HGB Hemoglobin, LDH Lactate dehydrogenase, LUC Large unstained cells, MCH
Mean corpuscular hemoglobin, MCHC Mean corpuscular hemoglobin concentration, MCV Mean corpuscular volume, MPV Mean platelet volume, PLT Platelets, RBC
Red blood cells, WBC White blood cells
The table shows complete blood counts in patients with and without circulating tumor cells (CTCs).
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antibody denosumab in patients with bone metastasis
strongly correlated with the absence of CTCs from their
peripheral circulation, suggesting a scenario in which the
treatment itself might influence CTC spread from the
bone tissue. Importantly, this correlation is not seen re-
garding treatment with the anti-bone resorption drug
bisphosphonate, possibly because of different adminis-
tration routes or dosing schedules [11] or, alternatively,
potential off-target binding of denosumab to proteins
other than receptor activator of nuclear factor κB ligand
(RANKL).
Although its focus was on clinical parameters, our
study did not provide molecular insights into the mech-
anism of action of denosumab in the context of its role
in inhibiting CTC generation. Yet, considering that most
denosumab-treated patients are characterized by bone
metastatic disease but no primary breast tumor (which
has been surgically removed prior to denosumab treat-
ment), CTCs represent derivatives of their bone meta-
static lesions. In this setting, we speculate that the effect
of denosumab in suppressing CTC generation could be
a result of RANKL inhibition within the bone, prevent-
ing the maturation of preosteoclasts into osteoclasts [12]
and protecting the bone from degradation, leading to a
lower likelihood of a bone metastatic lesion to shed CTCs.
However, we cannot exclude an action of denosumab on
breast cancer cells themselves, which have previously been
shown to express high receptor activator of nuclear factor
κB (RANK) levels [13, 14] and may be susceptible to its
inhibition. Prospective studies and molecular assays will
be needed to specifically dissect the role and mechanism
of action of denosumab in CTC generation.
Recently, a phase 3 clinical trial designed to determine
the long-term effects of denosumab treatment (D-CARE;
ClinicalTrials.gov, NCT01077154) showed no benefits in
metastasis-free survival and overall survival of patients
with breast cancer. Importantly, individuals within this
study were mainly patients with early breast cancer (i.e.,
stage IIB to IIIC), while our patient cohort was largely
dominated by patients with stage IV disease. Although
we are not aware of CTC enumeration data being evalu-
ated within the D-CARE study, it is possible that deno-
sumab might play a different role in the intravasation of
bone metastasis-derived CTCs (as seen in our study) as
opposed to primary tumor-derived CTCs (D-CARE).
Among other correlations, we observed an intriguing
association between the absence of HER2 expression in
the primary tumor and the presence of CTC clusters.
Table 5 Complete blood counts in patients with circulating tumor cell clusters
No CTC clusters (n = 61) CTC clusters (n = 12) P value Estimate (95% CI)
CA 15-3, mean (SD) 172.5 (324.45) 2554.6 (6387.64) 0.021 204.16 (9.7–515)
Alkaline phosphatase, mean (SD) 106.4 (104.27) 310.25 (525.57) 0.301 10 (− 12, 74.58)
Calcium (korr), mean (SD) 2.33 (0.14) 2.36 (0.35) 0.698 − 0.02 (− 0.16, 0.14)
CRP, mean (SD) 27.76 (44.47) 37.25 (58.6) 0.279 2.9 (− 4, 21.4)
LDH, mean (SD) 271 (102.59) 363.33 (329.24) 0.463 17 (− 26, 76)
RBC, 1012/L, mean (SD) 4.26 (0.6) 3.66 (0.93) 0.078 − 0.51 (− 1.16, 0.06)
HGB, g/L, mean (SD) 127.52 (20.18) 114.18 (29.19) 0.183 − 12 (− 30, 6)
HCT, L/L, mean (SD) 0.38 (0.05) 0.34 (0.08) 0.159 − 0.03 (− 0.09, 0.01)
MCV, fl, mean (SD) 87.7 (5.58) 91.73 (4.41) 0.033 4 (0–7)
MCH, pg, mean (SD) 29.8 (2.42) 31.24 (1.51) 0.064 1.1 (0–2.3)
MCHC, g/L, mean (SD) 339.8 (13.38) 340.64 (14.25) 0.646 2 (− 10, 10)
WBC, 109/L, mean (SD) 6.87 (2.25) 9.38 (3.99) 0.030 2.54 (0.26–4.68)
Neutrophils, 109/L, mean (SD) 4.94 (1.87) 6.65 (3.6) 0.177 1.22 (− 0.52, 3.68)
Lymphocytes, 109/L, mean (SD) 1.38 (0.69) 1.42 (1) 0.756 − 0.11 (− 0.62, 0.6)
Monocytes, 109/L, mean (SD) 0.41 (0.13) 0.5 (0.24) 0.336 0.06 (− 0.08, 0.26)
Eosinophils, 109/L, mean (SD) 0.16 (0.16) 0.17 (0.14) 0.974 0 (− 0.07, 0.1)
Basophils, 109/L, mean (SD) 0.04 (0.06) 0.04 (0.04) 0.983 0 (− 0.02, 0.02)
LUC, 109/L, mean (SD) 0.14 (0.19) 0.12 (0.11) 0.471 − 0.01 (− 0.05, 0.02)
PLT, 109/L, mean (SD) 278.02 (125.8) 251.5 (109.99) 0.667 − 15.84 (− 94, 47)
MPV, fl, mean (SD) 8.32 (1.62) 8.82 (0.87) 0.032 1 (0–1)
Abbreviations: CA 15-3 Cancer antigen 15-3, CRP C-reactive protein, HCT Hematocrit, HGB Hemoglobin, LDH Lactate dehydrogenase, LUC Large unstained cells, MCH
Mean corpuscular hemoglobin, MCHC Mean corpuscular hemoglobin concentration, MCV Mean corpuscular volume, MPV Mean platelet volume, PLT Platelets, RBC
Red blood cells, WBC White blood cells
The table shows complete blood counts in patients with and without circulating tumor cell clusters (CTC clusters)
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Although this result did not reach statistical significance,
our observation regarding HER2 does not seem to be in-
fluenced by the metastatic tropism of HER2-positive
breast cancers, and it might reveal important insights into
the signaling networks involving CTC cluster formation,
also considering HER2 expression fluctuations in CTCs
and breast cancer metastasis [15, 16]. In other words, we
speculate that HER2 signaling might influence cancer cells
to intravasate as single CTCs, whereas its absence might
point them toward collective invasion into the blood-
stream. This hypothesis will require experimental testing.
We also found that CTC clusters, but not CTCs in
general, are more prevalent in younger patients. Both
CTC clusters and younger age have been associated with
worse prognosis and reduced survival rates [2, 5, 17–20].
In this case, it is unlikely that younger age represents an
independent risk factor for CTC cluster formation, but
rather it may reflect an association with tumor aggres-
siveness [21].
Last, blood counts at the time of CTC collection pro-
vide evidence for applying well-established, cost-effective
and widespread blood-testing strategies to stratify pa-
tients with higher likelihood to present with detectable
CTCs. For instance, we find that lower RBC count has
good correlation with the presence of CTCs. Addition-
ally, CA 15-3 tumor antigen is highly increased in pa-
tients with CTC clusters, possibly reflecting a higher
tumor load but also tumors that are characterized by an
elevated shedding of mucin 1 (MUC-1)-containing cells
into the bloodstream [22]. A functional relationship be-
tween MUC-1 and CTC clusters remains to be investi-
gated. We also observed that higher MCV, higher MPV
and higher WBC counts correlate with the presence of
CTC clusters. We envision these parameters to be used
to stratify patient populations to conduct CTC-related
studies in the setting of advanced breast cancer.
Altogether, our study is meant as an exploratory ana-
lysis to evaluate the association of multiple clinical pre-
dictors with the presence of CTCs. Given the high
number of hypotheses tested and the relatively low num-
ber of patient samples in the study (n = 73), none of the
associations reported show a P value less than 0.05 after
adjustment for multiple comparisons, with the exception
of the correlation between denosumab treatment and
the presence of bone metastasis (adjusted P = 0.01). For
this reason, subsequent prospective and experimental
studies should be conducted to validate the associations
that are presented in this work, including the role of
denosumab in CTC shedding.
Conclusions
Our data provide evidence of the association between
treatment with the monoclonal antibody denosumab and
the absence of CTCs from the peripheral circulation of
patients with breast cancer. This finding suggests that
denosumab treatment may be beneficial to reduce cancer
spread in patients who are diagnosed with bone metastasis.
Although factors such as limited blood volume and
diverse CTC isolation technologies may influence CTC
detection rate in patients with cancer, the identification
of a set of clinical correlatives to CTCs in breast cancer
is likely to facilitate the identification of those patients
who would benefit the most from CTC analysis, including
genetic profile assessment for patient stratification [6, 23]
and testing of drug susceptibility [7]. As an added benefit
to this analysis, the identification of denosumab treatment
as a strategy to reduce CTC intravasation warrants further
investigation.
Additional files
Additional file 1: Table S1. Drug classification. The table shows the drug
classification used for the analysis, grouping drugs into targeted therapy,
chemotherapy, hormone therapy and immunotherapy. Abbreviations: cbx6
Chromobox 6, CDK4 Cyclin-dependent kinase 4, CDK6 Cyclin-dependent
kinase 6, EGFR Epidermal growth factor receptor, Her2 Human epidermal
growth factor receptor 2, mTOR Mechanistic target of rapamycin, PD-L1
Programmed cell death 1 ligand 1, VEGF Vascular endothelial growth factor.
(XLSX 10 kb)
Additional file 2: Table S2. Variable classification and statistical test
applied. The table shows the type of variable and statistical test used for
the analysis of individual clinicopathological parameters. Abbreviations: ER,
Estrogen receptor, HER2, Human epidermal growth factor receptor 2, PR
Progesterone receptor. (XLSX 10 kb)
Additional file 3: Table S3. Patient characteristics. The table shows the
characteristics of the 73 patients included in the study. Abbreviations: ER
Estrogen receptor, HER2 Human epidermal growth factor receptor 2, ID
Invasive ductal, IL Invasive lobular, NA Not available, PR Progesterone
receptor, ECOG Eastern Cooperative Oncology Group (as defined by Oken
et al. [24]). (XLSX 14 kb)
Additional file 4: Figure S1. Circulating tumor cell (CTC) capture strategy.
(a) Schematic drawing showing the size-based capturing principle of the
Parsortix microfluidic device (left). Plot showing the capture efficiency of the
Parsortix microfluidic device for MCF7 cells spiked in healthy blood samples
(right). Representative images of a captured MCF7 single cell, a cell cluster
(green) and a contaminant white blood cell (WBC; red) in the Parsortix
microfluidic cassette (bottom). (b) Representative images of a captured
single CTC, a CTC cluster (green) and a contaminant WBC (red) from a
breast cancer patient sample. (c) Bar graph showing the number of patients
in whom no CTCs, single CTCs or CTC clusters were found. (PDF 245 kb)
Additional file 5: Table S4. Therapy evaluation in patients with circulating
tumor cells. The table shows the types of therapy that patients with and
without circulating tumor cells (CTCs) underwent. (XLSX 9 kb)
Additional file 6: Table S5. Bisphosphonates or denosumab treatment.
The table shows whether bisphosphonates or denosumab was
administered to each of the patients included in the study. (XLSX 10 kb)
Additional file 7: Table S6. Clinical features of patients who were
treated or not with denosumab. The table shows clinical features of
patients who were treated or not with denosumab. Abbreviations: ER
Estrogen receptor, HER2 Human epidermal growth factor receptor 2, PR
Progesterone receptor. (XLSX 11 kb)
Additional file 8: Figure S2. Progression-free survival of patients who
were treated or not with denosumab. Kaplan-Meier curve showing the
progression-free survival probability of patients who were treated (red) or
not (green) with denosumab (top). P = 0.95 by pairwise log-rank test. The
table shows the number of patients at each time point (bottom).
(PDF 188 kb)
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Additional file 9: Table S7. Clinical features of patients with single
circulating tumor cell and circulating tumor cell clusters. The table shows
clinical features of patients in whom only single circulating tumor cells
(CTC single cell) or also clustered circulating tumor cells (CTC clusters)
were found. Abbreviations: ER Estrogen receptor, HER2 Human epidermal
growth factor receptor 2, PR Progesterone receptor. (XLSX 11 kb)
Additional file 10: Table S8. Complete blood counts in patients with
single circulating tumor cells and circulating tumor cell clusters. The table
shows complete blood counts in patients in whom only single circulating
tumor cells (single CTC) or also clustered circulating tumor cells (CTC
clusters) were found. Abbreviations: CA 15-3 Cancer antigen 15-3, CRP
C-reactive protein, HCT Hematocrit, HGB Hemoglobin, LDH Lactate
dehydrogenase, LUC Large unstained cells, MCH Mean corpuscular
hemoglobin, MCHC Mean corpuscular hemoglobin concentration, MCV
Mean corpuscular volume, MPV Mean platelet volume, PLT Platelets, RBC
Red blood cells, WBC White blood cells. (XLSX 10 kb)
Abbreviations
AF488: Alexa Fluor 488; CA 15-3: Cancer antigen 15-3; CRP: C-reactive
protein; CTC: Circulating tumor cell; EDTA: Ethylenediaminetetraacetic acid;
EGFR: Epidermal growth factor receptor; EpCAM: Epithelial cell adhesion
molecule; ER: Estrogen receptor; FITC: Fluorescein isothiocyanate;
HCT: Hematocrit; HER2: Human epidermal growth factor receptor 2;
HGB: Hemoglobin; LDH: Lactate dehydrogenase; LUC: Large unstained cells;
MCH: Mean corpuscular hemoglobin; MCHC: Mean corpuscular hemoglobin
concentration; MCV: Mean corpuscular volume; MPV: Mean platelet volume;
MUC-1: Mucin 1; PLT: Platelets; PR: Progesterone receptor; RANK: Receptor
activator of nuclear factor κB; RANKL: Receptor activator of nuclear factor κB
ligand; RBC: Red blood cells; WBC: White blood cells
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SUMMARY
Theabilityofcirculating tumorcells (CTCs) to formclus-
ters has been linked to increased metastatic potential.
Yet biological features and vulnerabilities of CTC clus-
ters remain largely unknown. Here, we profile the DNA
methylation landscape of single CTCs and CTC clus-
ters from breast cancer patients and mouse models
on a genome-wide scale. We find that binding sites
for stemness- and proliferation-associated transcrip-
tion factors are specifically hypomethylated in CTC
clusters, including binding sites for OCT4, NANOG,
SOX2, and SIN3A, paralleling embryonic stem cell
biology. Among 2,486 FDA-approved compounds, we
identifyNa+/K+ATPase inhibitors thatenable thedisso-
ciation of CTC clusters into single cells, leading to DNA
methylation remodeling at critical sites andmetastasis
suppression. Thus, our results link CTC clustering to
specific changes in DNA methylation that promote
stemnessandmetastasisandpoint tocluster-targeting
compounds to suppress the spread of cancer.
INTRODUCTION
Circulating tumor cells (CTCs) are those cells that depart from
cancerous lesions and enter the bloodstream (Alix-Panabie`res
and Pantel, 2013). Although extraordinarily rare compared with
blood cells and forced to strive for survival in circulation, CTCs
are considered to be precursors of metastasis in various cancer
types, including breast cancer (Aceto et al., 2015; Alix-Pana-
bie`res and Pantel, 2014). CTCs are found in the blood of cancer
patients as single CTCs and CTC clusters (Fidler, 1973; Liotta
et al., 1976), with the latter featuring a higher ability to seed
metastasis (Aceto et al., 2014). However, it is unknown what
drives their enhanced metastatic potential and what are the vul-
nerabilities of clustered CTCs.
Abnormal DNA methylation patterns, including both genome-
wide hypomethylation and hypermethylation, have been associ-
ated with several human cancers (Ehrlich, 2002, 2009; Feinberg
et al., 2006; Klutstein et al., 2016; Lee et al., 2006). Generally,
these cancer-associated epigenetic modifications appear to
affect distinct genomic areas, with hypomethylation favoring reg-
ulatory and repetitive elements versushypermethylation,which is
more frequent in CpG islands (Ehrlich, 2002). Both modifications
have the ability to alter the expression of neighboring genes and
contribute to the cancer phenotype (Ehrlich, 2009; Klutstein et al.,
2016). For regulatory elements, loss of DNA methylation at tran-
scription factor binding sites (TFBSs) can designate active tran-
scription factor networks or networks primed for activation at
later stages, e.g., during processes such as the derivation of
induced pluripotent stem cells from differentiated cells (Lee
et al., 2014) or cancer progression (Feinberg and Vogelstein,
1983). Although DNA methylation analysis of primary tumors is
extensively investigated (Feinberg and Vogelstein, 1983; Klut-
stein et al., 2016), the forces that shape the DNAmethylome dur-
ing metastatic dissemination are largely uncharacterized.
Here, we combine microfluidic-based CTC capture from
breast cancer patients and mouse models, single-cell resolution
DNA methylation and RNA expression analysis, a drug screen
with 2,486 FDA-approved compounds, and functional validation
studies inmousemodels to gain insights into the biology and vul-
nerabilities of CTC clusters. Our study provides a genome-wide
DNA methylation landscape of single and clustered CTCs in
breast cancer, highlighting fundamental differences that affect
metastasis and enabling the identification of cluster-targeting
compounds with immediate clinical applicability.
RESULTS
Identification of Differentially Methylated Regions in
CTC Clusters and Single CTCs
We first sought to identify active transcription factor networks by
means of accessible TFBSs in single and clustered human
98 Cell 176, 98–112, January 10, 2019 ª 2018 Elsevier Inc.
breast CTCs,matchedwithin individual liquid biopsies, through a
genome-wide single-cell resolution DNA methylation analysis.
To this end, blood samples were drawn from 43 patients with
progressive breast cancer and processed with the Parsortix de-
vice (Xu et al., 2015), a microfluidic technology that allows a size-
based, antigen-agnostic enrichment of CTCs from unprocessed
blood samples, specifically adapted to achieve a capture rate of
>97.2% for single CTCs and >99.3% for CTC clusters, and no
artificial cluster formation during sample processing (Figures
S1A and S1B). Upon capture, live CTCs were stained for cell sur-
face expression of EpCAM, HER2, and EGFR, and counter-
stained with antibodies against CD45 to identify contaminant
leukocytes (Figure S1C). Upon staining verification, we identified
matched single and clustered CTCs in 19%of the analyzed sam-
ples (8/43 patients), and a total of 18 marker-positive single
CTCs and 29 marker-positive CTC clusters from four patients
were individually micromanipulated and deposited in lysis buffer
for single-cell resolution whole-genome bisulfite sequencing
(Table S1) (Farlik et al., 2015, 2016). In parallel, we isolated spon-
taneously generated GFP-labeled single CTCs and CTC clusters
from threemouse xenograft models, including two human breast
CTC-derived cell lines (BR16 and BRx50) and the human breast
cancer cell lineMDA-MB 231 (lungmetastatic variant, referred to
as LM2) (Minn et al., 2005; Yu et al., 2014). In this setting, we indi-
vidually micromanipulated 71 single CTCs and 48 CTC clusters
(Table S1) and also processed them for single-cell resolution
whole-genome bisulfite sequencing (Farlik et al., 2015, 2016).
Samples with a low coverage (< 1,000 unique CpGs) or a low
bisulfite conversion efficiency (CG/CHG/CHH < 97%)—corre-
sponding to 10.7% of patient-derived samples and 0.8% of
xenograft-derived samples—were excluded from the analysis,
resulting in a total of 89 single CTCs and 71 CTC clusters from
patients and xenografts. On average, we achieved 3.68% CpG
coverage for single CTCs and 5.86% CpG coverage for CTC
clusters, in line with recent single-cell whole-genome bisulfite
sequencing studies (Farlik et al., 2015, 2016) (Figures S1D and
S1E; Table S2). As expected, principal component analysis
(PCA) mainly segregated CTCs based on the patient of origin
or the specific xenograft model (Figures S1F and S1G). Meta-
gene plot of CpG methylation revealed comparable methylation
levels between single CTCs and CTC clusters across CpG
islands, gene bodies, upstream (promoters) and downstream
regions, including a drop of CpG methylation around the tran-
scriptional start site, as expected (Figures S1H and S1I). We
then specifically investigated differentially methylated regions
(DMRs) between single CTCs and CTC clusters, evaluating
average methylation levels in overlapping 5-kb windows, as pre-
viously established for single-cell DMR analysis (Farlik et al.,
2015, 2016). For patient-derived CTCs, with this approach we
identified 3,347 DMRs with a R 80% methylation difference
between single CTCs and CTC clusters. Of these, 1,305 regions
were hypomethylated in CTC clusters and 2,042 were hypome-
thylated in single CTCs (Figure 1A). We then looked at xenograft-
derived CTCs, and to evaluate a comparable number of DMRs
as found in patients, we assessed overlapping regions with
a R 70% methylation difference between single CTCs and
CTC clusters. We found a total of 1,430 DMRs, of which 909 hy-
pomethylated in CTC clusters and 521 hypomethylated in single
CTCs (Figure 1B). We then analyzed DMRs from both patient-
and xenograft-derived CTCs using i-cisTarget (Herrmann et al.,
2012). With this analysis, among hypomethylated regions that
are specific to either single CTCs or CTC clusters, we found a
significant enrichment for several TFBSs, many of which over-
lapped between patient- and xenograft-derived CTCs (Figures
1C and 1D), thus allowing us to define specific hypomethylated
TFBSs that globally characterize either single CTCs or CTC
clusters in both patients and xenografts. Integrated gene
ontology (GO) and pathway analysis of global CTC cluster hypo-
methylated TFBSs revealed a remarkable enrichment for stem-
ness-related transcription factors that coordinately regulate
proliferation and pluripotency, including OCT4, NANOG, SOX2,
and SIN3A, paralleling embryonic stem cell (ESCs) biology (Fig-
ure 1E) (Kim et al., 2008; McDonel et al., 2012; Niwa, 2007; Sa-
unders et al., 2017; van den Berg et al., 2010). Differently, single
CTCs featured hypomethylation of other TFBSs, including those
that are occupied by MEF2C, JUN, MIXL1, and SHOX2,
commonly enriched in various cancers (Hong et al., 2014; Jiao
et al., 2010; Laszlo et al., 2015; Raymond et al., 2014), yet inde-
pendent of a core pluripotency network (Figure 1F) (Kim et al.,
2008, 2010). To gain insights into more subtle changes in
DNA methylation occurring specifically within promoters, gene
bodies, and super enhancer regions, we carried out hypergeo-
metric-based gene set enrichment analysis of genomic features
in xenograft-derived CTCs (displaying a higher homogeneity
compared to patient-derived CTCs). Consistently, this analysis
revealed hypermethylation and H3K27me3 repression of Poly-
comb-repressive complex 2 (PRC2) target gene promoters and
gene bodies (including those for SUZ12 and EED) in CTC clus-
ters (Figures S1J–S1L), as previously alluded to in cancer spec-
imens with stem-like and proliferative features (Avissar-Whiting
et al., 2011; Kron et al., 2013; Lauss et al., 2012; Reddington
et al., 2014; Wolff et al., 2010) and mirroring ESCs biology
(Lee et al., 2006).
Thus, CTC clusters are clearly distinguishable from single
CTCs based on their DNA methylation status at DMRs, where
they mainly feature hypomethylation of bindings sites for stem-
ness- and proliferation-associated TFs, such as OCT4, NANOG,
SOX2, and SIN3A (Figure S1M, shown for patient CTCs), accom-
panied by a subtler hypermethylation of PRC2 target genes in
promoters and gene bodies. This indicates that phenotypic dif-
ferences in circulation affect DNA methylation dynamics.
Cluster-Associated Hypomethylated Regions Correlate
with Poor Prognosis in Patients with Breast Cancer
We then tested whether the regions that are globally hypomethy-
lated in CTC clusters are also hypomethylated in primary breast
cancer. When analyzing bisulfite-sequencing data from The
Cancer Genome Atlas (TCGA), we found 673/2,214 (30.39%)
overlapping probes in 789 breast cancer patients, with 198
and 197 patients displaying either low (quantile Q1) or high
(quantile Q4) methylation levels, respectively, in addition to a
high correlation with genome-wide methylation levels (Figures
2A, S2A, and S2B). Progression-free survival (PFS) analysis on
this subset of patients showed that low methylation levels within
the regions that are hypomethylated in CTC clusters significantly
correlate with a poor prognosis (p < 0.05) (Figure 2B). In contrast,
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Figure 1. Whole-Genome Bisulfite Sequencing Analysis of CTCs from Breast Cancer Patients and Xenografts
(A) Heatmap showing methylation variable regions withR 80% methylation difference between patient-derived CTC clusters and single CTCs (false discovery
rate [FDR] < 0.05).
(B) Heatmap showing methylation variable regions withR 70% methylation difference between xenograft-derived CTC clusters and single CTCs (FDR < 0.05).
(C and D) Normalized enrichment score (NES) representing enrichment (NESR 3.4) of transcription factor binding sites (TFBSs) in CTC cluster hypomethylated
regions (blue) and single CTC hypomethylated regions (red) of patients (C) or xenografts (D), identified using i-cisTarget.
(E and F) Integrated gene ontology (GO) and pathway enrichment analysis of TFBSs identified using i-cisTarget in hypomethylated regions of both patient- and
xenograft-derived CTC clusters (E) or single CTCs (F). The bars represent the percentage of genes detected per GO and pathway term with p% 0.05.
See also Figure S1 and Tables S1 and S2.
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no correlation with PFS is observed for those regions that are hy-
pomethylated in single CTCs (Figures S2C–S2F). Of note, while
the majority of breast cancer patients in both quantile Q1 and
Q4 belong to the hormone receptor-positive subtype (ER+/
PR+), the proportion of patients with the HER2-positive subtype
is significantly lower in quantile Q1 compared to quantile Q4 for
both CTC cluster- and single CTC-associated hypomethylated
regions (Figures S2G–S2J).
Together, our patient PFS analysis revealed that CTC cluster-
associated hypomethylated regions are also hypomethylated at
the level of the primary tumor in a subset of breast cancer pa-
tients characterized by a poor prognosis, compared to patients
that display higher methylation levels in the same regions.
Proliferation-Related Genes Are Enriched in CTC
Clusters
Our DNA methylation analysis led us to hypothesize that CTC
clusters are characterized by active TF networks that support
both stemness and proliferation. To identify whether the stem-
ness- and proliferation-related TF networks are also transcrip-
tionally active in CTC clusters compared to single CTCs, we
performed single-cell resolution RNA sequencing analysis of
48 single CTCs and 24 CTC clusters, matched within individual
liquid biopsies and isolated from six breast cancer patients
with progressive metastatic disease, and of 49 single CTCs
and 54 CTC clusters isolated from three xenograft models (Fig-
ures S3A andS3B; Tables S1 andS3). First, we performed a tran-
scriptome-wide weighted gene co-expression network analysis
(WGCNA) and identified 32 co-expression modules, revealing
gene groups that are co-enriched in either single CTCs or CTC
clusters (Figure 3A). Particularly, with this approach we identified
two co-expression modules, containing total of 1,976 genes, en-
riched in patient-derived CTC clusters (p < 0.02; n = 1,544 for
red; n = 432 for pink expression modules), while no co-expres-
sion modules were found to be significantly enriched in single
CTCs (Figure 3B; Table S4). Gene ontology (GO) network anal-
ysis of the red and pink modules revealed an enrichment of
gene groups related to cell-cell junctions, cellular proliferation,
and platelet activation among others (Figure 3C). We then
repeated the same analysis with xenograft-derived CTCs. Tran-
scriptome-wide WGCNA identified 21 co-expression modules
(Figure 3D), of which four significantly enriched in xenograft-
derived CTC clusters and containing a total of 8,332 genes
(p < 0.003; n = 159 for magenta, n = 337 for green, n = 753 for
yellow, and n = 7,083 for turquoise expression modules), and
three significantly enriched in xenograft-derived single CTCs
and containing a total of 294 genes (p < 0.005; n = 202 for
gray, n = 41 for dark turquoise, and n = 51 for dark red) (Figure 3E;
Table S4). GO network analysis of the xenograft-derived CTC
cluster networks revealed an enrichment of genes related to
cell proliferation, DNA replication, cell-cell adhesion, and meta-
bolic processes, among others (Figure 3F). In contrast, GO
network analysis of the xenograft-derived single CTCs networks
pointed to different processes that included RNA splicing, ATP
metabolism, and ER stress response (Figure S3C). When specif-
ically asking which processes were commonly found enriched in
CTC clusters from both patients and xenografts, we identified
genes related to both cellular proliferation and cell-cell adhesion
(Figure 3G). While we previously reported upregulation of cell-
cell adhesion components in CTC clusters (Aceto et al., 2014),
whether cells within CTC clusters are also more proliferative
compared to single CTCs is poorly understood. To directly
address this point and validate our RNA sequencing findings,
we stained CTCs from both patients and xenografts with the pro-
liferation marker Ki67 and found that the percentage of Ki67-
positive cells is indeed greatly increased in CTC clusters
compared to matched single CTCs (Figures S3D–S3G).
In summary, our transcriptome-wide WGCNA revealed that
CTC clusters—additionally to upregulating cell-cell junction
components—are also characterized by a higher proliferation
rate compared to single CTCs, in line with our DNA methylation
results.
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Figure 2. CTC Cluster Hypomethylated Regions Are Associated with a Poor Prognosis in Breast Cancer Patients
(A) Percentage of DNA methylation (mean beta values) of overlapping probes identified in the TCGA breast cancer patient dataset. Patients are grouped in four
quantiles Q1-Q4, depending on the mean DNA methylation percentage of CTC cluster hypomethylated regions.
(B) Kaplan-Meier curve showing progression-free survival of breast cancer patients with overlapping probes in quantiles Q1 versus Q4 (top). The number of
patients that progressed at each time point is shown (bottom).
See also Figure S2.
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Figure 3. RNA Sequencing Analysis of Single CTCs and CTC Clusters from Breast Cancer Patients and Xenografts
(A) Weighted gene co-expression network analysis (WGCNA) in patient-derived single CTCs and CTC clusters, showing a hierarchical clustering tree of co-
expression modules. Each module corresponds to a branch, which is labeled by a distinct color shown underneath.
(B) WGCNA identifies 32 modules with highly correlated gene expression patterns in patient-derived single CTCs and CTC clusters. Correlations between each
module and CTC clusters or single CTCs are indicated by the intensity of red or green color, respectively. p value for each module is shown in brackets.
(C) GO term analysis of transcripts enriched in the red and pink expression modules of patient-derived CTC clusters.
(D) WGCNA in xenograft-derived single CTCs and CTC clusters, showing a hierarchical clustering tree of co-expression modules. Eachmodule corresponds to a
branch, labeled by a distinct color shown underneath.
(E) WGCNA identifies 21modules with highly correlated gene expression patterns in xenograft-derived single CTCs andCTC clusters. Correlations between each
module and CTC clusters or single CTCs are indicated by the intensity of red or green color, respectively. p value for each module is shown in brackets.
(F) GO term analysis of transcripts enriched in the magenta, green, yellow, and turquoise expression modules of xenograft-derived CTC clusters.
(G) Venn diagram showing the overlap of GO terms enriched in CTC clusters from patients and xenografts.
See also Figure S3 and Tables S3 and S4.
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Figure 4. Stemness-Related Gene Expression Analysis of Single CTCs and CTC Clusters from Breast Cancer Patients and Xenografts
(A) WGCNA of 302 stemness-related transcripts in patient-derived single CTCs and CTC clusters, showing a hierarchical clustering tree of co-expression
modules. Each module corresponds to a branch, which is labeled by a distinct color shown underneath.
(B) WGCNA identifies four modules with highly correlated gene expression patterns in patient-derived single CTCs and CTC clusters. Correlations between each
module and CTC clusters or single CTCs are indicated by the intensity of red or green color, respectively. p value for each module is shown in brackets.
(C) GO network analysis of patient-derived transcripts identified in the CTC cluster-associated blue and gray modules using iRegulon. The node size indicates
significance (p < 0.05), and color intensity corresponds to the percentage of genes that are associated to each GO category. Indicative GO categories are shown.
(D) GO term analysis of transcripts enriched in the blue and gray modules of patient-derived CTC clusters.
(E) Patient-derived CTC cluster-associated blue and gray module gene regulatory network analysis showing putative transcription factor dependence on SIN3A,
OCT4, and CBFB (green octagons).
(F) WGCNA of 302 stemness-related transcripts in xenograft-derived single CTCs and CTC clusters, showing a hierarchical clustering tree of co-expression
modules. Each module corresponds to a branch, labeled by a distinct color shown underneath.
(G) WGCNA identifies four modules with highly correlated gene expression patterns in xenograft-derived single CTCs and CTC clusters. Correlations between
each module and CTC clusters or single CTCs are indicated by the intensity of red or green color, respectively. p value for each module is shown in brackets.
(legend continued on next page)
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Stem-Cell-Related Genes Are Enriched in CTC Clusters
Our transcriptome-wide analysis revealed that the most signifi-
cant differences between single and clustered CTCs involve
the expression of cell-cell junction components and cell cycle
progression. Yet our DNA methylation analysis pointed to both
proliferation- and stemness-related TF networks being acces-
sible in CTC clusters. To specifically ask whether CTC clusters
would differ from single CTCs also in regard to the expression
of stemness-related genes (which may be regulated with more
subtle expression changes compared to cell cycle- and cell-
cell junction-related genes), we focused our analysis on 335
genes that were previously shown to be consistently upregulated
in mouse and human embryonic stem cells and embryonal car-
cinoma cells, as opposed to their differentiated counterparts
(Wong et al., 2008), and asked whether they are co-enriched in
CTC clusters. First, a subset of 302 of these 335 genes were
found to be expressed in our CTC samples from breast cancer
patients (cutoffR 3 transcripts per million). WGCNA with these
genes identified four expression modules co-enriched in either
single CTCs or CTC clusters. Particularly, we identified two co-
expression modules, containing a total of 85 genes, enriched
in patient-derived CTC clusters (n = 66 for blue; n = 19 for gray
expression module) and in two co-expression modules, contain-
ing 217 genes, enriched in patient-derived single CTCs (n = 156
for turquoise; n = 61 for brown) (Figures 4A and 4B; Table S4). GO
network analysis of these modules confirmed that CTC clusters
co-express stemness-related genes interconnected to cellular
proliferation, while single CTCs co-express genes more related
to metabolic processes (Figures 4C, 4D, and S4A; Table S4).
Importantly, TF target gene analysis (Janky et al., 2014) of CTC
cluster-enriched genes confirmed, among others, activity of
SIN3A and OCT4, in line with our DNA methylation findings (Fig-
ure 4E; Table S5). We then extended our analysis of the 302
stemness-related genes to xenograft-derived CTCs. In this
case, WGCNA revealed four expression modules, of which two
were found to be enriched in xenograft-derived CTC clusters
and containing a total of 153 genes (n = 151 for green; n = 2
for yellow expression module) (Figures 4F and 4G; Table S4), in
high concordance (85% overlap) with patient-derived modules
enriched in CTC clusters (Figure 4H; Table S4). TF target gene
analysis of those genes that are enriched in xenograft CTC clus-
ters also revealed the activity of several stemness- and prolifer-
ation-related TFs, including SIN3A, OCT4, NANOG, and SOX2
(Figure 4I; Table S5). Interestingly, the majority of these genes
also displays hypomethylated promoter regions in CTC clusters
compared to single CTCs (Figures S4B and S4C). Co-expression
modules found in single CTCs from patients and xenografts also
displayed significant overlap between each other (56.7%) (Fig-
ure S4D; Table S4), and TF analysis revealed the activity of
MYF6 and ASCL1, also displaying hypomethylated binding sites
in single CTCs (Figure S4E; Table S5).
Altogether, our gene expression data both at the transcrip-
tome-wide level and also focused on stem cell-related genes
strongly supports the model proposed with the DNAmethylation
analysis, suggesting that when compared to single CTCs, CTC
clusters are endowed with a stemness- and proliferation-related
network centered on the activity of key transcription factors
including OCT4, SOX2, NANOG, and SIN3A. Activation of these
programs may play a pivotal role in determining the metastasis-
seeding ability of CTC clusters.
Identification of FDA-Approved Cluster-Targeting
Agents
Next, we sought to identify actionable vulnerabilities of CTC
clusters, and to test whether the epigenetic and transcriptional
features of clustered CTCs are reversible upon cluster dissocia-
tion into single cells. To this end, we evaluated 2,486 FDA-
approved compounds (Table S6) for their ability to dissociate
clusters of human breast CTC-derived cells obtained from two
patients with breast cancer (BR16 and BRx50), without affecting
cellular viability. Cluster dissociation was assessed using an im-
age-based high-content screening system and comparing CTCs
treated with individual compounds to untreated CTCs as well as
40-mm-filtered single-cell suspension as negative and positive
controls, respectively (Figures 5A, S5A, and S5B). For the major-
ity of the 2,486 FDA-approved compounds, we observed no
detectable reduction in cell viability (>70% viability) or in the
mean CTC cluster size (> 450 mm2) of CTC-derived cells upon
treatment (gray circles; Figure 5B). Yet we identified 39 com-
pounds that significantly (p < 0.0001) reduced mean CTC cluster
size without compromising viability (orange circles; Figure 5B).
These compounds include inhibitors of Na+/K+ ATPase (n = 6),
histone deacetylase (HDAC) (n = 2), nucleotide biosynthesis
(n = 5), kinases (n = 3), GPCRs (n = 2), cholesterol biosynthesis
(n = 1), nuclear export (n = 1), tubulin (n = 10), DNA binding com-
pounds (n = 8), and antibiotics (n = 1) (Figures 5B and S5C).
Importantly, reducing compound concentration resulted in a
gradual increase in mean CTC cluster size in both CTC-derived
cell lines, followed by an increase in the number of nuclei de-
tected, and a slight improvement in mitochondrial membrane
potential and overall viability (Figures 5C and S5D). Under these
conditions, six compounds consistently led to a significant
decrease in mean CTC cluster size for both CTC-derived cell
lines, even at the lowest concentrations tested. These com-
pounds display similar functions and can be grouped into two
families based on their mechanism of action, namely the Na+/
K+-ATPase inhibitors digitoxin and ouabain octahydrate and
the tubulin binding agents rigosertib, podofilox, colchicine, and
vincristine sulfate (Figures 5C, S5C, and S5D).
Dissociation of CTC Clusters Leads to DNA Methylation
Remodeling of Key Sites
To assess whether CTC cluster dissociation into single cells
would lead to DNA methylation remodeling, we treated four
CTC-derived cell lines with the six CTC cluster-dissociating
compounds individually. We found that a prolonged treatment
(H) Venn diagram showing the overlap of CTC cluster-enriched transcripts between patients (blue and gray modules) and xenograft (yellow and green modules).
(I) Xenograft-derived CTC cluster-associated green and yellow module gene regulatory network analysis showing putative transcription factor dependence on
SIN3A, OCT4, NANOG, BHLHE40, RORA, and FOXO1 (green octagons) and on SOX2 (orange circle).
See also Figure S4 and Tables S4 and S5.
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(17 days) with 20 nM digitoxin or ouabain was unique in ensuring
the highest degree of CTC cluster dissociation while allowing
high viability and optimal proliferation rates comparable to un-
treated control cells (Figure S6A). Of note, the treatment period
of 17 days was chosen to allow all cells (treated and untreated)
to double at least 5 times and therefore enabling DNA methyl-
ation remodeling events to occur. Upon treatment, we pro-
cessed BR16 and Brx50 cells for WGBS and RNA sequencing
analysis to assess the molecular consequences of clusters
dissociation. First, WGBS analysis revealed that the treatment
did not affect global DNA methylation levels (data not shown).
Yet a number of DMRs that were hypomethylated in CTC clus-
ters gained methylation upon treatment (Figures S6B and
S6C). Within the CTC cluster regions that gained methylation,
i-cisTarget analysis showed enrichment for binding sites of
stemness-related TFs, such as OCT4, SOX2, and NANOG, and
for SIN3A, among others (Figure 6A). Simultaneously, RNA
expression analysis upon treatment with digitoxin or ouabain re-
vealed a high concordance between the expression changes of
stemness-related genes that were enriched in patient- and xeno-
graft-derived CTC clusters (r = 0.69; p < 2.2216; Figures 6B),
with the majority of these genes being downregulated as a
consequence of the treatment (p < 0.002; Figure 6B). TF analysis
revealed that downregulated genes were targets of OCT4,
NANOG, SOX2, and SIN3A transcription factors, among others
(Figure 6C). In contrast, TF analysis of those genes that were
upregulated as a consequence to CTC cluster dissociation
highlighted target genes of other TFs, independent from a core
pluripotency network (Kim et al., 2008) (Figure S6D). Thus,
CTC cluster dissociation into single cells with ouabain and
digitoxin leads to DNA methylation remodeling and gain in
methylation of critical binding sites for OCT4, SOX2, NANOG,
and SIN3A, paralleled by downregulation of their corresponding
target genes.
Inhibition of the Na+/K+ ATPase using ouabain and intracellular
increase of calcium levels have been previously shown to nega-
tively affect the formation of tight junctions and desmosomes in
epithelial cells (Nigam et al., 1992; Rajasekaran et al., 2001; Stu-
art et al., 1994). Here, to gain more insights into the mechanism
of action of Na+/K+ ATPase inhibitors in the context of CTC clus-
ters disruption, we tested whether the suppression of ATP pro-
duction and consequently, an increase in intracellular calcium
levels—using the proton uncouplers FCCP and CCCP (De-
maurex et al., 2009)—would also dissociate CTC clusters. Our
results show that treatment of CTC-derived cells with increasing
concentrations of FCCP and CCCP for 18 hr leads to a gradual
decrease of mean cluster size (Figure 6D), paralleled by a signif-
icant increase in intracellular Ca2+ levels (Figure 6D). Interest-
ingly, a similar gradual increase in intracellular Ca2+ is also
observed when treating with increasing concentrations of digi-
toxin and ouabain (Figure S6E). These results support a model
whereby intracellular Ca2+ increase leads to the inability of can-
cer cells to properly form cell-cell junctions.
To further confirm this model, we assessed whether cell-cell
junction disruption in CTC-derived cells would lead to clusters
dissociation as well as DNAmethylation remodeling at CTC clus-
ter-associated DMRs. To this end, we employed the CRISPR
technology to simultaneously knockout both claudin 3 (CLDN3)
and claudin 4 (CLDN4) in BR16 CTC-derived cells, two of the
highest-expressed tight junction proteins in CTC clusters (Table
S4). Using two independent sgRNAs for each gene, we gener-
ated three BR16 lines with double CLDN3/4 knockout, which
also displayed a significant reduction of mean CTC cluster size
(Figures S6F and S6G). Whole-genome bisulfite sequencing of
the CLDN3/4 double-knockout cells showed that, upon dissoci-
ation into single cells and similarly to the events that occurred
upon Na+/K+ ATPase inhibition, a number of CTC cluster-associ-
ated hypomethylated regions gained methylation (Figure 6E).
Interestingly, i-cisTarget analysis of the regions that gained
higher levels of methylation revealed an enrichment of binding
sites for OCT4, SOX2, NANOG, and SIN3A (Figure 6F), further
indicating that CTC clustering directly affects DNA methylation
dynamics at bindings sites for stemness- and proliferation-asso-
ciated TFs.
Together, our results indicate that Na+/K+ ATPase inhibition
leads to CTC clusters dissociation through the increase of the
intracellular Ca2+ concentration and the consequent inhibition
of cell-cell junction formation, resulting in DNA methylation re-
modeling at critical stemness- and proliferation-related bind-
ing sites.
Treatment with Na+/K+-ATPase Inhibitors Suppresses
Spontaneous Metastasis Formation
To test whether ouabain and digitoxin would also enable CTC
clusters disruption in vivo, we took a dual approach. First, we
tested whether a 17-day in vitro treatment with ouabain and digi-
toxin would translate into a reduced ability of the treated cells to
efficiently seed metastasis in untreated mice (Figure 7A). To this
end, upon treatment, BR16 cells stably expressing GFP-lucif-
erase were injected into the tail vein of NSG mice and
Figure 5. Screen for FDA-Approved Compounds that Dissociate CTC Clusters
(A) Representative images of unfiltered and filtered BR16CTC-derived cells stainedwith Hoechst (blue) and TMRM (orange) (left). Representative images of single
and clustered CTCs outline based on nuclei proximity as determined using the Colombus Image Analysis System (right). The plots show the mean CTC cluster
size (area in micrometers squared) and percentage (%) of viability of unfiltered versus filtered BR16 cells (n = 4; ***p < 0.001 by Student’s t test; ns, not significant)
(bottom).
(B) Effect of a 2-day treatment of BR16 cells with 2,486 FDA-approved compounds at 5 mMconcentration, plotted as mean CTC cluster size (area in micrometers
squared) versus percentage (%) of viability (n = 2). Thirty-nine FDA-approved compounds (orange circles) result in significant decrease in mean CTC cluster size
(p < 0.0001, F value = 7.71; DF = 38 using one-way ANOVA test; horizontal dashed red line, < 450 mm2) and > 70% detectable viability (vertical-dashed red line).
BR16 cells that were untreated (red) or 40 mm filtered (green) are shown as controls.
(C) The plot shows the mean CTC cluster size of BR16 cells treated with each of the 39 cluster-targeting compounds at four different concentrations. BR16 cells
that were untreated (red) or 40 mm filtered (green) are shown as controls (top panel). The heatmap shows the number of nuclei, mean TMRM intensity, and
percentage (%) of viability of BR16 cells treated with cluster-targeting compounds at the indicated concentrations (bottom). n = 2. Error bars represent SEM.
See also Figure S5 and Table S6.
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noninvasively monitored through luminescence imaging for their
ability to seed and propagate metastatic lesions. We found that
while the treatment with digitoxin or ouabain did not affect the
ability of BR16 cells to lodge in the lung tissue immediately after
injection (see ‘‘day 0’’; Figure 7B), it led to a reduced ability to
survive during the first day upon arrival, as confirmed by a
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Figure 6. Treatment with Na+/K+ ATPase Inhibitors and Tight Junction Dissociation Restores Methylation at Key Sites
(A) i-cisTarget analysis of CTC clusters hypomethylated regions, showingR 40%methylation increase upon in vitro treatment with 20 nM of digitoxin or ouabain.
Shown are enriched TFBSs in each CTC-derived cell line (NESR 3).
(B) The plot shows expression changes in stemness-related transcripts that are enriched in patient- and xenograft-derived CTC clusters (n = 168) upon treatment
of BR16 and BRx50 cells with 20 nM digitoxin or ouabain. Pearson’s correlation coefficient (r) and p values are shown.
(C) Gene regulatory network analysis of downregulated genes upon treatment with 20 nM digitoxin or ouabain in both BR16 and BRx50 (log FC%0.5), showing
putative dependence on OCT4, SOX2, NANOG, and SIN3A, among other TFs (green octagons). Downregulated genes that are not regulated by the TFs
mentioned above are shown in red.
(D) The plot shows the mean CTC cluster size of BR16 and BRx50 CTC-derived cells treated with FCCP or CCCP at different concentrations (n = 4). BR16 and
BRx50 cells that were untreated (red) or 40 mmfiltered (green) are shown as controls (top). The heatmap shows the percentage (%) of viability of treated cells at the
indicated concentrations (middle). The plot shows the mean cell intensity of Ca2+-bound Fluo-3 after treatment with FCCP or CCCP, relative to the untreated
control (red) (n = 4) (bottom). Error bars represent SEM.
(E) Heatmap showing methylation variable regions among CTC cluster hypomethylated regions that gainR 40%methylation upon CLDN3/4 double knockout in
BR16 cells.
(F) i-cisTarget analysis of CTC cluster hypomethylated regions, showingR 40%methylation increase upon CLDN3/4 double knockout in BR16 cells. Shown are
enriched TFBSs (NESR 3).
See also Figure S6 and Tables S2, S3, and S7.
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significant increase in the expression of cleaved caspase 3
compared to control cells (see ‘‘day 1’’; Figures 7B, S7A, and
S7B). Overall, this difference in the ability to survive during the
very early steps of metastasis seeding resulted in a delayedmet-
astatic outgrowth despite the absence of further treatment
in vivo, as measured during the course of 72 days upon injection
(Figure 7C).
Second, mimicking more closely the clinical setting, to assess
the effect of our CTC cluster-dissociation strategy for the spon-
taneous formation of CTC clusters and metastasis from a pri-
mary tumor, we injected BR16 cells in the mammary fat pad of
NSG mice. Fourteen weeks after primary tumor formation we
administered ouabain daily for three weeks and assessed CTC
composition and the occurrence of spontaneous metastatic le-
sions (Figure 7D). Importantly, we observed that ouabain treat-
ment reduced the frequency of spontaneously generated CTC
clusters while increasing the frequency of single CTCs (Fig-
ure 7E), without altering the size of the primary tumor nor overall
CTC numbers (Figures S7C and S7D). Along with a reduction in
the frequency of CTC clusters, ouabain treatment also resulted in
a remarkable suppression (80.7-fold) of the total metastatic
burden (Figures 7F and 7G). In a similar fashion, when adminis-
tering ouabain treatment to NSG mice carrying spontaneously
metastasizing LM2 tumors, we also observed an increase in
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Figure 7. Treatment with Na+/K+ ATPase Inhibitors Suppresses Spontaneous Metastasis Formation
(A) Schematic representation of the experiment.
(B) The plots show the total bioluminescence flux at day 0 (left) and day 1 (right) upon tail vein injection of BR16 cells pre-treated with 20 nM digitoxin or ouabain.
n = 5 for controls and ouabain, n = 4 for digitoxin; *p < 0.05 by Student’s t test. ns, not significant. Error bars represent SEM.
(C) Metastasis growth curve over 72 days upon tail vein injection of BR16 cells pre-treatedwith 20 nMdigitoxin or ouabain. n = 5; *p < 0.05; **p < 0.01 by Student’s
t test. Error bars represent SEM.
(D) Schematic representation of the experiment.
(E) The plots show the percentage (%) of spontaneously generated single CTCs and CTC clusters detected in the blood of BR16 xenografts treated with ouabain.
n = 5; ***p < 0.001 by Student’s t test. error bars represent SEM.
(F) The plot shows the metastatic index of BR16 xenografts treated with ouabain. n = 11 for controls, n = 5 for ouabain; **p < 0.01 by Student’s t test. Error bars
represent SEM.
(G) Representative images of the bioluminescence signal measured in brain and in liver of control and ouabain-treated NSG mice.
See also Figure S7.
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the proportion of single CTCs and a decrease in CTC clusters
(Figure S7E), without any change in the primary tumor size nor
overall CTC numbers (Figures S7F and S7G), leading to a
reduced metastatic burden compared to control (Figure S7H).
Together, these results demonstrate that Na+/K+ ATPase inhi-
bition in vivo suppresses the ability of a cancerous lesion to
spontaneously shed CTC clusters, leading to a remarkable
reduction in metastasis seeding ability.
DISCUSSION
Our study provides a comprehensive genome-wide analysis of
the DNA-methylation events that characterize CTCs in patients
and xenografts. Surprisingly, we find that phenotypic differ-
ences—such as the ability of CTCs to navigate through the
bloodstream as single cells or multicellular clusters—shape the
DNA methylome. Clustering of CTCs results in hypomethylation
of binding sites that are typically occupied by master stemness
and proliferation regulators, including OCT4, NANOG, SOX2,
and SIN3A, and hypermethylation of Polycomb target genes.
More globally, we also find that the DNA methylation profile of
CTC clusters is detected at the level of the primary tumor in a
subset of breast cancers that are characterized by a poor prog-
nosis. CTC clusters dissociation into single cells with Na+/K+
ATPase inhibitors or through cell-cell junction knockdown en-
ables DNA methylation remodeling at critical sites, highlighting
a direct connection between clustering and methylation status.
As a result, Na+/K+ ATPase inhibitors treatment emerges as a
new strategy to significantly reduce the spread of cancer,
providing a rationale for using these compounds in clinical
studies.
Our results suggest that CTC clusters may share several prop-
erties that commonly feature stem cell biology. For instance,
OCT4, NANOG, SOX2, and SIN3A are predominantly active in
embryonic stem cells (ESCs), simultaneously regulating self-
renewal and proliferation (Kim et al., 2008; McDonel et al.,
2012; Niwa, 2007; van den Berg et al., 2010). In addition, ESCs
rely on Polycomb-mediated repression of differentiation genes
and chromatin remodeling to maintain their active pluripotency
network (Lee et al., 2006). Cell-cell junction activity has been
shown in several instances to safeguard pluripotency and to
be required for a complete reprogramming of somatic cells
into stem cells, and disruption of cell-cell junctions (e.g., through
targeting of E-cadherin) in human ESC results into OCT4,
NANOG, and SOX2 downregulation along the loss of stemness
features (Li et al., 2010a, 2010b, 2012; Pieters and van Roy,
2014). Thus, by analogy with stem cell biology, elevated expres-
sion of cell-cell junction components in cancer cells may not only
enable their intravasation in the bloodstream as multicellular
clusters but also their ability to retain stem-like features that facil-
itate metastasis initiation.
Identifying FDA-approved compounds that dissociate CTC
clusters provides a new tool to reduce the spread of cancer.
Our results demonstrate that CTC clusters disruption into single
cells via the inhibition of the Na+/K+ ATPase has a dual, yet inter-
connected effect. The fact that clusters dissociation leads to
DNA methylation remodeling at critical sites provides a direct
link between a phenotypic state of the cells (i.e., clustered versus
single) and DNA methylation dynamics. Second, CTC clusters
disruption increases the proportion of single CTCs in the blood-
stream but suppresses overall metastasis formation, indicating
that targeting CTC clusters could be a valuable therapeutic strat-
egy. In this regard, while we cannot exclude that an anti-cluster
treatment might be beneficial also at the late disease stages in
those patients whose metastasis may seed other metastases
(McPherson et al., 2016; Reiter et al., 2017; Zhang et al., 2017),
in vivo data suggest that treatment with ouabain and digitoxin
should be administered early, ideally at the time of localized dis-
ease and before dissemination to distant sites, with the objective
to prevent CTC cluster formation.
Ouabain and digitoxin are cardiac glycosides with a similar
chemical structure, used in low doses for the treatment of
hypotension and cardiac arrhythmias, acting through nonselec-
tive inhibition of the Na+/K+ ATPase (Altamirano et al., 2006;
Schwartz, 1976). Upon inhibition of the Na+/K+ ATPase, cellular
uptake of Na+ occurs, leading to a simultaneous increase in
intracellular Ca2+ and impaired translocation of desmosomal
and tight junction proteins to the cellular membrane (Altamirano
et al., 2006; Arispe et al., 2008). Based on this, our experi-
mental evidences support a model whereby pharmacological
inhibition of the Na+/K+ ATPase either directly or indirectly
(i.e., by depletion of available ATP) leads to a concomitant in-
crease in intracellular Ca2+ levels and CTC cluster disruption
through suppression of functional cell-cell junction assembly
(Cavey and Lecuit, 2009; Kim et al., 2011).
Together, our study provides key insights into the biology of
CTCs and highlights a fundamental connection between
phenotypic features of CTCs (such as their ability to circulate
as multicellular clusters) and DNA methylation dynamics at
critical stemness- and proliferation-related sites. Further, we
identify the Na+/K+ ATPase inhibitors ouabain and digitoxin
as FDA-approved agents capable to dissociate CTC clusters
into single cells and to suppress spontaneous metastasis for-
mation in xenograft models, providing a rationale for applying
these compounds for the treatment of patients with breast
cancer.
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Detection of circulating tumour cell clusters in human
glioblastoma
Ilona Krol1, Francesc Castro-Giner1,2, Martina Maurer3, Soﬁa Gkountela1, Barbara Maria Szczerba1, Ramona Scherrer1,
Niamh Coleman 4, Suzanne Carreira4, Felix Bachmann3, Stephanie Anderson3, Marc Engelhardt3, Heidi Lane3,
Thomas Ronald Jeffry Evans5, Ruth Plummer6, Rebecca Kristeleit7, Juanita Lopez4 and Nicola Aceto1
Human glioblastoma (GBM) is a highly aggressive, invasive and hypervascularised malignant brain cancer. Individual circulating
tumour cells (CTCs) are sporadically found in GBM patients, yet it is unclear whether multicellular CTC clusters are generated in this
disease and whether they can bypass the physical hurdle of the blood–brain barrier. Here, we assessed CTC presence and
composition at multiple time points in 13 patients with progressing GBM during an open-label phase 1/2a study with the
microtubule inhibitor BAL101553. We observe CTC clusters ranging from 2 to 23 cells and present at multiple sampling time points
in a GBM patient with pleomorphism and extensive necrosis, throughout disease progression. Exome sequencing of GBM CTC
clusters highlights variants in 58 cancer-associated genes including ATM, PMS2, POLE, APC, XPO1, TFRC, JAK2, ERBB4 and ALK.
Together, our ﬁndings represent the ﬁrst evidence of the presence of CTC clusters in GBM.
British Journal of Cancer (2018) 119:487–491; https://doi.org/10.1038/s41416-018-0186-7
INTRODUCTION
Human glioblastoma (GBM) is the most common and aggressive
primary brain cancer in adults.1 Yet, despite its characteristic
invasive features and hypervascularity determined by angiogenic
recruitment, only 0.4–2% of GBM patients develop metastasis
outside of the central nervous system.2 The rarity of these
metastatic events has been attributed to the short-term survival of
patients after initial GBM diagnosis, leaving insufﬁcient time for
establishment of extracranial lesions, as well as to the presence of
the blood–brain barrier, which physically separates the brain from
the rest of the body.3 Circulating tumour cells (CTCs) are cancer
cells that detach from a primary tumour lesion or a metastatic
deposit and enter the bloodstream.4 Although individual CTCs
have been sporadically observed in GBM,5–8 it is unclear whether
multicellular CTC clusters9 are generated and are able to pass
through the blood-brain barrier in patients with GBM.
MATERIALS AND METHODS
Patient selection and recruitment
Patients were participants in the GBM arm of the ongoing study
‘An open-label Phase 1/2a study of oral BAL101553 in adult
patients with advanced solid tumours and in adult patients with
recurrent or progressive glioblastoma or high-grade glioma’
(NCT02490800). The main eligibility criteria for GBM patients in
the study are measurable disease, deﬁned by contrast-enhancing
magnetic resonance imaging (MRI), and an Eastern Cooperative
Oncology Group performance status of ≤ 2. The study was
conducted in accordance with the Declaration of Helsinki (2000)
and the International Conference on Harmonisation Guidelines for
Good Clinical Practice. The study was approved by each study
centre’s Research Ethics Committee and all patients provided
written informed consent before enrolment.
Mouse experiments
All mouse experiments were carried out according to institutional
and cantonal guidelines (approved mouse protocol 2781, cantonal
veterinary ofﬁce of Basel-City). To measure GBM CTC intravascular
aggregation, Nod Scid Gamma mice (The Jackson Laboratory, Bar
Harbor, Maine, USA) were injected through the tail vein with a 1:1
mixture of T98G-GFP and T98G-RFP GBM cells, and upon injection,
whole blood was withdrawn through a heart puncture and
processed with the Parsortix device to characterise CTC
composition.
GBM CTC enumeration
To test the GBM cell capture rate, healthy donor blood samples
were drawn in three different collection tubes: CF DNA blood
collection tube (BCT) (Streck, 218997), CellSave (CellSearch,
7900005) and Cyto-Chex BCT (Streck, 213386). The blood was
then spiked with 300 human GBM T98G cells (Sigma, 92090213,
CRL-1690) stably expressing green ﬂuorescent protein (GFP).
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T98G-GFP cells were generated by transduction with UBC-GFP-
T2A-Luc-expressing lentiviral particles (SBI, BLIV201PA-1-SBI). After
incubation at room temperature (RT) for 24, 48, 72, and 96 h,
samples were processed with the Parsortix microﬂuidic system for
CTC enrichment. After wash with phosphate-buffered saline (PBS),
Parsortix cassettes were scanned and GFP-positive cells were
counted using Leica DMI 6000 microscope. To test artiﬁcial
clustering of CTCs within the Parsortix cassettes, we spiked
100 single T98G-GFP and 100 single T98G-RFP into CF DNA BCT
(Streck, 218997) tubes containing healthy donor blood. Upon
processing through the Parsortix microﬂuidic system, we enum-
erated the ratios between single colour CTC and multicolour CTCs
as a direct measure of on-chip CTC aggregation.
Tumour volume measurements
The enhancing tumour volume (cm3) and the corresponding FLAIR
signal abnormality volume (cm3) in patients were calculated with
Horos, an open source medical image viewer (LGPL license at
Horosproject.org, sponsored by Nimble Co LLC d/b/a Purview in
Annapolis, MD US).
CTC capture from GBM patients
Patients’ blood samples were collected into the Streck CF DNA
BCTs (Streck, 218997) and directly shipped at controlled tempera-
ture (RT). Samples were then loaded into the Parsortix microﬂuidic
device within 24–48 h after collection from the patient and
immediately processed for CTC enrichment. CTCs were
then enriched from blood samples at 16 °C in disposable Parsortix
cassettes (GEN3D6.5, ANGLE) according to the manufacturer’s
instruction and with a customised processing ﬂow rate of 0.33mm/
s in the narrowest cassette gap (6.5 μm). After separation, GBM
cells within cassettes were washed with PBS and further processed
for immunostaining with antibodies against EGFR (Cell Signaling),
Ki67 (Sigma), EB1 (kindly provided by Basilea Pharmaceutica), and
CD45 (Thermo Fischer). As an additional conﬁrmation, putative
CTCs as well as a matched primary tumour biopsy of patient 4 were
stained with antibodies against SOX2 (Cell Signaling).
Micromanipulation and exome sequencing
CTCs were released from the Parsortix cassette into ultra-low
attachments culture plates. Cells were picked using micromani-
pulation (CellCelector, ALS) and transferred to RTL Plus buffer
(Qiagen) within individual microcentrifuge tubes. Next, genomic
DNA was ampliﬁed using the MDA method (GenomiPhi V3, GE
Healthcare) and subject to Illumina library preparation with
SureSelect XT Human All Exon V6+ Cosmic kit (Agilent Technol-
ogies). Sequencing was performed on HiSeq 2500 platform
(Illumina) with 101 bp paired-end mode. For primary tumour
sequencing, three 10 μm-thick parafﬁn sections from a primary
tumour biospy were digested in DNA digestion buffer (50 mM Tris-
HCl pH 8.5, 1 mM EDTA pH 8.0 and 0.5% Tween with addition of
Proteinase K) in an eppendorf tube at 56 °C for 1 h, followed by 1 h
incubation at 90 °C and 5min at 95 °C. Samples were then kept on
ice until RNase A treatment was performed (30minutes at 37 °C).
Next, DNA was precipitated using 7.5 M ammonium acetate and
100% isopropanol. After washing with 70% ethanol, the DNA
pellet was air dried and then resuspended in standard Tris-
containing buffer. Sequencing was performed on HiSeq 2500
platform (Illumina).
Exome-sequencing data analysis and mutation calling
After quality control performed with FastQC (v0.11.4), reads were
mapped to the GRCh38 human reference genome using BWA-
mem (v0.7.13) algorithm and sorted using Samtools (v1.3.1). Reads
were then processed using Picard MarkDuplicates (v2.9.0) to
remove duplicated reads and realigned using GATK IndelRealign-
ment (v3.7.0) to improve alignment accuracy around indels. We
used the interactive platform Ginkgo (http://qb.cshl.edu/ginkgo) to
compute and plot the copy number proﬁles of single-cells. Input
bed ﬁles were generated from BAM alignments using BEDTools
(v2.26.0) and genomic coordinates were converted from GRCh38
to GRCh37 UCSC liftOver tool. Ginkgo was run with a using variable
bin size of 500 kb simulated with 101 bp with BWA and normalised
read counts for cell segmentation. Variants were identiﬁed using
Monovar (20160514 update) for low-input DNA samples and
bcftools (version 1.6) for primary GBM of patient 4. Resulting
variants were annotated using snpEff (v4.3p) with Ensembl
GRCh38.86 gene models. Putative somatic SNV were deﬁned as
variants not present in the white blood cell (WBC) pool and whose
frequency in the dbSNP (build 150) was < 1%. In addition, a more
stringent set of somatic single nucleotide variants (SNVs) was
obtained by ﬁltering out loci that were covered with < 5 reads in
the WBC pool. Candidate somatic driver variants were deﬁned as
variants annotated with high or moderate impact according to
snpEff, previously reported in the COSMIC (version 81) or located in
recurrently mutated genes in gliobastoma according to the CGC
database (version 81). Data analysis was conducted in R (version
3.4.0). Data visualisation was performed with the R package UpSetR
and the Bioconductor package GenVisR.
RESULTS
CTC detection strategy in GBM patients
Patients selected for CTCs investigation were part of an ongoing
open-label Phase 1/2a study arm of oral BAL101553, a water-
soluble microtubule inhibitor, in adult individuals with recurrent or
progressive GBM or high-grade glioma. Upon informed consent,
serial peripheral blood samples were drawn in Streck tubes from
13 GBM patients at time points related to BAL101553 administra-
tion, including (1) within the 2 weeks before the ﬁrst study-drug
treatment; (2) pre-dose, (3) 2 h post-dose and (4) 24 h post-dose
on Cycle 1 Day 1; and pre-dose on (5) Cycle 1 Day 8, (6) Cycle 1
Day 22 and (7) Cycle 2 Day 22 (Fig. 1a). Blood samples were then
processed within 48 h for CTC enumeration and characterisation.
To investigate CTC number and composition in GBM patients, we
made use of a commercially available CTC detection method, the
Parsortix microﬂuidic technology, customised to detect both
single and clustered GBM CTCs in an antigen-independent
manner and at > 98% capture efﬁciency, up to 48 h upon
ﬁxation in Streck CF DNA tubes (see methods and Supplementary
Fig. 1a-c), and without the occurrence of artiﬁcial CTC aggregates
during processing (Supplementary Fig. 1d,e). Brieﬂy, blood
samples were run through the Parsortix microﬂuidic cassette at
a ﬂow rate corresponding to 0.33 ml/s in the narrowest channel
section, ensuring label-free physical capture of CTCs and their
separation from blood components (Fig. 1b). Upon capture, CTCs
were stained with a dedicated GBM CTC antibody cocktail
containing antibodies against EGFR, Ki67 and the microtubule-
associated protein EB1, as well as against the WBC marker CD45 to
exclude leukocyte contamination (Supplementary Fig. 2). Putative
GBM CTCs were scored positive when corresponding to at least
one of these criteria: (1) cell diameter of at least 9 μm and negative
CD45 staining, and/or (2) positive EGFR, Ki67 or EB1 staining and
negative CD45 staining. With these parameters, and using healthy
blood donors (n= 3) to deﬁne a false-positive detection threshold,
we found that 7/13 patients were positive for at least 3 putative
CTCs per 10 ml of blood during at least 1 time point (Fig. 1c).
Importantly, radiological imaging determined that none of the 13
patients enroled in the study developed extracranial metastasis
(data not shown), and no association was observed between
functional MRI volume and the presence of CTCs, most likely due
to the small patient cohort (n= 13) (Supplementary Fig. 3).
Detection of GBM CTC clusters
Among patients that resulted positive for putative GBM CTCs, we
focused on a 43-year-old female patient (4), featuring the highest
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number of CTC events in the peripheral circulation. The patient
had a ﬁrst surgical resection of a right parietal GBM, which showed
a high-grade astrocytic tumour with pleomorphism, mitoses,
extensive necrosis and prominent vascular proliferation. Following
surgery, the patient underwent chemoradiotherapy comprising
standard radiation plus concomitant and subsequent adjuvant
temozolomide. Imaging at the end of adjuvant treatment
suggested progressive disease, requiring a second surgical
resection followed by procarbazine/lomustine/vincristine (PCV)
chemotherapy and re-irradiation. Further disease progression was
noted and subsequently the patient was enroled onto the
BAL101553 clinical trial (Supplementary Fig. 4a). MRI of the brain
before commencing BAL101553 therapy and CTC enumeration
showed enhancing tumour areas in the posterior aspect of the
right parietal lobe, inﬁltrating the corpus callosum and extending
periventricular along the occipital horn of the right lateral ventricle
and inferiorly into the temporal lobe (Supplementary Fig. 4b).
There were no other abnormalities seen on baseline whole-body
radiological imaging (data not shown). CTC analysis revealed the
presence of clusters of putative CTCs in the blood of this patient,
ranging from 2 to 23 cells and expressing various combinations of
EGFR, Ki67 and EB1 markers, yet negative for CD45 (Fig. 1d and
Supplementary Fig. 4c). As a further validation step, putative GBM
CTC clusters, as well as a biopsy from the primary GBM of patient 4
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Fig. 1 Identiﬁcation of GBM CTC clusters. a Schematic overview of the CTC isolation strategy (red) in GBM patients undergoing treatment with
BAL101553. Each patient underwent several blood draws: one or two blood draws before BAL101553 treatment (pre-tx), four during the ﬁrst
BAL101553 cycle and one during the second BAL101553 cycle. b Schematic representation of our CTC enrichment strategy with the Parsortix
microﬂuidic device. CTCs are captured with a size-based antigen-agnostic approach, while red and white blood cells ﬂow through the device.
c Plot showing the mean number of CTCs found at each sampling time point (pre-treatment: pre-TX; cycle 1 and cycle 2) in 13 GBM patients.
Healthy donors samples (HD; n= 3) provide a false-positive threshold of two putative CTCs per 10 ml blood. Patients with > 2 putative CTCs
per 10 ml of blood during at least one time point are shown in red. d Plot showing the number of cells per each GBM CTC cluster isolated from
patient 4. e Plot showing the number of GBM CTC clusters per 10ml of blood identiﬁed in patient 4 during each blood draw, both pre-
treatment (pre-TX) and post-treatment (cycle 1 and cycle 2) with BAL101553. P= 0.462 by Student’s t-Test. NS: not signiﬁcant. f Schematic
representation of the CTC isolation strategy by ﬂow reversion and picking with a micromanipulator. g Putative somatic mutations in
glioblastoma candidate driver genes found in GBM CTC clusters. The central panel shows the mutated genes coloured by the predicted
consequence of the mutations. The top panel shows the number of mutations per sample and the left panel shows the percentage of samples
that have a mutation in each represented gene
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were stained with the GBM marker SOX2, revealing SOX2-positive
cells in both specimens (Supplementary Fig. 4d, e). Similar to
breast cancer,9 we also conﬁrmed that GBM CTCs are not able to
form intravascular aggregates upon injection in the venous
circulation of mice (Supplementary Fig. 5a,b), indicating that the
putative CTC clusters observed in patient 4 are likely to be direct
derivatives of the primary GBM tumour. As a relatively stable
number of putative CTC clusters were observed in the samples
taken prior to and after initiation of BAL101553 therapy, it does
not appear as though the treatment itself impacted on CTC
clusters release at this dose level (Fig. 1e).
Exome sequencing of GBM CTC clusters
To assess whether the cell clusters isolated from the patient of
interest were bona ﬁde GBM cells, we released them in solution
from the Parsortix device and, with a semi-automatic micro-
manipulator, we deposited each cluster individually into lysis
buffer (Fig. 1f), followed by DNA ampliﬁcation and library
preparation for exome sequencing. Six samples were success-
fully sequenced, including one WBC pool as germline control
and ﬁve putative GBM CTC clusters. We obtained an average of
41 million reads per sample, corresponding to a median
coverage depth of 32.6 × and an average breadth of 18.7%, in
range with typical performance of single-cell-resolution exome
sequencing of ﬁxed cells10 (Supplementary Fig. 6a and Suppl.
Table 1). To address whether our putative GBM CTC clusters
were indeed of cancer origin, we adopted two parallel
approaches. First, we inferred DNA copy number variations
(CNVs) from exome-sequencing data in all our samples (see
Methods section). In general, while CNV assessment from single-
cell-resolution exome sequencing cannot precisely determine
CNV in exact regions due to the relative low coverage and
possible ampliﬁcation biases, we sought to use it to investigate
general aneuploidy trends across cells. We found that while
predicted ploidy for WBC control pool was 2, all putative GBM
CTC clusters displayed a predicted ploidy ranging from 2.2 to
4.1, suggesting a higher degree of genomic rearrangements
compared with the WBC control pool (Supplementary Fig. 6b).
Second, we identiﬁed variations at the nucleotide level in both
the WBC control pool as well as the putative GBM CTC clusters.
Genetic variations identiﬁed in both the putative CTC clusters
and the WBC control pool were considered likely to be part of
the patient’s germline variants and not included for further
analyses. We then interrogated speciﬁc GBM-associated genes
(see Methods section) and found among them a premature
STOP codon in ATM gene and missense variants in PMS2 and
POLE genes in GBM CTC clusters (Fig. 1g and Suppl. Table 2). Of
note, the region corresponding to the STOP codon in ATM gene
and the majority of the other variants were covered and found
to contain a wild-type sequence in the WBC pool control sample
(Suppl. Table 2). More generally, when interrogating the whole
exome of the putative GBM CTC clusters, we found that they
were carrying at total of 116 variants (possibly both driver and
passenger mutations) comprised in a total of 58 cancer-
associated genes (i.e., genes that were reported in the COSMIC
database and whose corresponding substitutions were leading
to either structural variants, premature STOP codon, or missense
variants) including APC, XPO1, TFRC, JAK2, BRCA2, ERBB4 and ALK,
in addition to the GBM-associated genes ATM, PMS2 and POLE
(Supplementary Fig. 6c and Suppl. Table 3). Further, despite the
notorious difﬁculties in capturing the entire mutational hetero-
geneity of an individual’s primary GBM with a single biopsy,11
we asked whether any of the mutations found at the level of
GBM CTC clusters were also detectable in the primary tumour.
Deep sequencing of a matched primary tumour biopsy of
patient #4 revealed that 16 out of 116 GBM CTC cluster
mutations were indeed also found in the primary tumour (Suppl.
Table 3), including mutations in POLE, BRCA2, ALK, and TFRC
(Suppl. Table 4). Importantly, several of these loci that contained
mutations both in the primary tumour and GBM CTC clusters
were covered and found to contain a wild-type sequence in the
WBC pool control sample (Suppl. Table 4), conclusively
demonstrating the GBM origin of the isolated CTC clusters.
Together, our results provide the ﬁrst evidence that GBM can
release clustered CTCs, characterised by a distinct mutational
proﬁle, which pass beyond the blood–brain barrier and reach the
peripheral circulation.
DISCUSSION
Although CTC clusters have been highlighted as highly-efﬁcient
metastatic precursors,9 they remain a poorly characterised feature
of the metastatic process, mainly due to their dilution factor in the
blood of patients and challenges to isolate them without
disrupting cell–cell interactions. As further confounding factors,
physiological features such as the localisation of the primary
tumour, circulation dynamics and entrapment in capillary beds
may strongly inﬂuence the number of detected CTC clusters in the
peripheral circulation of a given patient.
Our work provides the ﬁrst evidence that circulating glioblas-
toma clusters can overcome the blood–brain barrier and reach the
peripheral circulation. Yet, much remains to be understood in
regard to their biology and clinical relevance in this disease,
possibly using larger patient cohorts. In the future, it will be of
interest to explore the transcriptome of CTC clusters, to deﬁne
their genetic heterogeneity as compared with the primary tumour,
and to assess whether or not their presence in the peripheral
circulation correlates with GBM aggressiveness. We speculate that
since cancer cells are able to enter the blood circulation as clusters
in a non-epithelial cancer such as GBM, a limited cell–cell junction
repertoire12–14 may still be sufﬁcient to sustain CTC clustering and
ensure the preservation of multicellular structures beyond
vascular barriers. Further studies will be needed to test this
hypothesis and to identify key factors involved in CTC cluster
generation and passage through physical barriers. In addition, the
identiﬁcation of the essential cell–cell junction requirements to
maintain CTC clustering may lead to the development of novel
cluster-targeting agents.
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ABSTRACT
The development of a metastatic disease is recognised
as the cause of death of over 90% of patients
diagnosed with cancer. Understanding the biological
features of metastasis has been hampered for a long
time by the difficulties to study widespread cancerous
lesions in patients, and by the absence of reliable
methods to isolate viable metastatic cells during
disease progression. These difficulties negatively
impact on our ability to develop new agents that are
tailored to block the spread of cancer. Yet, recent
advances in specialised devices for the isolation of
circulating tumour cells (CTCs), hand-in-hand with
technologies that enable single cell resolution
interrogation of their genome and transcriptome, are
now paving the way to understanding those molecular
mechanisms that drive the formation of metastasis.
In this review, we aim to summarise some of the latest
discoveries in CTC biology in the context of several
types of cancer, and to highlight those findings that
have a potential to improve the clinical management of
patients with metastatic cancer.
INTRODUCTION
Despite remarkable improvements in early
detection of cancerous lesions, combined
with surgical removal and treatment of the
primary tumour, the development of a meta-
static disease remains the main cause of
death for the vast majority of patients with
cancer. Currently, worldwide, more than
seven million people per year die as a conse-
quence of a metastatic disease (WHO).
Clearly, these numbers reﬂect our limited
understanding of the biology of cancer in
the metastatic setting, and the need to over-
come a number of clinical as well as tech-
nical limitations to better comprehend how
to efﬁciently target metastasis in patients.
Clinically, patients with a metastatic disease
are often characterised by the presence of
one or more micrometastatic and macrome-
tastatic foci throughout various organs.1 Only
some of these foci are clinically detectable at
the time of metastasis diagnosis, while many
more foci are likely to be present but below
detection limit, yet posing a signiﬁcant risk
in terms of disease progression.1 2 In this
context, treatment strategies for patients with
metastasis are often based on the patho-
logical and molecular characterisation of the
primary tumour, while little or no informa-
tion is available from the various metastatic
lesions that are present at that speciﬁc
moment. A main reason for this is that
metastases are hardly accessible for direct
sampling. However, the consequence is that
we still treat metastasis based on information
obtained from a primary tumour, an
approach that has led to no success. Further,
we now started to be aware of the fact that
metastasis is an evolutionary process, where
metastatic subclones with a unique muta-
tional proﬁle may emerge along with cancer
progression at any time, resulting in a high
degree of heterogeneity and signiﬁcant dif-
ferences from the primary tumour of origin.3
Technically, our current understanding of
cancer heterogeneity, especially in the meta-
static setting, argues that even if we were able
to biopsy most of the metastatic lesion in a
given patient, we would still face the issue of
cellular heterogeneity within each lesion.4
However, newly established protocols now
enable a single cell resolution interrogation
of the genome and transcriptome of cancer
cells, and their application to the metastasis
ﬁeld holds the promise to deﬁne its molecu-
lar drivers with high precision.5
While metastasis remains very challenging
for a direct biopsy, recent developments in
microﬂuidics technologies are enabling the
capture of live circulating tumour cells
(CTCs) from the blood of patients with
various types of cancer.6 Most excitingly,
given the short half-life of CTCs in circula-
tion,7 in the metastatic setting CTCs are a
direct derivative of metastasis. Pragmatically,
they can be seen as an opportunity to
isolate, in real time, live cancer cells that
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are derived from proliferating metastatic lesions in
patients, thereby empowering a single cell resolution
analysis of metastasis from a minimally invasive liquid
biopsy.
It is important to mention that CTCs are extraordinar-
ily rare in the blood of patients with cancer (on average,
one CTC per billion normal blood cells), even in those
patients with progressing metastatic disease.8 In fact,
detection of CTCs greatly varies depending on the tech-
nology used for their isolation. The majority of plat-
forms currently available for CTC isolation rely on the
expression of cell surface markers or physical properties
to distinguish CTCs from normal blood components.9–15
For epithelial cancer types that generally express high
levels of epithelial cell adhesion molecule (EpCAM), the
CellSearch system is currently the only Food and Drug
Administration (FDA)-approved device in the clinical
setting.12 13 16 On the other hand, size-based enrich-
ment platforms, such as Parsortix and ScreenCell, take
advantage of the slightly bigger size of CTCs compared
with red and white blood cells (WBCs; ∼12–25 μm for a
single CTC vs 8 and 7–15 μm for a red and WBC,
respectively).17–19 Key to CTC enumeration and charac-
terisation are also newly developed microﬂuidic devices,
such as the spiral biochip based on hydrodynamic
forces, or the CTC-iChip which uses a combination of
hydrodynamic cell separation and immunomagnetic
depletion of antibody-tagged WBCs to isolate larger
CTCs.15 20 However, an unbiased assessment of CTC
number and molecular characteristics still requires to
overcome a very high degree of technical difﬁculties,
reviewed elsewhere, such as the need for
antigen-independent CTC enrichment techniques,14
devices for single cell manipulation with minimal
losses,21 22 DNA and RNA ampliﬁcation protocols for
single cells with low sequence biases23 and bioinfor-
matics tools that facilitate single cell data normalisa-
tion and analyisis.24 These technologies are now
within reach, and are likely to enable a comprehen-
sive characterisation of metastatic cells in the near
future.
In this review, we aim to summarise some of the most
signiﬁcant discoveries in CTC biology in different cancer
types, focusing on those that are likely to impact our
understanding of the metastatic process.
THE BIOLOGY OF CTCS IN DIFFERENT CANCER TYPES
The analysis of CTCS in several cancer types has already
allowed a better understanding of the metastatic
process, as well as it has highlighted the use of CTCs as
a non-invasive source of information for individualised
medicine. However, much work remains to be done to
gain those insights that will allow the development of
new metastasis-tailored therapies. While most of our
understanding of CTC biology derives from the analysis
of breast and prostate CTCs, recently we also witnessed
important advances in colorectal, pancreatic and lung
cancer, as well as in melanoma and glioblastoma multi-
forme (GBM).
Breast cancer
Breast cancer is the second most common cancer in the
world, and by far the most common cancer in women,
with more than 1.6 million new cases each year. A vast
proportion of breast cancers are cured with surgery;
however, the development of metastasis still accounts for
more than 500 000 deaths per year worldwide (WHO).
Breast cancer is the cancer in which most studies
related to CTCs have been carried out. For example,
breast CTCs have been shown to be predictors of
decreased survival in patients with early breast cancer,
before or after chemotherapy, with prognosis being
worst in those patients with at least ﬁve CTCs per 30 mL
of blood.25 Along these lines, systemic spread of breast
cancer has been shown to start early during tumour pro-
gression in patients and mouse models, where CTCs are
released from a growing primary tumour mass and dis-
seminate to distant organs, leading to the development
of metastasis.26 In the metastatic setting, high CTC
counts have also been shown to be predictive of bad
prognosis, including those patients who were newly diag-
nosed with metastatic breast cancer and were about to
start ﬁrst-line systemic treatment.27 28
One of the key aspects that emerged from the analysis
of breast CTCs is their remarkable heterogeneity, both
considering the expression of speciﬁc cancer-associated
markers, and also their phenotypic characteristics such
as tumour-seeding potential. For instance, CTCs fre-
quently lack estrogen receptor (ER) expression in
patients with metastatic breast cancer who were diag-
nosed with ER-positive primary tumours, and these
CTCs show a high degree of intrapatient heterogeneity
which may reﬂect a mechanism to escape endocrine
therapy.29 30 Similarly, the expression of the human epi-
dermal growth factor receptor 2 (HER2) on CTCs is often
not concordant with the HER2 status of the primary
tumour, and a subset of patients with HER2-negative
primary tumour will develop HER2-positive CTCs during
disease progression.31 These ﬁndings have clear implica-
tions for what concerns targeted therapy approaches, and
highlight the need to characterise CTCs in real time to
deﬁne the best treatment for individual patients.
In terms of phenotypic characteristics, signiﬁcant
efforts have been conducted on breast CTCs to identify
mesenchymal-like cells among them, and also determine
which CTCs in a patient are more likely to successfully
form metastasis at a distant site. Epithelial-to-mesenchymal
transition (EMT) has been observed in human CTCs
from patients with breast cancer, highlighting the occur-
rence of mesenchymal-like CTCs during disease progres-
sion.8 In an index patient who received longitudinal
blood monitoring for epithelial and mesenchymal CTCs
along treatment, reversible shifts between these cell fates
accompanied each cycle of response to therapy and
disease progression, suggesting that EMT may occur as a
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consequence to treatment failure.8 Although EMT has now
been shown to occur in human specimens, it is important
to highlight that the requirement of EMT for the develop-
ment of metastasis is still highly controversial.32 33
A clinically relevant question regarding CTC biology is
whether dissecting CTC heterogeneity in breast cancer
can help to identify CTC populations with increased
tumour-seeding potential. In this regard, it was recently
shown that in patients with breast cancer, the metastasis
initiating CTCs were conﬁned in a subpopulation of
EpCAM-positive CTCs that also expressed CD44, CD47
and the tyrosine kinase receptor c-MET.34 This ﬁnding
was supported by evidence in mouse xenograft models,
and based on the increased ability of EpCAM+/CD44+/
CD47+/c-MET+ CTCs to form bone, lung and liver
metastases when transplanted in the femoral cavity of
immunocompromised mice, compared with the entire
population of EpCAM-expressing CTCs.34 These
metastasis-initiating markers were also expressed in
patient metastases as judged by histological assessment.34
Interestingly, another recent study identiﬁed a brain
metastasis expression signature in the EpCAM-negative
fraction of breast CTCs, deﬁned as a subpopulation of
HER2+/EGFR+/HPSE+/Notch1+ CTCs.35 These results
indicate that multiple subpopulations of metastasis-
initiating CTCs can be present in the peripheral blood
of patients with breast cancer.
In addition to markers, certain physical properties of
CTCs were also recently linked to increased metastatic
potential. In mouse xenograft models, CTC clusters were
shown to carry a 23-fold to 50-fold increased metastatic
potential compared with single CTCs.7 In patients with
breast cancer, the presence of CTC clusters is also asso-
ciated with decreased metastasis-free survival and the
development of new metastatic foci.7 Interestingly, these
CTC clusters were shown to arise from oligoclonal
expansion of tumour cell groupings, rather than from
the aggregation of single CTCs in the vasculature or the
proliferation of a single CTC. Detailed molecular proﬁl-
ing of single and clustered CTCs from patients with
metastatic breast cancer identiﬁed the cell–cell junction
component plakoglobin to be required for CTC cluster
formation. Further, plakoglobin expression in the
primary tumour of patients with breast cancer is asso-
ciated with a reduced metastasis-free survival.7 In a sep-
arate study, CTC clusters were also shown to have an
increased metastatic potential and to express keratin14,
a marker that was previously found expressed in basal
breast cells.36 Additionally, CTC clusters are found in
some instances in association to WBCs, platelets and
ﬁbroblasts, which in turn may promote survival and
shape the molecular proﬁle of the cells they are in
contact with, further promoting heterogeneity and
tumour-seeding potential.7 37–39 These results highlight
CTC clusters as extraordinarily efﬁcient metastatic pre-
cursors in breast cancer, and the need to further reﬁne
their characterisation in breast and other cancer types,
to identify their key vulnerabilities.
Prostate cancer
Prostate cancer is the second most common cancer in
men, with ∼1.1 million new cases each year worldwide,
leading to more than 300 000 deaths per year (WHO).
Patients with prostate cancer succumb to this disease
because of the development of a metastatic disease that
is resistant to therapeutic agents, and that usually
involves the bone as the primary metastatic site.40
In advanced prostate cancer, similarly to breast cancer,
CTC enumeration has been used as a prognostic tool for
disease progression and survival;41 however, in localised
prostate cancer, a clear correlation between CTC
numbers and clinical outcome has not been found.42 43
More generally, prostate cancer is frequently respon-
sive to androgen deprivation therapy, given the high
expression and requirement of the androgen receptor
(AR) in the development and progression of this
disease.40 However, the effectiveness of AR inhibitors in
recurrent metastatic disease is highly variable. While
direct sampling of metastatic lesions in these patients is
challenging, CTC analysis may be key to reveal the
mechanisms of innate or acquired resistance to
AR-targeted therapies. For this reason, most recent
studies have been focusing on performing detailed
molecular characterisation of CTCs isolated from
patients with metastatic prostate cancer. For example,
whole exome sequencing of CTCs was employed to
detect somatic single nucleotide variants in patients with
prostate cancer.44 In this study, the mutational proﬁle of
CTCs was compared with that of the primary tumour
and metastasis and showed a high degree of similarity,
establishing a proof-of-concept that CTC genomics can
be used in the clinic as a non-invasive method to assess
the mutational landscape of metastatic prostate cancer.44
In a similar approach, whole genome ampliﬁcation of
CTCs isolated from castration-resistant patients with
prostate cancer was used to assess copy number aberra-
tions.45 In this study, the majority of aberrations found
in CTCs were also present in the primary tumour;
however, copy number gains at the AR locus were found
speciﬁcally in CTCs, arguing that they could have
emerged as a consequence of AR therapy resistance.45
In a recent study that employed single cell resolution
RNA sequencing of CTCs, putative stem cell markers,
such as ALDH7A1, CD44 and KLF4, as well as markers
for cell proliferation were enriched in prostate CTCs
compared with primary tumours.46 Of note, in this
study, single prostate CTCs displayed a signiﬁcant hetero-
geneity, including the expression of AR gene mutations
and splicing variants, such as AR-v7, previously shown to
confer resistance to antiandrogen therapies.46 47
Retrospective analysis of CTCs from patients who were
progressing under AR-targeted treatment, compared
with untreated cases, showed a remarkable activation of
non-canonical Wnt signalling pathway. Ectopic expres-
sion of Wnt5a in prostate cancer cells attenuated the
antiproliferative effects of AR inhibition, whereas its sup-
pression in drug-resistant cells restored partial sensitivity
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to anti-AR treatment.46 Altogether, these studies provide
evidence that CTC analysis in patients with metastatic
prostate cancer is an opportunity to reveal those key
mechanisms of resistance to AR inhibitors, as well as to
identify those patients who would beneﬁt the most from
a targeted treatment.
Colorectal cancer
Colorectal cancer (CRC) is the second most common
cancer in women and the third most common cancer in
men, with a total of more than 1.3 million new cases
each year. Owing to the development of a metastatic
disease, usually affecting the liver at ﬁrst, almost 700 000
patients succumb to this disease yearly worldwide
(WHO).
CTCs have been observed in patients with CRC, in the
metastatic as well as non-metastatic setting.48–50 Notably,
the number of CTCs in CRC was also shown to be
important in predicting the development of tumour
recurrence and emergence of distant metastasis.48 51–53
More generally however, the number of CTCs detected
in the peripheral blood of patients with CRC is much
lower compared with other cancers such as breast cancer.
Along this line, a recent study compared CTC numbers
in blood drawn from peripheral or mesenteric blood in
patients with CRC, and found a higher number of CTCs
in mesenteric blood samples (median of 2.7–4 CTCs in
mesenteric blood vs 0–2 CTCs in peripheral blood), indi-
cating that a considerable portion of CTCs are likely to
be trapped in the liver before they reach the peripheral
circulation, as the liver is the ﬁrst ﬁlter organ that CTC
will encounter on release from the primary tumour mass
in the colon.54 Thus, CTC isolation efforts should also
take into account the site of the primary tumour mass
(and eventually of each of the metastatic deposits) as
well as the blood circulation dynamics to efﬁciently
capture the most viable cancer cells in circulation.
CTCs from patients with metastatic CRC have also
been the ﬁrst to be sequenced at the single cell level.
Single cell array comparative genomic hybridization
(CGH) and parallel sequencing of 68 CRC-associated
genes conﬁrmed the presence of driver mutations in
genes such as APC, KRAS or PIK3CA in the primary
tumour, metastasis and corresponding CTCs from two
patients.55 However, certain mutations were only visible
in CTCs, probably due to their low frequency in the
primary tumour and metastatic deposits.55 These results
suggest that liquid biopsy in patients with CRC is highly
promising strategy to monitor tumour genomes in real
time and facilitate personalised therapy.
Pancreatic cancer
Pancreatic ductal adenocarcinoma (PDAC) is diagnosed
in more than 300 000 individuals each year (World
Cancer Research Fund, WCRF). Owing to its highly
aggressive nature and the fact that early stages of this
cancer do not usually produce symptoms, PDAC is
almost always fatal, with a 5-year survival rate at ∼5%
(WCRF). The development of metastasis is the main
cause of death in patients with this disease.
Patients with PDAC have been examined for the pres-
ence of CTCs in their bloodstream, which were detected
with various technologies and at various concentra-
tions.56–59 However, individually, these studies failed to
ﬁnd a clear correlation between CTC abundance and
prognosis. Taken together into a meta-analysis on 623
patients, CTC-positive patients with PDAC showed a
worse prognosis compared with patients with no detect-
able CTCs, independently from the detection method
that was used.60
Alterations in the gene encoding KRAS are a key
feature in PDAC, and KRAS mutations have been
accordingly found in PDAC CTCs.61 Along the line of a
molecular characterisation of PDAC CTCs, single cell
resolution RNA sequencing of human and mouse PDAC
CTCs has highlighted the expression of extracellular
matrix (ECM) genes in these cells,59 as well as the activa-
tion of Wnt signalling.62 In these studies, mouse PDAC
CTCs showed upregulation of Wnt2,62 low-proliferative
signatures, enrichment of the stem cell-associated gene
ALDH1A2, a biphenotypic expression of epithelial and
mesenchymal markers and the expression of IGFBP5, a
gene transcript enriched at the epithelial–stromal inter-
face in PDAC primary tumours.59 Yet, both mouse and
human PDAC CTCs displayed a very high expression of
stromal-derived ECM proteins, including SPARC, whose
knockdown in cancer cells suppressed cell migration
and invasiveness.59 These results highlight that PDAC
CTCs may employ expression of Wnt signalling effectors
and ECM proteins to facilitate their route to metastasis.
However, further studies are required to identify effect-
ive therapeutic targets with potential to suppress the
spread of PDAC cells.
Lung cancer
Lung cancer has been the most common cancer in the
world for several decades, with ∼1.8 million new cases
diagnosed each year (WHO). Lung cancer is also the
most common cause of cancer-related death, with ∼1.6
million deaths worldwide due to this disease, yearly.
Lung cancer is a key example in targeted therapy
approaches, since patients with non-small-cell lung
cancer (NSCLC) harbouring activating mutations in the
EGFR gene demonstrate a signiﬁcant progression-free
survival beneﬁt when treated with EGFR tyrosine kinase
inhibitors (TKIs).63 However, the majority of patients
that are initially responding will develop acquired resist-
ance after 12–24 months of treatment. Mechanisms to
TKI resistance include the development of a recurrent
T790M EGFR mutation, ampliﬁcation of signalling
molecules that bypass EGFR inhibition (such as MET
and HER2), mutations in other oncogenic drivers
(eg, PIK3CA and B-RAF) and conversion to small-cell
lung cancer (SCLC).64–69 In this context, the possibility
to interrogate lung cancer genotype in real time
through liquid biopsies is of paramount importance. In
4 Gkountela S, et al. ESMO Open 2016;1:e000078. doi:10.1136/esmoopen-2016-000078
Open Access
 o
n
 13 February 2019 by guest. Protected by copyright.
http://esm
oopen.bmj.com/
ESM
O
 O
pen: first published as 10.1136/esm
oopen-2016-000078 on 3 August 2016. Downloaded from
 
patients with EGFR-mutant NSCLS, it was previously
shown that an allele-speciﬁc assay was able to detect the
emergence of T790M mutations in CTCs during ﬁrst-
line therapy.70 Subsequently, other studies conﬁrmed
that the analysis of lung CTCs can enable the monitor-
ing of evolving tumour genotype in some patients.71–74
In addition to their genotype, physical characteristics of
NSCLC CTCs have been studied, revealing that NSCLC
CTCs appear as single or clustered, with the latter being
mostly negative for the proliferation marker Ki67.75
In SCLS, CTCs have been detected in great numbers
and their abundance clearly correlates with a reduced
overall survival.76 More speciﬁcally, patients with more
than 50 CTCs per 7.5 mL of blood have an overall sur-
vival of 5.4 months, compared with patients with <50
CTCs per 7.5 mL of blood, characterised by an overall
survival of 11.5 months.76 CTCs in SCLC are detected as
both single CTCs and CTC clusters, with the latter
appearing protected from anoikis and with an increased
resistance to cytotoxic drugs.76 Interestingly, CTCs from
patients with SCLC have been also recently employed
for transplantation in immunocompromised mice, thus
recapitulating the features of the tumour growing in the
donor patient.77 In this model, genomic analysis of the
CTC-derived xenografts revealed a high degree of simi-
larity to the original tumour, and a similar responsive-
ness to platinum and etoposide chemotherapy,77 thereby
providing an excellent platform to guide precision
medicine.
Melanoma
Melanoma is diagnosed in more than 230 000 patients
per year worldwide, and approximately one-ﬁfth of these
patients are lost each year (WCRF). The main cause of
death in patients with melanoma is the development of
a systemic metastatic disease, affecting most frequently
organs such as the liver, bone and brain.78
In the past 5 years however, a paradigm shift has
occurred in the treatment of this disease. First, a better
understanding of the genetic landscape of melanoma
has allowed the development of targeted therapies with
efﬁcacy against this disease. One above all, is the discov-
ery that B-RAF oncogene is mutated in ∼50% of melano-
mas, and that patients with this genotype beneﬁt from
therapy with B-RAF and MEK inhibitors,79–81 although
most will develop resistance within 12 months.82–84
Second, the understanding of key pathways controlling
the immune system has led to the development of
immune checkpoint inhibitors such as antibody antago-
nists of CTLA-4 and PD-1, which individually confer a
signiﬁcant survival beneﬁt to a subset of patients, and
even better responses when combined.85–89 However, at
present it is still unclear which patients will beneﬁt from
these agents, therefore the identiﬁcation of biomarkers
of response is a priority. More speciﬁcally, in melanoma,
acquired resistance to therapy seems to be driven by the
clonal expansion of resistant tumour cells.90 While
repeated biopsies to study genomic alterations along
therapy are invasive, difﬁcult to obtain and prone to be
confounded by intratumoural heterogeneity, the analysis
of CTCs may result as a powerful weapon to stratify
patients in light of the best treatment option.
Since melanoma is not an epithelial cancer, CTCs are
extraordinarily hard to isolate from the blood of
patients, because they do not express common CTC
markers such as EpCAM or epithelial cytokeratins that
would distinguish them from normal blood cells.
However, their isolation is now achievable through
antigen-agnostic techniques.14 This is enabling a better
understanding of their biology, and highlighting the pos-
sibility to stratify patients before treatment. Melanoma
CTC xenografts have been also recently developed, and
hold the promise to serve as a platform to screen various
therapeutic agents in vivo, while gaining insights into
tumour evolution dynamics.91 Further, melanoma CTCs
have been detected in patients along B-RAF-targeted
therapy, with their number increasing during disease
progression.92 Lastly, a recent report has shown that the
number of melanoma CTCs in patients is much higher
when blood is taken from the arterial, rather than
venous, circulation.93 Along the lines of what is discussed
above for CRC, these results indicate a better, although
rather inconvenient for the patient, source of blood sam-
pling for melanoma CTCs. Altogether, these studies
demonstrate the ability to isolate and characterise mel-
anoma CTCs from patients, and may be key in the
future to achieve patient stratiﬁcation before the admin-
istration of targeted therapy or immunotherapy.
Glioblastoma multiforme
Worldwide, there are an estimated 240 000 cases of brain
and nervous system tumours per year, with GBM being
the most common, and the most lethal, of these
tumours (WHO). Unlike other tumours, patients with
GBM die because of the consequences of tumour
growth in the primary tumour site, and development of
metastasis is extremely rare.94
Major challenges in the treatment of GBM include the
inability to excise tumour cells inﬁltrating into normal
brain tissue, the poor penetration of therapeutic agents
into the central nervous system (CNS), the difﬁculty in
distinguishing tumour responses from recurrence using
standard imaging criteria and the inherent risks asso-
ciated with brain biopsies needed to monitor tumour
evolution during disease progression.94 In this context, it
has been clear for long time that the possibility to
isolate GBM CTCs from liquid biopsies may signiﬁcantly
help in understanding GBM biology. However, until very
recently, it has been unclear whether GBM cancer cells
would be able to cross the blood–brain barrier and be
detectable in the peripheral circulation. Further, simi-
larly to melanoma and unlike many epithelial cancer
types, CNS malignancies do not express EpCAM, a
marker that is commonly used for CTC detection. Thus,
the isolation of GBM CTCs has been hampered by a
number of exceptionally hard challenges.
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However, in 2014, three groups reported the successful
isolation and characterisation of CTCs from the periph-
eral blood of patients with GBM.95–97 In a ﬁrst study,
glial ﬁbrillary acidic protein-expressing CTCs were
detected in 29/141 patients with GBM.95 These CTCs
were identiﬁed in the density gradient puriﬁed mono-
nuclear fraction of peripheral blood and further valid-
ation was based on the expression of EGFR mutations
and aberrations that matched the primary GBM
tumours. However, there was no correlation between
CTC enumeration and clinical outcome before or after
surgery in these patients.95 In a second study, using a
strategy based on telomerase activity, GBM CTCs were
successfully detected in a number of patients.96
Speciﬁcally, CTCs were detected in 8/11 preradiother-
apy patients as opposed to 1/8 in postradiotherapy
patients, indicating that CTC enumeration in GBM
could be useful in identifying patients who are at high
risk of recurrence.96 In the third study, using the
CTC-iChip platform combined with a speciﬁc staining
optimised to distinguish GBM cells from any other
blood cell, CTCs were found in 13/33 patients with
GBM.97 These CTCs were identiﬁed using a cocktail of
ﬂuorescent probes targeting ﬁve known high-grade
glioma markers, termed ‘STEAM’ (SOX2, Tubulin β-3,
EGFR, A2B5, c-MET).97 As further validation, CTCs
were shown to harbour EGFR gene ampliﬁcations that
corresponded to the primary GBM tumour. Additional
single cell resolution expression analyses identiﬁed a
high enrichment of mesenchymal-associated transcripts,
such as SERPINE1, TGFB1, TGFB2 and vimentin at the
expense of neural lineage markers, compared with
matched primary tumours. Interestingly, these mesen-
chymal markers were also expressed by RNA-ISH at dis-
tinct areas of the primary tumour and predominantly at
the invasive edge of the deep white matter tracts, the
area of the tumour that is associated with GBM cell inva-
sion.97 Nevertheless, in this study there was no clear cor-
relation between CTC presence and clinical outcome of
these patients.97 Altogether, these studies were instru-
mental to demonstrate for the ﬁrst time the presence of
CTCs in patients with GBM, and warrant further investi-
gations to gain more insights into the biology of this
disease.
Culturing CTCs for personalised medicine
While the analysis of freshly isolated CTCs might be a
phenomenal opportunity to stratify patients and to
guide precision medicine in the future, the extremely
low abundance of these cells in the peripheral blood of
patients with cancer remains a challenge in the context
of personalised drug screenings. The possibility of
expanding CTCs in culture has only very recently been
achieved, carrying important implications for persona-
lised medicine.
The ﬁrst study reporting successful culture of CTCs
was performed with samples from patients affected by
brain metastatic breast cancer.35 In this study, a fraction
of EpCAM-negative CTCs was found to carry a HER2/
EGFR/HPSE/Notch1 protein signature and to be par-
ticularly prone to form brain metastasis. These cells were
cultured, and on transplantation in mice, these CTC cell
lines were highly invasive and capable to generate brain
and lung metastasis in animal models.35 However, the
ﬁrst example of CTC cultures with the aim of individua-
lised drug testing was provided in a different study.98 In
that study oligoclonal CTC cultures were derived from
six patients with ER-positive breast cancer, and subjected
to genome sequencing of a panel of cancer-associated
mutational hotspots. Data analysis revealed pre-existing
as well as acquired mutations in PIK3CA, ESR1 and
FGFR2 genes, among others. Drug sensitivity testing ex
vivo and xenografts of each CTC cell line revealed key
(personalised) vulnerabilities as a proof-of-concept.98 In
another study, CTCs as well as tumour biopsies derived
from patients with prostate cancer were expanded as
long-term organoid cultures.99 Seven newly generated
organoid cell lines were shown to recapitulate the
molecular diversity of prostate cancer subtypes, includ-
ing TMPRSS2-ERG fusion, SPOP, FOXA1 and PIK3R1
mutations, SPINK1 overexpression, and loss of CHD1,
p53 and RB tumour suppressor.99 Other studies that fol-
lowed could then show for the ﬁrst time a successful
CTC culture establishment from CRC100 and lung
cancer,101 paving the way to a detailed molecular and
phenotypic analysis of CTCs in these diseases as well.
Altogether, several groups have now successfully estab-
lished long-term CTC cultures from different cancer
types. In the context of personalised medicine however,
much work remains to be done. For instance, establish-
ment of CTC-derived cell lines nowadays still requires
several months, and it is only possible from a restricted
number of patients, usually those with the highest
numbers of CTCs.98–101 During this time, most CTCs iso-
lated from a patient will die in culture, and only some
will be able to successfully grow and establish a cell line.
During this process, the corresponding patient in the
clinic is likely to undergo additional treatment cycles,
which are expected to reshape the molecular portrait of
his/her disease.102 103 In this scenario, a drug screening
on CTC-derived cells would not be up to date with the
patient’s disease. For CTC cultures to become a strategy
that enables real-time personalised medicine, much pro-
gress needs to be made in order to achieve drug suscep-
tibility testing within only a few weeks, if not just days,
after the blood is drawn. Thus, increasing the success
rates of CTC culture assays along with the development
of more rapid culture strategies is of paramount import-
ance for achieving personalised drug screenings from
liquid biopsy, as well as to enable most patients with
cancer to beneﬁt from this approach.
CONCLUSIONS
In the past few years, the CTC ﬁeld has witnessed out-
standing advances. First, it is now possible to efﬁciently
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isolate CTCs in an antigen-agnostic fashion.7 15 18 20
This allows an unbiased CTC enrichment strategy in epi-
thelial cancers, and also permits the isolation of CTCs
from cancers of non-epithelial origin, such as GBM and
melanoma. Second, several CTC-enrichment technolo-
gies are now able to release viable CTCs in solution,
thereby empowering their micromanipulation or
culture, and separation from contaminant blood cells
after ﬁrst-step enrichment.7 46 98 Third, single cell reso-
lution sequencing of the genome or transcriptome of
CTCs has been achieved,5 showing that it may represent
an extraordinary opportunity to characterise the muta-
tional proﬁle of metastatic cells in real time, to interro-
gate patient samples longitudinally during treatment, as
well as to dissect fundamental pathways that orchestrate
the metastatic process. Fourth, several groups have
shown the ability to expand CTCs in culture or as xeno-
grafts with the goal of testing individualised drug suscep-
tibility, and creating new CTC-derived lines that
represent highly clinically relevant models to study how
metastasis occurs at the molecular level.98–101
These extraordinary discoveries in the CTC ﬁeld,
however, should be seen as the starting point of a
journey that promises to bring liquid biopsies into clin-
ical practice. Signiﬁcant steps ahead are urgently
needed to achieve standardised protocols for real-time
CTC monitoring and molecular interrogation, early
during primary tumour onset and also later during
metastatic disease progression, most likely in conjunc-
tion with the analysis of cell-free DNA in patients with
cancer.104 At the same time, CTC culturing needs to be
achieved in a much faster time frame in order to beneﬁt
patients. Last but not least, several outstanding questions
remain unanswered in the CTC and metastasis ﬁelds.
For example, we still do not know what triggers the gen-
eration of CTCs (single or clustered) from a primary
tumour or metastatic deposit, what is the true evolution
pattern of metastasis at the single cell level before and
after therapy and what are the targets to inhibit in order
to prevent or suppress the haematogenous spread of
cancer cells in patients. Answers to these questions are
now within reach, and hold great promise to improve
the clinical management of patients who suffer from
metastatic cancers.
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